
<html lang="en"     class="pb-page"  data-request-id="dba54428-39fd-4bf1-837f-9c0f777944ca"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01641;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents" /></meta><meta name="dc.Creator" content="Hanfang  Liu" /></meta><meta name="dc.Creator" content="Jing  Ma" /></meta><meta name="dc.Creator" content="Yingguang  Li" /></meta><meta name="dc.Creator" content="Kexin  Yue" /></meta><meta name="dc.Creator" content="Linrong  Li" /></meta><meta name="dc.Creator" content="Zhuoqing  Xi" /></meta><meta name="dc.Creator" content="Xiao  Zhang" /></meta><meta name="dc.Creator" content="Jianing  Liu" /></meta><meta name="dc.Creator" content="Kai  Feng" /></meta><meta name="dc.Creator" content="Qi  Ma" /></meta><meta name="dc.Creator" content="Sitong  Liu" /></meta><meta name="dc.Creator" content="Shudi  Guo" /></meta><meta name="dc.Creator" content="Peng George  Wang" /></meta><meta name="dc.Creator" content="Chaojie  Wang" /></meta><meta name="dc.Creator" content="Songqiang  Xie" /></meta><meta name="dc.Description" content="Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We..." /></meta><meta name="Description" content="Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 25, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01641" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01641" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01641" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01641" /></link>
        
    
    

<title>Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01641" /></meta><meta property="og:title" content="Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0011.jpeg" /></meta><meta property="og:description" content="Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We herein report that homospermidineplatin (4a), a polyamine-Pt(IV) prodrug, can potently inhibit tumor growth in situ and reverse cisplatin resistance as expected, and more importantly, 4a displays remarkably elevated antimetastatic activity in vivo (65.7%), compared to those of cisplatin (27.0%) and oxaliplatin (19.6%). The underlying molecular mechanism indicates that in addition to targeting nuclear DNA, 4a can modulate polyamine metabolism and function in a manner different from that of cisplatin. By upregulating SSAT and PAO, 4a downregulates the concentrations of Put, Spd, and Spm, which favors the suppression of fast-growing tumor cells. Moreover, the p53/SSAT/β-catenin and PAO/ROS/GSH/GSH-Px pathways are involved in the inhibition of 4a-induced tumor metastasis. Our study implies a promising strategy for the design of platinum drugs for the treatment of terminal cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01641"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01641">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01641&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01641&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01641&amp;href=/doi/10.1021/acs.jmedchem.9b01641" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11324-11334</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01580" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01666" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hanfang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanfang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanfang++Liu">Hanfang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Ma</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#264b474c4f4841664e43485308434253084548"><span class="__cf_email__" data-cfemail="0a676b6063646d4a626f647f246f6e7f246964">[email protected]</span></a>. Phone: (86) 0371-23880680. Fax: (86) 0371-23880680.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ma">Jing Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingguang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingguang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingguang++Li">Yingguang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kexin Yue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kexin Yue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kexin++Yue">Kexin Yue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linrong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linrong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linrong++Li">Linrong Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhuoqing Xi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhuoqing Xi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div><div class="loa-info-affiliations-info">Henan University of Science and Technology Second Affiliated Hospital, Luoyang 471000, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhuoqing++Xi">Zhuoqing Xi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiao Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao++Zhang">Xiao Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianing Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianing Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Medicine, Henan University Minsheng College, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianing++Liu">Jianing Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Medicine, Henan University Minsheng College, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Feng">Kai Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qi Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qi Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Ma">Qi Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sitong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sitong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sitong++Liu">Sitong Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shudi Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shudi Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shudi++Guo">Shudi Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peng George Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng George Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The State Key Laboratory of Microbial Technology and National Glycoengineering Research Center, Shandong University, Qingdao 266237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng+George++Wang">Peng George Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3335-6794" title="Orcid link">http://orcid.org/0000-0003-3335-6794</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chaojie Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chaojie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#a2d5c1c8d1dad3e2cac7ccd78cc7c6d78cc1cc"><span class="__cf_email__" data-cfemail="d9aebab3aaa1a899b1bcb7acf7bcbdacf7bab7">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chaojie++Wang">Chaojie Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6782-0650" title="Orcid link">http://orcid.org/0000-0001-6782-0650</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Songqiang Xie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Songqiang Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Institute of Chemical Biology, Henan University, North Jinming Avenue, Kaifeng 475004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0c7465697f7d4c7a657c226469627922696879226f62"><span class="__cf_email__" data-cfemail="5e26373b2d2f1e28372e70363b302b703b3a2b703d30">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Songqiang++Xie">Songqiang Xie</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1663-3078" title="Orcid link">http://orcid.org/0000-0002-1663-3078</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01641&amp;href=/doi/10.1021%2Facs.jmedchem.9b01641" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11324–11334</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 25, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 October 2019</li><li><span class="item_label"><b>Published</b> online</span>25 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01641" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01641</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11324%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHanfang%2BLiu%252C%2BJing%2BMa%252C%2BYingguang%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b01641%26title%3DPolyamine-Based%2BPt%2528IV%2529%2BProdrugs%2Bas%2BSubstrates%2Bfor%2BPolyamine%2BTransporters%2BPreferentially%2BAccumulate%2Bin%2BCancer%2BMetastases%2Bas%2BDNA%2Band%2BPolyamine%2BMetabolism%2BDual-Targeted%2BAntimetastatic%2BAgents%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11334%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01641"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">779</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01641" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hanfang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Yingguang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Kexin&quot;,&quot;last_name&quot;:&quot;Yue&quot;},{&quot;first_name&quot;:&quot;Linrong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhuoqing&quot;,&quot;last_name&quot;:&quot;Xi&quot;},{&quot;first_name&quot;:&quot;Xiao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jianing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Sitong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shudi&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;George Wang&quot;},{&quot;first_name&quot;:&quot;Chaojie&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Songqiang&quot;,&quot;last_name&quot;:&quot;Xie&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;11324-11334&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01641&quot;},&quot;abstract&quot;:&quot;Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We herein report that homospermidineplatin (4a), a polyamine-Pt(IV) prodrug, can potently inhibit tumor growth in situ and reverse cisplatin resistance as expected, and more importantly, 4a displays remarkably elevated antimetastatic activity in vivo (65.7%), compared to those of cisplatin (27.0%) and oxaliplatin (19.6%). The underlying molecular mechanism indicates that in addition to targeting nuclear DNA, 4a can modulate polyamine metabolism and function in a manner different from that of cisplatin. By upregulating SSAT and PAO, 4a downregulates the concentrations of Put, Spd, and Spm, which favors the suppression of fast-growing tumor cells. Moreover, the p53/SSAT/β-catenin and PAO/ROS/GSH/GSH-Px pathways are involved in the inhibition of 4a-induced tumor metastasis. Our study implies a promising strategy for the &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01641&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01641" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01641&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01641" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01641&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01641" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01641&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01641&amp;href=/doi/10.1021/acs.jmedchem.9b01641" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01641" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01641" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01641%26sid%3Dliteratum%253Aachs%26pmid%3D31765154%26genre%3Darticle%26aulast%3DLiu%26date%3D2019%26atitle%3DPolyamine-Based%2BPt%2528IV%2529%2BProdrugs%2Bas%2BSubstrates%2Bfor%2BPolyamine%2BTransporters%2BPreferentially%2BAccumulate%2Bin%2BCancer%2BMetastases%2Bas%2BDNA%2Band%2BPolyamine%2BMetabolism%2BDual-Targeted%2BAntimetastatic%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D11324%26epage%3D11334%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292098" title="Platinum">Platinum</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291503" title="Organic polymers">Organic polymers</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Diverse platinum drug candidates have been designed to improve inhibitory potency and overcome resistance for orthotopic tumors. However, the antimetastatic properties have rarely been reported. We herein report that homospermidineplatin (<b>4a</b>), a polyamine-Pt(IV) prodrug, can potently inhibit tumor growth <i>in situ</i> and reverse cisplatin resistance as expected, and more importantly, <b>4a</b> displays remarkably elevated antimetastatic activity <i>in vivo</i> (65.7%), compared to those of cisplatin (27.0%) and oxaliplatin (19.6%). The underlying molecular mechanism indicates that in addition to targeting nuclear DNA, <b>4a</b> can modulate polyamine metabolism and function in a manner different from that of cisplatin. By upregulating SSAT and PAO, <b>4a</b> downregulates the concentrations of Put, Spd, and Spm, which favors the suppression of fast-growing tumor cells. Moreover, the p53/SSAT/β-catenin and PAO/ROS/GSH/GSH-Px pathways are involved in the inhibition of <b>4a</b>-induced tumor metastasis. Our study implies a promising strategy for the design of platinum drugs for the treatment of terminal cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">One of the major causes of death in cancer patients and a major obstacle in present chemotherapy are tumor metastasis. Approximately 90% of cancer patient deaths are due to metastatic cancer.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Current anticancer agents can cure well-defined primary tumor, but they have limited impacts on metastatic cells.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> Pt(II) drugs and new Pt(IV) agents prevail in the treatment of cancer, but they are less effective in the treatment of metastatic tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Thus, the design of novel antimetastatic therapeutic agents, including new Pt agents, represents an area in need of urgent attention. Recently, a surge in the activity of Pt drugs, based on a great deal of mechanistic information, has been aimed at developing nonclassical Pt(IV) complexes that operate via mechanisms of action distinct from those of the approved drugs.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a> Our projects<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and others<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> previously focused on using bioactive moieties to achieve enhanced pharmacological effects, such as the modification of axial ligands to tune the lipophilicity or kinetics and the generation of dual-targeted or multitargeted Pt(IV) complexes. Unfortunately, both Pt(II) and Pt(IV) complexes failed to provide simultaneous anticancer and antimetastatic activity <i>in vitro</i> and <i>in vivo</i>.</div><div class="NLM_p">Advances in our understanding of polyamine metabolism and function and their alterations in cancer have led to a resurgence in the interest of targeting polyamine metabolism as an anticancer strategy.<a onclick="showRef(event, 'cit13a cit13b cit13c'); return false;" href="javascript:void(0);" class="ref cit13a cit13b cit13c">(13a−c)</a> The requirements for polyamine metabolism are dysregulated in cancer, thus making polyamine function and metabolism attractive targets for therapeutic intervention. Natural products with a polyamine moiety have been found to prevent tumor cell invasion.<a onclick="showRef(event, 'cit13d cit13e cit13f'); return false;" href="javascript:void(0);" class="ref cit13d cit13e cit13f">(13d−f)</a> Our group<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> has provided significant evidence that some polyamine conjugates could potently inhibit tumor growth and metastasis <i>in vivo</i>. The polyamines spermidine (Spd) and spermine (Spm) and their diamine precursor putrescine (Put) are naturally occurring polycationic alkylamines that are essential for eukaryotic cell growth.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The intracellular pathway of mammalian polyamine catabolism is a two-step process, the rate of which is controlled by the activity of the inducible enzymes spermidine/spermine N1-acetyltransferase (SSAT) and N1-acetylpolyamine oxidase (APAO). Moreover, polyamine transporters (PTs) are also overexpressed in most types of cancer cells, the identity of which is still unknown.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Therefore, polyamine conjugates have become an appealing strategy for the targeted delivery of anticancer drugs with antimetastatic activity.</div><div class="NLM_p">Moreover, recent advances in p53 regulation of ammonia metabolism through the urea cycle controlling polyamine biosynthesis and catabolism indicate that polyamine metabolism and function are closely associated with cisplatin resistance.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Targeting polyamine metabolism and function may imply a practical strategy for the design of Pt drugs to overcome cisplatin resistance in a totally new field.</div><div class="NLM_p">On the basis of the key role of polyamine in mediating antitumor and antimetastatic efficacy, we rationally designed multiaction Pt prodrugs targeting polyamine function and metabolism. We first designed and synthesized polyamine-Pt(IV) conjugates <b>4</b> and <b>5</b> with the classical unsymmetrically substituted polyamine analogues <b>1–3</b>, some of which have entered Phase III clinical trials<a onclick="showRef(event, 'cit13a cit13b cit13c'); return false;" href="javascript:void(0);" class="ref cit13a cit13b cit13c">(13a−c)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S1</a>). Two clinical Pt(II) drugs, cisplatin and oxaliplatin, were selected for the construction of Pt(IV) complexes <b>4–7</b> to investigate the influence of different Pt cores on antitumor activity. Compounds <b>6a</b> and <b>7a</b>, without a polyamine modification, were also designed to investigate the targeting properties of polyamine. We also synthesized the released polyamine ligand <b>8a</b> to study how the effects come about. Feasible routes to <b>4–8</b> are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Schemes S1–S3</a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of homospermidineplatin (<b>4a</b>), Pt(IV) prodrugs without polyamine modified (<b>6a</b>), and the released polyamine ligand <b>8a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Synthesis and Characterization of Polyamine-Pt(IV) Conjugates</h3><div class="NLM_p last">We established feasible routes to <b>4</b> and <b>5</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Schemes S1–S3</a>) that are described in detail in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Supporting Information</a>. Asymmetrically functionalized Pt(IV) compounds <b>e</b> and <b>z</b> can be obtained by the reaction of oxide-cisplatin and oxide-oxaliplatin with palmitic anhydride and then succinic anhydride.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> In this series, compounds <b>4</b> and <b>5</b> bear a hydrophobic polyamine chain varying in connecting formats from <b>d</b> (4 + 4) to <b>q</b> (3 + 3 + 3) to <b>y</b> (3 + 3 + 3). The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compounds <b>4</b> and <b>5</b>. All new compounds were characterized by <sup>1</sup>H, <sup>13</sup>C, and <sup>195</sup>Pt NMR spectroscopy, ESI-MS (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figures S2–S29</a>), and CHN elemental analysis.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Stability of <b>4a</b></h3><div class="NLM_p last">The stability in water was evaluated using compound homospermidineplatin (<b>4a</b>). We observed that <b>4a</b> is highly stable in water, as evidenced by the lack of change in the HPLC chromatogram after 24 h (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S30</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Approximately 70% of <b>4a</b> remained unchanged even after 48 h in RPMI 1640, suggesting that the compound is stable in biological media. Pt levels in A549 and A549cisR cells with no dependence on aminoguanidine (AG) indicated improved metabolic stability (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S31</a>).<a onclick="showRef(event, 'cit13f'); return false;" href="javascript:void(0);" class="ref cit13f">(13f)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.3.  <i>In Vitro</i> Cytotoxicity Effects</h3><div class="NLM_p">The <i>in vitro</i> anticancer activity of these newly synthesized polyamine-Pt(IV) compounds was assessed by using the MTT assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Table S3</a>).<a onclick="showRef(event, 'cit15c cit15d'); return false;" href="javascript:void(0);" class="ref cit15c cit15d">(15c,d)</a> The oxaliplatin-based Pt(IV) compound <b>5a</b> is less active than the corresponding cisplatin-based analogue <b>4c</b>. For cisplatin-based scaffolds (<b>4a–4c</b>), <b>4a</b> with the homospermidine moiety is more potent than its alkynyl (<b>4b</b>) and cyclopropyl (<b>4c</b>) counterparts. <b>4a</b> is significantly more active than cisplatin and oxaliplatin in all of the tested cancer cells with some potencies in the nanomolar range, IC<sub>50</sub> values of which are almost 30-fold lower than those of cisplatin and oxaliplatin. The RF (resistance factor) values of polyamine-platinum(IV) conjugates <b>4</b> and <b>5</b> (RF = 0.24–0.84) are 5–17-fold lower than that of cisplatin (RF = 4.01), indicating its better ability to overcome cisplatin resistance. Moreover, polyamine-platinum(IV) conjugates <b>4</b> and <b>5</b> (SI = 1.47–4.52) show lower cytotoxicity in normal cells HL-7702, with selectivity index (SI) values 3–12-fold higher than those of cisplatin and oxaliplatin (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Table S4</a>). A similar tendency was observed by ICP-MS (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S32</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values (concentrations of 50% inhibition of cell proliferation) (micromolar) of Pt(IV) Prodrugs<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">SMMC7721</th><th class="colsep0 rowsep0" align="center" char=".">HeLa</th><th class="colsep0 rowsep0" align="center" char=".">MDA-MB-231</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center" char=".">HCT-116</th><th class="colsep0 rowsep0" align="center" char=".">A549cisR</th><th class="colsep0 rowsep0" align="center" char=".">A549</th><th class="colsep0 rowsep0" align="center" char=".">RF<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.99 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.96 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">1.32 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.50 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.99 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">1.41 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">2.70 ± 0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">15.48 ± 1.90</td><td class="colsep0 rowsep0" align="char" char=".">10.98 ± 1.09</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">14.58 ± 1.89</td><td class="colsep0 rowsep0" align="char" char=".">6.96 ± 0.69</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="char" char=".">>20</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>20</td><td class="colsep0 rowsep0" align="char" char=".">>50</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="char" char=".">23.37 ± 1.26</td><td class="colsep0 rowsep0" align="char" char=".">15.02 ± 1.23</td><td class="colsep0 rowsep0" align="char" char=".">32.48 ± 1.49</td><td class="colsep0 rowsep0" align="char" char=".">9.60 ± 0.60</td><td class="colsep0 rowsep0" align="char" char=".">5.30 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">42.89 ± 1.89</td><td class="colsep0 rowsep0" align="char" char=".">10.20 ± 0.89</td><td class="colsep0 rowsep0" align="char" char=".">4.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">23.51</td><td class="colsep0 rowsep0" align="char" char=".">15.65</td><td class="colsep0 rowsep0" align="char" char=".">24.61</td><td class="colsep0 rowsep0" align="char" char=".">19.20</td><td class="colsep0 rowsep0" align="char" char=".">5.35</td><td class="colsep0 rowsep0" align="char" char=".">30.42</td><td class="colsep0 rowsep0" align="char" char=".">3.78</td><td class="colsep0 rowsep0" align="char" char=".">7.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oxaliplatin</td><td class="colsep0 rowsep0" align="char" char=".">11.77 ± 1.88</td><td class="colsep0 rowsep0" align="char" char=".">14.17 ± 1.29</td><td class="colsep0 rowsep0" align="char" char=".">17.72 ± 0.89</td><td class="colsep0 rowsep0" align="char" char=".">11.62 ± 0.78</td><td class="colsep0 rowsep0" align="char" char=".">5.89 ± 0.29</td><td class="colsep0 rowsep0" align="char" char=".">38.97 ± 3.23</td><td class="colsep0 rowsep0" align="char" char=".">10.00 ± 1.23</td><td class="colsep0 rowsep0" align="char" char=".">3.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">11.89</td><td class="colsep0 rowsep0" align="char" char=".">14.76</td><td class="colsep0 rowsep0" align="char" char=".">13.42</td><td class="colsep0 rowsep0" align="char" char=".">23.24</td><td class="colsep0 rowsep0" align="char" char=".">5.95</td><td class="colsep0 rowsep0" align="char" char=".">27.64</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char=".">7.50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated for 48 h, and the cell viability was determined by MTT assays. An average of three measurements. ND = not determined.</p></div><div class="footnote" id="t1fn1"><sup><sup>b</sup></sup><p class="last">The RF (resistance factor) is defined as (IC<sub>50</sub> value in A549cisR cells)/(IC<sub>50</sub> value in A549 cells).</p></div><div class="footnote" id="t1fn2"><sup><sup>c</sup></sup><p class="last">FI (fold increase) is defined as IC<sub>50</sub>(cisplatin)/IC<sub>50</sub>(<b>4a</b>).</p></div><div class="footnote" id="t1fn3"><sup><sup>d</sup></sup><p class="last">FI (fold increase) is defined as IC<sub>50</sub>(oxaliplatin)/IC<sub>50</sub>(<b>4a</b>).</p></div></div></div><div class="NLM_p last">Additionally, polyamine-platinum(IV) conjugate <b>4a</b> exhibited better cell-killing effects than the Pt(IV) prodrugs <b>6a</b> and <b>7a</b> without polyamine modified, and especially the released polyamine ligand <b>8a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), indicating that polyamine plays an important role in the synthesized platinum(IV) conjugates. Among these compounds, <b>4a</b> displays the highest cytotoxicity. Therefore, we focus on <b>4a</b> for the following tests.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4.  <i>In Vivo</i> Antitumor and Antimetastatic Activities</h3><div class="NLM_p">Our group<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and others<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> emphasize the importance of the potential antimetastatic activities of polyamine conjugates, and cisplatin is well-known to be a poor metastasis inhibitor.</div><div class="NLM_p">To evaluate if <b>4a</b> with a polyamine motif can prevent tumor metastasis, an <i>in vitro</i> transwell assay was conducted. Compared with cisplastin, <b>4a</b> could inhibit breast cancer migration more potently in a dose-dependent manner as illustrated in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S33</a>. This prompted us to further test the <i>in vivo</i> antitumor and antimetastatic activities of <b>4a</b>.</div><div class="NLM_p">As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Table S3</a>, the IC<sub>50</sub> of <b>4a</b> in MCF-7 cells is 0.50 μM, which is the highest in all tested cancer cells, indicating a better therapeutic effect in breast cancer. Cellular drug uptake and DNA platination of <b>4a</b> in lung carcinoma cell lines A549 and A549cisR, hepatocellular carcinoma cell line SMMC-7721, and breast cancer cell line MCF-7 were also tested by ICP-MS (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S34</a>). The highest Pt levels in MCF-7 suggest a potential therapy for breast cancer. Therefore, we tested the <i>in vivo</i> antitumor and antimetastatic activities of <b>4a</b> in the breast cancer model.</div><div class="NLM_p">Metastasis is the main factor affecting mortality in cancer patients, and the lung is one of the most common sites.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, we injected 4T1 breast cancer cells via the tail vein to assess whether <b>4a</b> was effective against pulmonary metastasis <i>in vivo</i>. Surprisingly, <b>4a</b> significantly reduced the number of tumor metastatic nodules (65.78%) as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, which was 3-fold higher than that of cisplatin (27.03%) and oxaliplatin (19.65%). In addition, the body weight of the mice after treatment with <b>4a</b> showed no significant difference with the control group (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Moreover, the variations in the organ weight indices implied that <b>4a</b> had no obvious pathological changes compared with the control group in the <i>in vivo</i> toxicological profile experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S35</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> antimetastatic activity of <b>4a</b>, <b>6a</b>, cisplatin, and oxaliplatin in 4T1 breast carcinoma tumors every 2 days for a total of four treatments. (A) Body weight of mice during treatment with <b>4a</b>, <b>6a</b>, cisplatin, oxaliplatin, and a control group for 14 days. (B) Statistics of lung metastasis nodules from mice after treatment with <b>4a</b>, <b>6a</b>, cisplatin, oxaliplatin, and a control group for 14 days. (C) Representative images of pulmonary metastasis from mice treated with control, <b>6a</b> (14 mg/kg, 4.8 mg of Pt/kg), oxaliplatin (5 mg/kg, 2.46 mg of Pt/kg), cisplatin (5 mg/kg, 3.26 mg of Pt/kg), <b>4a1</b> (5 mg/kg, 1.20 mg of Pt/kg), <b>4a2</b> (10 mg/kg, 2.40 mg of Pt/kg), and <b>4a3</b> (20 mg/kg, 4.80 mg of Pt/kg) by intravenous delivery once every 2 days (<i>n</i> = 8 mice per group). **<i>P</i> < 0.01; ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further evaluate the potential safety of the polyamine conjugates <i>in vivo</i>, we conducted an acute toxicity study of <b>4a</b>, <b>6a</b>, cisplatin, and oxaliplatin using 5-week-old BALB/c mice. Both the MTD and LD<sub>50</sub> values of <b>4a</b> are nearly 6–10-fold higher than those of <b>6a</b>, cisplatin, and oxaliplatin in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Table S5</a>. The ratios of the cytotoxicity (IC<sub>50</sub>) to MCF-7 cells to the animal lethal dose values (LD<sub>50</sub>) of <b>4a</b> were used as a measure of the therapeutic index.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> The results show that <b>4a</b> is the safest complex with a therapeutic index that is >33-fold higher than that of the clinical drug cisplatin and oxaliplatin.</div><div class="NLM_p">We also tested the <i>in vivo</i> antitumor activity of <b>4a</b> in the breast cancer model (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). On day 13, the average tumor volume was 1025 mm<sup>3</sup> for the control group and 400 mm<sup>3</sup> for <b>4a</b>, which were 61% and 36% lower than those of the control and oxaliplatin-treated groups, respectively, indicating marked antitumor activity <i>in vivo</i>. Upon treatment with <b>4a</b>, the tumor weight decreased significantly to 29% of that in the control group. <b>4a</b>, with the inhibition ratio of 75.44%, was better than that of cisplatin (57.06%) and oxaliplatin (54.22%). Furthermore, the acceptable toxicity of <b>4a</b> was confirmed by measuring the change in body weight (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). After the last injection, the body weight of <b>4a</b> returned to 107% and that of cisplatin decreased to 80% of the initial weight. These results indicate that <b>4a</b> is highly efficient in inhibiting tumor growth <i>in vivo</i>. Moreover, the variations in the organ weight indices of <b>4a</b> had no obvious pathological changes compared with the control group in the <i>in vivo</i> toxicological profile experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S36</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> antitumor activity of <b>4a</b>, polyamine ligand <b>8a</b>, <b>6a</b> without polyamine modified, cisplatin, and oxaliplatin in 4T1 breast carcinoma tumors. Eight mice each received the vehicle, cisplatin (5 mg/kg, 3.26 mg of Pt/kg), oxaliplatin (5 mg/kg, 2.46 mg of Pt/kg), cisplatin and polyamine ligand (1:1, 5 mg of cisplatin/kg + 5 mg of polyamine ligand/kg), <b>4a</b> (5 mg/kg, 1.20 mg of Pt/kg; 10 mg/kg, 2.40 mg of Pt/kg; 20 mg/kg, 4.80 mg of Pt/kg), <b>6a</b> (14 mg/kg, 4.8 mg of Pt/kg), or <b>8a</b> (20 mg/kg) intravenously (i.v.) every 2 days for a total of four treatments. (A) Body weight of the mice during treatment. (B) Tumor weight in each group at the end of the experiment. (C) Tumor growth as a function of time. (D) Images of the tumors at the end of the experiment. Definitions: first horizontal line, control group; second line, polyamine ligand <b>8a</b> group; third line, <b>6a</b> group; fourth line, oxaliplatin group (5 mg/kg, 2.46 mg of Pt/kg); fifth line, cisplatin and polyamine ligand group; sixth line, cisplatin group (5 mg/kg, 3.26 mg of Pt/kg); seventh line, <b>4a</b> group (5 mg/kg, 1.20 mg of Pt/kg); eighth line, <b>4a</b> group (10 mg/kg, 2.40 mg of Pt/kg); ninth line, <b>4a</b> group (20 mg/kg, 4.80 mg of Pt/kg). **<i>P</i> < 0.01; ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.5.  <b>4a</b> Is Transported by PTs</h3><div class="NLM_p">For the first time, we rationally discovered and evaluated homospermidineplatin (<b>4a</b>), a polyamine-Pt(IV) prodrug providing simultaneous enhanced anticancer and antimetastatic activity <i>in vitro</i> and <i>in vivo</i>. More efforts were thus conducted to illustrate the underlying molecular mechanism.</div><div class="NLM_p last">One crucial question in polyamine-conjugate chemistry is whether <b>4a</b> is actively transported by PTs.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Spd, a natural PT ligand, is usually used to compete with the polyamine conjugate for the PTs. The decreased cellular concentration of the polyamine conjugate by the added Spd indicated that the polyamine conjugate enters the cell by PTs. Cellular uptake and platination of nuclear DNA were first monitored in the absence and presence of Spd (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S37</a>). A 68% decrease in the rate of cellular uptake and a 50% decrease in nuclear DNA were observed in the presence of 20 μM Spd. Under similar conditions, the cellular uptake of <b>6a</b> and cisplatin did not significantly change. The same results can be observed in MCF-7 cells in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S38</a>. It is reasonable that an increase in the cellular viability (23%) of <b>4a</b> with Spd, accompanied by the reduced level of drug accumulation, was also observed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S37C</a>. In summary, the uptake assays support the hypothesis that PTs were at least partially involved in the cellular entrance of <b>4a</b>.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.6.  Cellular Accumulation and Distribution of Pt in A549 and A549cisR Cells</h3><div class="NLM_p">Next, the cellular accumulation and distribution of Pt in A549 and A549cisR cells were measured (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The Pt accumulation of <b>4a</b> in A549cisR cells was almost 23 times greater than those of cisplatin and <b>6a</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). In addition, the Pt levels in A549cisR and A549 genomic DNA were 19.74 and 18.78 ng of Pt per 2 × 10<sup>5</sup> cells, respectively, which were 2–6-fold higher than those of cisplatin and <b>6a</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cellular uptake and distribution following an 8 h incubation with 10 μM <b>4a</b> in A549 and A549cisR cells. (A) Accumulation of Pt in A549 and A549cisR cells upon 10 μM treatment for 8 h. (B) Platination levels of nuclear DNA extracts from A549 and A549cisR cells after an 8 h incubation with 10 μM tested compounds. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.7.  Apoptosis Induced by DNA Damage and DNA Binding Properties after Reduction</h3><div class="NLM_p">To further determine if apoptosis was induced by DNA damage, flow cytometry experiments using Annexin V/PI double staining were conducted (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S39</a>). Treatment with <b>4a</b> (5 μM) resulted in A549cisR cell apoptosis with early apoptotic cells (33.00%) and late apoptotic cells (37.50%), which were higher than that of cisplatin (15 μM). We also investigated the reduction and DNA binding properties of cisplatin and <b>4a</b> with ascorbic acid using 5′-dGMP as the DNA model for the inherent proficiency of the Pt prodrugs to bind at the N7 position of guanine bases.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The fractions that contained unknown peaks were separated and identified by ESI-MS analysis, observing the same products as cisplatin (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S40 and Table S6</a>). The higher FI of the <b>4a</b>/cisplatin inhibition ratio with the same Pt levels in genomic DNA in A549cisR cells (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S41</a>) indicated that the mechanism of <b>4a</b> was different from that of cisplatin (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Table S7</a>).</div><div class="NLM_p">We further examined the expression levels of phospho-histone H2A-X (Ser139) by immunoblotting (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S42</a>) to determine whether <b>4a</b> can cause DNA damage.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> We can see a slight increase in the level of phospho-histone H2A-X (Ser139) after treatment with <b>4a</b> compared with cisplatin and <b>6a</b>.</div><div class="NLM_p">Due to the weak influence of <b>4a</b> on phospho-histone H2A-X (Ser139), we tested the change in the p53 gene and p53 protein, which also plays an important role in cell apoptosis and cisplatin resistance. We observed after treatment with <b>4a</b>, the levels of the p53 protein and p53 gene were 3-fold higher than that of cisplatin (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Recently, it has been reported that ureagenesis and ammonia metabolism, including SSAT, have a strong influence on p53.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Markedly higher levels of polyamines, including Put, Spd, and Spm (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B), and a lack of p53 function (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) in A549cisR cells treated with cisplatin were observed for the first time, which was totally contrary to the case of <b>4a</b>, indicating that polyamine metabolism and function are good targets to overcome cisplatin resistance and targeting polyamine metabolism and function is a practical strategy for the design of Pt drugs to overcome cisplatin resistance in a totally new field. We next examined polyamine metabolism and function because such properties may be the main factors significantly affecting the activity of <b>4a</b>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of different concentrations of <b>4a</b> and cisplatin on p53 protein and gene expression in A549cisR cells. (A) Effect of <b>4a</b> and cisplatin on p53 protein in A549cisR cells after a 24 h treatment. (B) qRT-PCR analysis of the p53 transcriptional level was performed with total RNAs purified from A549cisR cells treated with <b>4a</b> and cisplatin after 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.8.  By Promoting p53/SSAT/β-Catenin and PAO/ROS/GSH/GSH-Px Pathways, <b>4a</b> Significantly Inhibits Tumor Metastasis and Overcomes Cisplatin Resistance</h3><div class="NLM_p">Next, two key catabolism enzymes SSAT and PAO in the polyamine cycle were determined to explore the detailed reason. We found <b>4a</b> markedly upregulated the expression of SSAT in A549cisR cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A), which is totally opposite to cisplatin (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Our group also found that the β-catenin signaling pathway is vital in SSAT-regulated cell migration and invasion.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Next, β-catenin was also assessed. The downregulation of β-catenin after treatment with <b>4a</b> indicates significant antitumor migration activity, which also cannot be observed in the cisplatin group (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of different concentrations of (A) <b>4a</b> and (B) cisplatin on SSAT expression in A549cisR cells after a 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of (A) <b>4a</b> and (B) cisplatin on β-catenin expression in A549cisR cells at 10 μM after a 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to SSAT, PAO is another critical catabolism enzyme. Moreover, one of the crucial reasons for Pt drug resistance is that Pt drugs are easily poisoned by S-containing proteins.<a onclick="showRef(event, 'ref6 cit7a'); return false;" href="javascript:void(0);" class="ref ref6 cit7a">(6,7a)</a> Cisplatin bound to a S-containing protein is immediately excreted through multidrug resistance protein.<a onclick="showRef(event, 'ref6 cit7a ref18'); return false;" href="javascript:void(0);" class="ref ref6 cit7a ref18">(6,7a,18)</a> With an increase in the levels of PAO, polyamine conjugates can also upregulate oxidizing substances ROS and downregulate reducing substances such as GSH and GSH-Px to overcome cisplatin resistance. Surprisingly, we found that the relative PAO activity upon <b>4a</b> treatment is almost 2–10-fold higher than those of <b>6a</b>, <b>8a</b>, and cisplatin (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). Our group previously reported<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> a significant accumulation of ROS is closely related to PAO activity.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>4a</b> affects polyamine metabolism and function by upregulating PAO and ROS and downregulating GSH and GSH-Px. (A) Effect of <b>4a</b>, <b>8a</b>, cisplatin, and <b>6a</b> on PAO expression in A549cisR cells at 10 μM after a 24 h treatment. (B) Effect of <b>4a</b>, cisplatin, and <b>6a</b> on PAO expression in A549 cells at 10 μM after a 24 h treatment. (C) Effect of <b>4a</b>, cisplatin, and <b>6a</b> on ROS expression in A549cisR cells at 10 μM after a 24 h treatment: yellow, homospermidineplatin <b>4a</b>; green, cisplatin; red, control group. (D and E) GSH and GSH-Px expression in A549 and A549cisR cells after a 24 h treatment with <b>4a</b>, <b>8a</b>, <b>6a</b>, and cisplatin, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ROS content measured by FCM (flow cytometry) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C) in A549cisR cells after treatment with <b>4a</b> was also higher than that of cisplatin. High levels of oxidizing ROS can decrease the levels of reducing substances, such as GSH and GSH-Px. The contents of GSH and GSH-Px in A549cisR cells upon treatment with 10 μM <b>4a</b> were 3-fold lower than that of the control group in panels D and E of <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. The significantly elevated cellular levels of PAO are believed to be among the major reasons for the marked cytotoxicity of <b>4a</b> to overcome cisplatin resistance. We also found the P-gp is also partially involved in the mechanism of <b>4a</b> to overcome cisplatin resistance (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Figure S43</a>).</div><div class="NLM_p"><b>4a</b> significantly upregulated two key catabolism enzymes, SSAT and PAO, in the polyamine cycle. Upregulated SSAT and PAO can decrease the concentrations of Put, Spd, and Spm to promote polyamine metabolism and suppress fast-growing tumor cells. Next, the contents of endogenous polyamine, Spm, Spd, and Put in A549 and A549cisR cells were measured, which plays an important role in polyamine metabolism and function (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compared with <b>6a</b>, cisplatin, and the control group, <b>4a</b> preferentially downregulated the concentrations of Put, Spd, and Spm in A549 and A549cisR cells. Moreover, the significantly downregulated SSAT and p53 and the upregulated Put, Spd, and Spm (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) after treatment with cisplatin in A549cisR cells, which is totally opposite from the case of <b>4a</b>, imply that targeting polyamine metabolism and function is a practical strategy for the design of Pt drugs to overcome cisplatin resistance in a totally new field.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of <b>4a</b>, <b>6a</b>, and cisplatin on polyamine metabolism and function. Polyamine (Put, Spd, and Spm) concentrations in (A) A549 and (B) A549cisR cells after a 24 h treatment with or without <b>4a</b>. Cisplatin and <b>6a</b> are the reference drugs. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Taken together, our findings provide the first example of polyamine-platinum(IV) prodrugs, targeting polyamine catabolic enzymes SSAT and PAO by PTs to regulate tumor high polyamine microenvironment and overcome cisplatin resistance, providing simultaneous enhanced anticancer and antimetastatic activity (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Prodrug <b>4a</b> induces apoptosis and causes DNA damage by upregulating the p53 gene and p53 protein. The possible mechanism of polyamine-Pt(IV) complexes is targeting SSAT and PAO to downregulate Put, Spd, and Spm in A549cisR cells, which is totally opposite from the case for cisplatin. The β-catenin signaling pathway is vital in <b>4a</b>-regulated cell migration and invasion <i>in vitro</i> and <i>in vivo</i>. With an increase in the levels of PAO, polyamine conjugates upregulate oxidizing substances ROS and downregulate reducing substances such as GSH and GSH-Px to overcome cisplatin resistance.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Proposed mechanism of action for polyamine-Pt(IV) prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The discovery of the potential role of homospermidineplatin, a polyamine-Pt(IV) prodrug, broadens our strategy for the design of more potential antimetastatic agents, although the details of the homospermidineplatin antimetastatic mechanism require further exploration. Markedly higher levels of the polyamines Put, Spd, and Spm, the downregulation of SSAT, and a lack of p53 function after treatment with cisplatin in A549cisR cells imply that polyamine metabolism and function are good targets for overcoming cisplatin resistance, which is totally opposite from the case for the polyamine-Pt(IV) prodrug. This evidence may be beneficial to the discovery of new Pt drugs to overcome cisplatin resistance in a totally new field and for the treatment of terminal cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.1.  HPLC Studies</h3><div class="NLM_p last">The purities of all target compounds were determined by HPLC [Waters E2695-2998 instrument equipped with a Venusil MP C18 column (150 mm × 4.6 mm, 5 μm)]. The purities of the platinum complexes (<b>4–7</b>) were confirmed to be ≥95% by analytical HPLC. The method for determining the purity of target compounds and the purities are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">Tables S1 and S2</a>, respectively.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.2.  General Procedure for the Synthesis of Compound <b>4a1</b></h3><div class="NLM_p last">To a solution of <b>e</b> (0.38 mmol) in DMF (10 mL) was added a DMF solution (0.5 mL) containing HATU (0.57 mmol). This mixture stirred for 10 min at room temperature. A DMF solution containing <b>d</b> (1.5 mmol) and DIPEA (0.92 mmol) was added to the resulting solution. The mixture was stirred at room temperature for 24 h in the dark. The DMF was then removed under vacuum to afford a yellow oil. Compound <b>4a1</b> was purified by silica gel column chromatography as a yellow solid in 50% yield: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.17–3.10 (m, 2H), 3.11–2.78 (m, 6H), 2.71–2.53 (m, 2H), 2.46 (s, 2H), 2.38–2.20 (m, 2H), 1.55 (t, <i>J</i> = 16.9 Hz, 8H), 1.43 (d, <i>J</i> = 7.2 Hz, 28H), 1.27 (s, 16H), 0.91 (t, <i>J</i> = 16.6 Hz, 3H); <sup>13</sup>C NMR (300 MHz, MeOD) δ 175.08, 174.30, 164.74, 158.27, 157.17, 80.47, 80.10, 55.67, 40.87, 40.39, 40.08, 37.00, 32.95, 30.71, 30.37, 28.77, 28.18, 27.51, 26.90, 23.63, 14.51.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.3.  General Procedure for the Synthesis of Compound <b>4a</b></h3><div class="NLM_p last">Intermediate <b>4a1</b> was dissolved in EtOH (10 mL) and stirred at 0 °C for 10 min. Then, 4 M HCl was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 24–48 h and monitored by TLC. The solution typically gave a faint yellow solid as a precipitate. The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compound <b>4a</b>: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.19 (d, <i>J</i> = 20.4 Hz, 6H), 2.95 (dd, <i>J</i> = 17.3, 7.4 Hz, 6H), 2.53 (t, <i>J</i> = 6.2 Hz, 2H), 2.40 (d, <i>J</i> = 6.6 Hz, 2H), 2.28 (t, <i>J</i> = 7.6 Hz, 2H), 1.88–1.38 (m, 10H), 1.21 (s, 24H), 0.82 (t, <i>J</i> = 6.2 Hz, 3H); <sup>13</sup>C NMR (300 MHz, MeOD) δ 184.14, 182.29, 175.55, 40.18, 39.29, 37.07, 33.08, 32.87, 32.73, 30.81, 30.68, 30.57, 30.48, 30.37, 27.36, 27.02, 25.65, 24.44, 24.28, 23.74, 14.45; <sup>195</sup>Pt NMR (86 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1233; ESI-MS (positive ion mode) <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd 812.4297, obsd 812.4259. Calcd for C<sub>28</sub>H<sub>63</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>5</sub>Pt: C, 37.93%; H, 7.16%; N, 7.90%. Found: C, 38.10%; H, 7.12%; N, 7.92%.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.4.  General Procedure for the Synthesis of Compound <b>4b1</b></h3><div class="NLM_p last">To a solution of <b>e</b> (0.38 mmol) in DMF (10 mL) was added a DMF solution (0.5 mL) containing HATU (0.57 mmol). This mixture stirred for 10 min at room temperature. A DMF solution containing <b>q</b> (1.5 mmol) and DIPEA (0.92 mmol) was added to the resulting solution. The mixture was stirred at room temperature for 24 h in the dark. The DMF was then removed under vacuum to afford a yellow oil. Compound <b>4b1</b> was purified by silica gel column chromatography as a yellow solid in 47% yield: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.28–3.16 (m, 2H), 3.09 (d, <i>J</i> = 11.2 Hz, 11H), 2.63–2.42 (m, 2H), 2.35 (d, <i>J</i> = 7.5 Hz, 2H), 2.23 (s, 2H), 1.96–1.40 (m, 8H), 1.35 (s, 27H), 1.28–0.87 (m, 22H), 0.78 (t, <i>J</i> = 6.1 Hz, 3H); <sup>13</sup>C NMR (300 MHz, MeOD) δ 175.19, 174.36, 157.16, 156.55, 81.57, 80.94, 73.18, 46.24, 46.04, 45.81, 37.99, 37.01, 33.02, 32.73, 32.50, 30.76, 30.63, 30.51, 30.43, 30.29, 30.19, 28.83, 26.97, 25.99, 23.69, 19.34, 14.51.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.5.  General Procedure for the Synthesis of Compound <b>4b</b></h3><div class="NLM_p last">Intermediate <b>4b1</b> was dissolved in EtOH (10 mL), and the mixture stirred at 0 °C for 10 min. Then, 4 M HCl was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 24–48 h and monitored by TLC. The solution typically gave a faint yellow solid as a precipitate. The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compound <b>4b</b>: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.73 (m, 1H), 3.28–2.83 (m, 18H), 2.43 (d, <i>J</i> = 22.4 Hz, 4H), 2.25–1.39 (m, 8H), 0.93 (s, 24H), 0.78 (s, 3H); <sup>13</sup>C NMR (300 MHz, MeOD) δ 176.16, 170.19, 152.41, 87.01, 73.92, 46.42, 46.24, 34.97, 34.79, 33.13, 33.03, 31.27, 30.71, 30.63, 30.52, 30.43, 30.32, 30.15, 30.03, 26.09, 24.34, 23.69, 19.41, 14.40; <sup>195</sup>Pt NMR (86 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1236; ESI-MS (positive ion mode) <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd 881.4134, obsd 881.4167. Calcd for C<sub>32</sub>H<sub>69</sub>Cl<sub>5</sub>N<sub>6</sub>O<sub>5</sub>Pt: C, 38.81%; H, 7.02%; N, 8.49%. Found: C, 38.89%; H, 7.12%; N, 8.38%.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.6.  General Procedure for the Synthesis of Compound <b>4c1</b></h3><div class="NLM_p last">To a solution of <b>e</b> (0.38 mmol) in DMF (10 mL) was added a DMF solution (0.5 mL) containing HATU (0.57 mmol). This mixture was stirred for 10 min at room temperature. A DMF solution containing <b>y</b> (1.5 mmol) and DIPEA (0.92 mmol) was added to the resulting solution. The mixture was stirred at room temperature for 24 h in the dark. The DMF was then removed under vacuum to afford a yellow oil. Compound <b>4c1</b> was purified by silica gel column chromatography as a yellow solid in 40% yield: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.74 (d, <i>J</i> = 6.1 Hz, 2H), 3.22 (s, 16H), 2.60 (d, <i>J</i> = 32.1 Hz, 7H), 1.77 (m, 5H), 1.40 (m, 54H), 0.92 (s, 2H), 0.78 (s, 2H), 0.63 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 182.08, 173.24, 156.65, 156.21, 155.48, 79.68, 79.42, 79.33, 54.39, 46.85, 45.26, 44.92, 43.95, 42.61, 32.20, 31.96, 31.87, 29.68, 29.63, 29.31, 28.71, 28.45, 27.73, 25.72, 22.64, 18.01, 14.08, 12.35, 8.02.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.7.  General Procedure for the Synthesis of Compound <b>4c</b></h3><div class="NLM_p last">Intermediate <b>4c1</b> was dissolved in EtOH (10 mL), and the mixture stirred at 0 °C for 10 min. Then, 4 M HCl was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 24–48 h and monitored by TLC. The solution typically gave a faint yellow solid as a precipitate. The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compound <b>4c</b>: <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 4.10–3.98 (m, 1H), 3.10 (m, 21H), 2.59 (d, <i>J</i> = 28.9 Hz, 4H), 2.42 (s, 3H), 2.24–1.58 (m, 12H), 1.31–0.97 (m, 6H); <sup>13</sup>C NMR (300 MHz, D<sub>2</sub>O) δ 179.71, 179.55, 49.15, 48.99, 48.92, 48.75, 40.24, 40.09, 34.46, 34.42, 34.35, 33.74, 30.00, 29.97, 29.90, 27.00, 26.78, 17.62, 7.70; <sup>195</sup>Pt NMR (86 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1234; ESI-MS (positive ion mode) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 893.4276, obsd 893.4278. Calcd for C<sub>32</sub>H<sub>71</sub>Cl<sub>5</sub>N<sub>6</sub>O<sub>5</sub>Pt: C, 38.73%; H, 7.21%; N, 8.47%. Found: C, 38.65%; H, 7.32%; N, 8.42%.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.8.  General Procedure for the Synthesis of Compound <b>5a1</b></h3><div class="NLM_p last">To a solution of <b>z</b> (0.38 mmol) in DMF (10 mL) was added a DMF solution (0.5 mL) containing HATU (0.57 mmol). This mixture was stirred for 10 min at room temperature. A DMF solution containing <b>y</b> (1.5 mmol) and DIPEA (0.92 mmol) was added to the resulting solution. The mixture was stirred at room temperature for 24 h in the dark. The DMF was then removed under vacuum to afford a yellow oil. Compound <b>5a1</b> was purified by silica gel column chromatography as a yellow solid in 39% yield: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.05 (dd, <i>J</i> = 17.1 Hz, 18H), 2.49 (d, <i>J</i> = 8.4 Hz, 7H), 1.89–1.00 (m, 65H), 0.84 (d, <i>J</i> = 6.8 Hz, 2H), 0.71 (d, <i>J</i> = 5.7 Hz, 2H), 0.55 (s, 3H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 175.65, 172.54, 165.32, 156.77, 155.60, 79.44, 46.93, 45.38, 44.92, 36.23, 32.01, 31.95, 29.81, 29.76, 29.67, 29.50, 29.44, 29.31, 28.84, 28.56, 27.94, 27.82, 25.85, 25.80, 22.76, 14.19, 8.14.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.9.  General Procedure for the Synthesis of Compound <b>5a</b></h3><div class="NLM_p last">Intermediate <b>5a1</b> was dissolved in EtOH (10 mL), and the mixture stirred at 0 °C for 10 min. Then, 4 M HCl was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 24–48 h and monitored by TLC. The solution typically gave a faint yellow solid as a precipitate. The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compound <b>5a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.02 (m, 13H), 2.33 (m, 5H), 1.38 (s, 32H), 1.19 (s, 11H), 0.74 (m, 4H), 0.52 (m, 2H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 171.73, 171.42, 155.65, 154.48, 45.81, 44.31, 43.99, 42.65, 35.23, 30.89, 30.83, 28.69, 28.64, 28.55, 28.38, 28.32, 28.19, 27.72, 27.44, 26.75, 24.68, 21.64, 13.07, 7.02; <sup>195</sup>Pt NMR (86 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1611; ESI-MS (positive ion mode) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 994.5522, obsd 994.5533. Calcd for C<sub>40</sub>H<sub>79</sub>Cl<sub>3</sub>N<sub>6</sub>O<sub>9</sub>Pt: C, 44.10%; H, 7.31%; N, 7.71%. Found: C, 44.18%; H, 7.29%; N, 7.79%.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.10.  General Procedure for the Synthesis of Compounds <b>6a</b> and <b>7a</b></h3><div class="NLM_p last">The synthetic routes of <b>6a</b> and <b>7a</b> have been reported by our group.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">4.11.  General Procedure for the Synthesis of Compound <b>8a</b></h3><div class="NLM_p last">Our group has reported the synthetic route of <b>d</b>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> After reaction with succinic anhydride overnight, the intermediate was dissolved in EtOH (10 mL) and stirred at 0 °C for 10 min to give the target compound <b>8a1</b>: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.17 (s, 3H), 2.98 (m, 9H), 2.61–2.32 (m, 4H), 1.85 (m, 10H), 1.55 (d, <i>J</i> = 6.6 Hz, 4H), 1.23 (s, 8H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 174.85, 172.29, 155.53, 155.39, 81.15, 80.59, 58.04, 50.24, 29.49, 28.68, 28.40, 28.35, 28.25, 28.10. Then, 4 M HCl was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 24–48 h and monitored by TLC. The solution typically gave a faint yellow solid as a precipitate. The solid was filtered, washed several times with absolute ethanol, and dried under vacuum to give the pure target compound <b>8a</b>: <sup>1</sup>H NMR (300 MHz, MeOD) δ 3.44–3.24 (m, 2H), 3.15–2.92 (m, 10H), 1.78 (dt, <i>J</i> = 44.0, 22.1 Hz, 11H); <sup>13</sup>C NMR (300 MHz, MeOD) δ 173.01, 171.47, 46.50, 28.29, 28.23, 27.81, 27.75, 27.51.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.12.  <i>In Vitro</i> Cellular Cytotoxicity Assays</h3><div class="NLM_p">Cells seeded in 96-well plates were incubated in a 5% CO<sub>2</sub> atmosphere in 100 μL of complete medium at 37 °C for 24 h. Then, 100 μL of freshly prepared culture medium containing drugs at different concentrations was added, and the mixture incubated for an additional 48 h. MTT (5 mg/mL, 20 μL) was added, and the mixture incubated for 3 h. Finally, the medium was removed, and DMSO (150 μL) was added. The absorbance was measured at 570 nm using a Bio-Rad 680 microplate reader. The IC<sub>50</sub> values were calculated using GraphPad Prism. Technical repetitions and independent experiments were based on three parallel experiments.</div><div class="NLM_p">For cytotoxicity assays using the PAT inhibitor Spd, a procedure similar to that described above was followed, except that A549cisR cells (5000 cells/well) were seeded on a 96-well plate in 100 μL of RPMI and incubated for 24 h at 37 °C. Spd-containing RPMI medium was used for serial dilution of the platinum compound-containing concentrated solutions, and 100 μL was added per well. The cytotoxicity profiles of the compounds were evaluated using the MTT assay.</div><div class="NLM_p last">A PAO, GSH, and GSH-Px Preparation Kit (containing reduced and oxidized glutathione) was used for the isolation of PAO, GSH, and GSH-Px in A549 and A549cisR cells, and concentrations of PAO, GSH, and GSH-Px treated with several agents in the A549 and A549cisR cellular assays were also measured with a microplate reader according to the procedure as described in our previous projects.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.13.  <i>In Vivo</i> Antitumor and Antimetastasis Assays</h3><div class="NLM_p">In compliance with the Guide for the Care and Use of Laboratory Animals, we chose 5-week-old healthy female BALB/c mice (from the Laboratory Animal Center, Academy of Military Medical Science, Beijing, China, catalog no. SCXK 2016-0006), weighing 18–22 g. 4T1 cells (1 × 10<sup>6</sup> cells per mouse) were injected via the tail vein for the determination of lung metastasis and anticancer activity. <b>4a</b> was dissolved in a glucose injection and immediately used after preparation. All animal procedures were performed following the protocol approved by the Institutional Animal Care and Use Committee at Henan University. The <i>in vivo</i> projects were approved by the ethical committee (approved ethical vote HUSOM-2016-316).</div><div class="NLM_p">For antimetastatic activity <i>in vivo</i>, the tumor cells were inoculated for 7 days to ensure the growth of pulmonary metastasis before drug treatment. On day 8, we injected via the tail vein compound <b>4a</b> (5.0, 10, or 20 mg/kg), oxaliplatin (5 mg/kg, positive control), or normal saline (negative control) every 2 days for a total of four treatments with the randomly grouped mice (<i>n</i> = 8 mice per group). On day 15, we anesthetized and euthanized the mice and removed the lungs. We counted the lung metastasis nodules of each mouse after fixation with 4% paraformaldehyde for 1 day.</div><div class="NLM_p">For the solid tumor study, tumors were 80–120 mm<sup>3</sup> in volume after 1 week. Then, mice were injected via the tail vein with <b>4a</b> (5.0, 10, or 20 mg/kg), oxaliplatin (5 mg/kg, positive control), or physiological saline (negative control) every 2 days for a total of four treatments. The mice were weighed every 2 days, and the tumor volume was measured with a Vernier caliper.</div><div class="NLM_p last">The mice were sacrificed by anesthesia, and the tumor tissues were removed and weighed. We calculated the inhibition rate as follows: inhibition rate (%) = [(average tumor weight of negative control group – average tumor weight of the drug-treated or positive control group)/(average tumor weight of control group)] × 100%. Moreover, on the last day, we removed and weighed the organs (heart, liver, kidney, lung, and spleen) of the mice. We calculated the organ weight index as follows: organ index (%) = (organ weight/body weight) × 100%.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.14.  <i>In Vivo</i> MTD and LD<sub>50</sub> Antitumor Assays</h3><div class="NLM_p last">The maximum tolerated dose (MTD) (<i>n</i> = 10 mice per group) was evaluated by calculating the body weight loss (mean weight loss of <15% and <15% toxic deaths), and the lethal dose values (LD<sub>50</sub>) (<i>n</i> = 10 mice per group) were determined. The TI value was calculated according to the procedure as previously described.<a onclick="showRef(event, 'cit12b'); return false;" href="javascript:void(0);" class="ref cit12b">(12b)</a></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">4.15.  Transwell Migration Assay</h3><div class="NLM_p last">Transwell migration assays were performed by using a modified Boyden’s chamber in a 24-well cell culture plate with an 8 μm pore. Chambers were washed three times with PBS. Then the medium with the tested compound was placed in the lower chamber, and cells were seeded in the top chamber. Cells were treated with <b>4a</b> or cisplatin at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. After incubation for 24 h, nonmigrated cells on the top surface of the membrane were gently scraped away with a cotton swab. The migrated cells were fixed with 4% paraformaldehyde for 20 min and stained with 0.2% crystal violet. Images were recorded using a Leika inverted microscope.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.16.  Cellular Platinum Uptake and DNA Platination</h3><div class="NLM_p last">Cellular uptake was measured in A549, A549cisR, SMMC-7721, and MCF-7 cells. A549, A549cisR, SMMC-7721, and MCF-7 cells were seeded in six-well plates overnight and then incubated with 10 μM homospermidineplatin <b>4a</b> or cisplatin for 8 h. Subsequently, the cells were washed three times with PBS buffer and harvested by trypsinization. The harvested cells were concentrated and digested with nitric acid for ICP-MS. The cell numbers were counted before digestion. A Genomic DNA mini preparation kit was used for the isolation of DNA in A549, A549cisR, SMMC-7721, and MCF-7 cells, and Pt concentrations in the cellular DNA of A549, A549cisR, SMMC-7721, and MCF-7 cells digested by nitric acid were also measured by ICP-MS.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.17.  Annexin V-FITC/Propidium Iodide Staining</h3><div class="NLM_p last">Apoptosis of A549cisR cells was evaluated using Annexin V-FITC/PI staining detected by flow cytometry. Cells were plated into six-well plates at a density of 1 × 10<sup>5</sup> cells/well. After being cultured for 24 h, cells were hatched with <b>4a</b> (5 or 10 μM) or cisplatin (15 μM) for 24 h. Then cells were harvested, washed three times with PBS to remove unbound dyes, and stained according to the manufacturer’s protocol. Analysis was performed by flow cytometry (BD Biosciences, San Jose, CA).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.18.  Western Blot Assay</h3><div class="NLM_p last">To detect the expression of the related proteins phospho-histone H2A-X (Ser139), p53, ODC, and SSAT, Western blot analysis was performed. Cells were treated with <b>4a</b> at concentrations of 5, 10, and 15 μM for 24 h, harvested, and centrifuged. The cell pellets were washed three times with ice-cold PBS and then lysed with RIPA buffer (Beyotime, Jiangsu, China). Using a BCA assay kit (Beyotime), we determined the total concentration of protein. After that, we denatured the total lysates in 5× SDS loading buffer at 100 °C for 10 min. Using 12% SDS–PAGE for 2 h, we separated equal amounts of total proteins and then transferred the proteins onto PVDF membranes. The membranes were blocked with 5% dried skimmed milk in TBST at room temperature for 1 h. After incubation with the corresponding primary antibodies overnight at 4 °C, the membranes were washed three times with TBST and incubated with the appropriate HRP-conjugated secondary antibody. Protein expression was detected using the ECL plus reagents (Beyotime).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.19.  Detection of Polyamine Oxidase (PAO)</h3><div class="NLM_p last">The total PAO level was measured using a GSH assay kit according to the manufacturer’s instructions (Hepeng Biotechnology, catalog no. HEPENGBIO156). Briefly, after being treated with <b>4a</b> (10 μM) for 24 h, cells were washed twice with Reagent A (3 mL) and then collected with a cell scraper. Pellets were resuspended in Reagent A (3 mL) by centrifugation at 300<i>g</i> for 5 min. The supernatant were resuspended in Reagent B (500 μL), vortexed immediately, and then lysed by three freeze–thaw cycles. After cell lysates were centrifuged at 16000<i>g</i> for 5 min at 4 °C, the supernatant containing total PAO was transferred to another precooling tube. To quantify the total level of PAO, 10 μL of supernatant was mixed with 240 μL (200 μL of Reagent C, 25 μL of Reagent D, and 15 μL of Reagent E) of total PAO assay buffer for 3 min at 37 °C, and then 10 μL of Reagent F was added. The absorbance was read at 440 nm by using the microplate reader.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.20.  Reactive Oxygen Species Assay</h3><div class="NLM_p last">Reactive oxygen species (ROS) were examined with the fluorescent probe DCFH-DA and detected by flow cytometry as we previously described.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.21.  Detection of Total Glutathione (GSH)</h3><div class="NLM_p last">The total glutathione (containing reduced and oxidized glutathione) level was measured using a GSH assay kit according to the manufacturer’s instructions (Solarbio Biochemical Assay Division, Beijing, China, catalog no. 20180226). Briefly, after being treated with <b>4a</b> (10 μM) for 24 h, cells were washed twice with PBS by centrifugation at 600<i>g</i> for 5 min. Pellets were resuspended in protein removal buffer, vortexed immediately, and then lysed by three freeze–thaw cycles. After cell lysates had been centrifuged at 12000<i>g</i> for 10 min at 4 °C, the supernatant containing total glutathione was transferred to another tube. To quantify the total glutathione level, 10 μL of the supernatant was mixed with 150 μL of total glutathione assay buffer for 5 min, and then 50 μL of NADPH (0.16 mg/mL) was added. The absorbance was read at 405 nm by using the microplate reader.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.22.  Detection of Total Glutathione Peroxidase (GSH-Px)</h3><div class="NLM_p last">The total GSH-Px level was measured using the GSH-Px assay kit according to the manufacturer’s instructions (Leagene Biotechnology, Beijing, China, catalog no. 0309A18). Briefly, after being treated with <b>4a</b> (10 μM) for 24 h, cells were washed twice with PBS by centrifugation at 12000<i>g</i> for 10 min. Pellets were resuspended in protein removal buffer, vortexed immediately, and then lysed by three freeze–thaw cycles. After cell lysates had been centrifuged at 12000<i>g</i> for 10 min at 4 °C, the supernatant containing total GSH-Px was transferred to another tube. To quantify the total GSH-Px level, 0.2 mL of the supernatant was mixed with 0.4 mL of total GSH-Px assay buffer for 5 min at 37 °C, and then 0.25 mL of benzoic acid was added. The absorbance was read at 422 nm by using the microplate reader.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">4.23.  Polyamine Content Assay</h3><div class="NLM_p">In addition to using a model G1321A fluorescence detector, we quantified the polyamine (putrescine, spermidine, and spermine) content in A549cisR cells by using HPLC (Agilent 1260, Agilent Technologies) according to our previous reported.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p last">The polyamines were separated on a C18 chromatographic column (25 mm × 4.6 mm, 5 μm) with dansyl chloride as the derivation reagent and 1,6-diaminohexane as the internal standard substance using a methanol/water mixture (from 65:35 to 100:0, 30 min gradient elution) (excitation at 340 nm and emission at 515 nm). The polyamines (putrescine, spermidine, and spermine) were converted to the corresponding dansyl derivatives and separated on a C18 analytical column by eluting with an ethyl acetate/water gradient. 1,6-Diaminohexane was used as the internal standard.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01641" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01641?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01641</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Full experimental details, NMR data, and bioassay information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf">jm9b01641_si_001.pdf (3.96 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_002.csv">jm9b01641_si_002.csv (0.49 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01641" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ma</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#513c303b383f361139343f247f3435247f323f"><span class="__cf_email__" data-cfemail="87eae6edeee9e0c7efe2e9f2a9e2e3f2a9e4e9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chaojie Wang</span> - <span class="hlFld-Affiliation affiliation">The
Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6782-0650" title="Orcid link">http://orcid.org/0000-0001-6782-0650</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9cebfff6efe4eddcf4f9f2e9b2f9f8e9b2fff2"><span class="__cf_email__" data-cfemail="98effbf2ebe0e9d8f0fdf6edb6fdfcedb6fbf6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Songqiang Xie</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute of Chemical Biology, Henan University, North Jinming Avenue, Kaifeng 475004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1663-3078" title="Orcid link">http://orcid.org/0000-0002-1663-3078</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d2aabbb7a1a392a4bba2fcbab7bca7fcb7b6a7fcb1bc"><span class="__cf_email__" data-cfemail="abd3c2ced8daebddc2db85c3cec5de85cecfde85c8c5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanfang Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingguang Li</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kexin Yue</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linrong Li</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuoqing Xi</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span>; 
    <span class="hlFld-Affiliation affiliation">Henan
University of Science and Technology Second Affiliated Hospital, Luoyang 471000, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao Zhang</span> - <span class="hlFld-Affiliation affiliation">The
Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianing Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Medicine, Henan University Minsheng College, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Feng</span> - <span class="hlFld-Affiliation affiliation">School
of Medicine, Henan University Minsheng College, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Ma</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sitong Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shudi Guo</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Institute for Innovative Drug Design and Evaluation, Henan University, North Jinming Avenue, Kaifeng 475004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng George Wang</span> - <span class="hlFld-Affiliation affiliation">The State
Key Laboratory of Microbial Technology and National Glycoengineering
Research Center, Shandong University, Qingdao 266237, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3335-6794" title="Orcid link">http://orcid.org/0000-0003-3335-6794</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.L. and J.M. contributed equally to this work, and J.M. is also the first corresponding author.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Natural Science Foundation of China (Grants 21807025, 81772832, and 81573465), the China Postdoctoral Science Foundation (Grant 2018M640673), a Postdoctoral Research Grant in Henan Province (Grant 001802020), Key Scientific Research Projects in Henan Colleges and Universities (Grant 19A350002), the Program for Innovative Research Team (in Science and Technology in University of Henan Province) (Grant 19IRTSTHN004), the Project of Innovation and Entrepreneurship Support Program for College Students of Henan University Minsheng College (Grant MSCXCY2018058), Henan University (Grants 201910475012 and 2019102004), the Scientific Research Cultivating Program for Young Talents in Henan Medical School (Grant 2019006), and the key scientific research projects of universities in Henan province (Grant 13A350095).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PTs</td><td class="NLM_def"><p class="first last">polyamine transporters</p></td></tr><tr><td class="NLM_term">SSAT</td><td class="NLM_def"><p class="first last">spermidine/spermine N1-acetyltransferase</p></td></tr><tr><td class="NLM_term">PAO</td><td class="NLM_def"><p class="first last">N1-acetylpolyamine oxidase</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">GSH-Px</td><td class="NLM_def"><p class="first last">glutathione peroxidase</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">Spd</td><td class="NLM_def"><p class="first last">spermidine</p></td></tr><tr><td class="NLM_term">Spm</td><td class="NLM_def"><p class="first last">spermine</p></td></tr><tr><td class="NLM_term">Put</td><td class="NLM_def"><p class="first last">putrescine</p></td></tr><tr><td class="NLM_term">LD<sub>50</sub></td><td class="NLM_def"><p class="first last">lethal dose of 50%</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">ICP-MS</td><td class="NLM_def"><p class="first last">inductively coupled plasma mass spectrometry</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 19 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruix, J.</span></span> <span> </span><span class="NLM_article-title">Bruix, Hepatocellular carcinoma</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1255</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)61347-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2FS0140-6736%2811%2961347-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=22353262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC38vjslOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1245-1255&author=A.+Fornerauthor=J.+M+Llovetauthor=J.+Bruix&title=Bruix%2C+Hepatocellular+carcinoma&doi=10.1016%2FS0140-6736%2811%2961347-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocellular carcinoma</span></div><div class="casAuthors">Forner Alejandro; Llovet Josep M; Bruix Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9822</span>),
    <span class="NLM_cas:pages">1245-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death.  Patients with cirrhosis are at highest risk of developing this malignant disease, and ultrasonography every 6 months is recommended.  Surveillance with ultrasonography allows diagnosis at early stages when the tumour might be curable by resection, liver transplantation, or ablation, and 5-year survival higher than 50% can be achieved.  Patients with small solitary tumours and very well preserved liver function are the best candidates for surgical resection.  Liver transplantation is most beneficial for individuals who are not good candidates for resection, especially those within Milano criteria (solitary tumour ≤5 cm and up to three nodules ≤3 cm).  Donor shortage greatly limits its applicability.  Percutaneous ablation is the most frequently used treatment but its effectiveness is limited by tumour size and localisation.  In asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread not amenable to curative treatments, chemoembolisation can provide survival benefit.  Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer.  Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOX8RK_5ylfwWRJ3OJdH_qfW6udTcc2ebqhDc7zHuQr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjslOhuw%253D%253D&md5=9c13d87d11d47ff8555b73abbaad5558</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961347-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961347-0%26sid%3Dliteratum%253Aachs%26aulast%3DForner%26aufirst%3DA.%26aulast%3DLlovet%26aufirst%3DJ.%2BM%26aulast%3DBruix%26aufirst%3DJ.%26atitle%3DBruix%252C%2520Hepatocellular%2520carcinoma%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1245%26epage%3D1255%26doi%3D10.1016%2FS0140-6736%2811%2961347-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">miR-187–3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.canlet.2016.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27544906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2016&pages=380-390&author=C.+Douauthor=Z.+Liuauthor=M.+Xuauthor=Y.+Jiaauthor=Y.+Wangauthor=Q.+Liauthor=W.+Yangauthor=X.+Zhengauthor=K.+Tuauthor=Q.+Liu&title=miR-187%E2%80%933p+inhibits+the+metastasis+and+epithelial-mesenchymal+transition+of+hepatocellular+carcinoma+by+targeting+S100A4&doi=10.1016%2Fj.canlet.2016.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4</span></div><div class="casAuthors">Dou, Changwei; Liu, Zhikui; Xu, Meng; Jia, Yuli; Wang, Yufeng; Li, Qing; Yang, Wei; Zheng, Xin; Tu, Kangsheng; Liu, Qingguang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">380-390</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MiR-187-3p, a novel cancer-related microRNA, was previously reported to play promoting or suppressive roles in different malignancies.  However, the expression level, biol. function, and underlying mechanisms of miR-187-3p in hepatocellular carcinoma (HCC) remain unknown.  This study demonstrated that miR-187-3p was significantly down-regulated in HCC tissues and cell lines, and was assocd. with advanced TNM stage and metastasis in HCC.  Functional studies confirmed that miR-187-3p could inhibit the metastasis of HCC both in vitro and in vivo.  Moreover, we proved that miR-187-3p could prevent the epithelial-mesenchymal transition (EMT) of HCC cells.  Mech., S100A4 was a direct downstream target of miR-187-3p, and mediated the functional influence of miR-187-3p in HCC.  Furthermore, miR-187-3p and S100A4 expression was evidently correlated with adverse clin. features and poor prognosis of HCC.  Lastly, we showed that hypoxia was responsible for the significantly decreased level of miR-187-3p in HCC, and miR-187-3p was involved in the promoting effects of hypoxia on the metastasis and EMT of HCC cells.  Taken together, miR-187-3p inhibits the metastasis and EMT in HCC by targeting S100A4. miR-187-3p can serve as a prognostic indicator and a promising therapeutic target for HCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRH2rv97Fj7Vg90H21EOLACvtfcHk0lgGDNKTL6AJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7fL&md5=a8950572421a81f6bdd6f1b442c1d6f8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DmiR-187%25E2%2580%25933p%2520inhibits%2520the%2520metastasis%2520and%2520epithelial-mesenchymal%2520transition%2520of%2520hepatocellular%2520carcinoma%2520by%2520targeting%2520S100A4%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D381%26spage%3D380%26epage%3D390%26doi%3D10.1016%2Fj.canlet.2016.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valastyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tumor metastasis: molecular insights and evolving paradigms</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.cell.2011.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=22000009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=275-292&author=S.+Valastyanauthor=R.+A.+Weinberg&title=Tumor+metastasis%3A+molecular+insights+and+evolving+paradigms&doi=10.1016%2Fj.cell.2011.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Metastasis: Molecular Insights and Evolving Paradigms</span></div><div class="casAuthors">Valastyan, Scott; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-292</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Metastases represent the end products of a multistep cell-biol. process termed the invasion-metastasis cascade, which involves dissemination of cancer cells to anatomically distant organ sites and their subsequent adaptation to foreign tissue microenvironments.  Each of these events is driven by the acquisition of genetic and/or epigenetic alterations within tumor cells and the co-option of nonneoplastic stromal cells, which together endow incipient metastatic cells with traits needed to generate macroscopic metastases.  Recent advances provide provocative insights into these cell-biol. and mol. changes, which have implications regarding the steps of the invasion-metastasis cascade that appear amenable to therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqOPVKwPqtbVg90H21EOLACvtfcHk0lgGDNKTL6AJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3N&md5=fa62d15c6b61bf90cfcdc1d51bbe98b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DValastyan%26aufirst%3DS.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTumor%2520metastasis%253A%2520molecular%2520insights%2520and%2520evolving%2520paradigms%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D275%26epage%3D292%26doi%3D10.1016%2Fj.cell.2011.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, A. M.</span></span> <span> </span><span class="NLM_article-title">Cancer metastases: so close and so far</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">djv236</span>, <span class="refDoi"> DOI: 10.1093/jnci/djv236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1093%2Fjnci%2Fdjv236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26283653" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&pages=djv236&author=C.+Sonnenscheinauthor=A.+M.+Soto&title=Cancer+metastases%3A+so+close+and+so+far&doi=10.1093%2Fjnci%2Fdjv236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv236%26sid%3Dliteratum%253Aachs%26aulast%3DSonnenschein%26aufirst%3DC.%26aulast%3DSoto%26aufirst%3DA.%2BM.%26atitle%3DCancer%2520metastases%253A%2520so%2520close%2520and%2520so%2520far%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2015%26volume%3D107%26spage%3Ddjv236%26doi%3D10.1093%2Fjnci%2Fdjv236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ran, S.</span></span> <span> </span><span class="NLM_article-title">The role of TLR4 in chemotherapy-driven metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2410</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1158%2F0008-5472.CAN-14-3525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=25998620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2405-2410&author=S.+Ran&title=The+role+of+TLR4+in+chemotherapy-driven+metastasis&doi=10.1158%2F0008-5472.CAN-14-3525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of TLR4 in Chemotherapy-Driven Metastasis</span></div><div class="casAuthors">Ran, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2405-2410</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tumor resistance to cytotoxic drugs is one of the main obstacles to successful cancer therapy.  Emerging evidence suggests that chemoresistance is promoted by substances released from dead and damaged cells that activate the host repair program orchestrated by Toll-like receptor-4 (TLR4).  TLR4 is often overexpressed in malignant and tumor-infiltrating immune cells.  In addn. to endogenous ligands released by therapy-induced tumor destruction, TLR4 is directly activated by paclitaxel, one of the most commonly used chemotherapeutic drugs against various human cancers.  TLR4 activation promotes local and systemic inflammation, leading to induction of multiple circuits that create a regenerative environment favoring local recurrence and metastasis.  Of particular importance is TLR4-mediated recruitment of endothelial progenitors derived from immature myeloid cells.  These cells play a major role in rebuilding tumor-assocd. lymphatic and blood vessels, thereby promoting lymphatic and hematogenous metastasis.  The latter is further enhanced by the premetastatic niche generated by mobilization of myeloid provascular cells to distant organs.  This review summarizes the recent evidence demonstrating that paclitaxel and other clin. used anticancer drugs actively induce metastasis even while shrinking the primary tumor.  Better understanding of the mechanisms underlying TLR4-dependent chemotherapy-driven metastasis might be the key to overcoming challenges of cancer eradication.  Cancer Res; 75(12); 2405-10. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWGx96uNFs8LVg90H21EOLACvtfcHk0lgGDNKTL6AJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtb0%253D&md5=1e974998a7963b99bb052f145a097475</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3525%26sid%3Dliteratum%253Aachs%26aulast%3DRan%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520TLR4%2520in%2520chemotherapy-driven%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D2405%26epage%3D2410%26doi%3D10.1158%2F0008-5472.CAN-14-3525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The Next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+generation+of+platinum+drugs%3A+targeted+Pt%28II%29+agents%2C+nanoparticle+delivery%2C+and+Pt%28IV%29+prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0liBeCqpPyo5bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520generation%2520of%2520platinum%2520drugs%253A%2520targeted%2520Pt%2528II%2529%2520agents%252C%2520nanoparticle%2520delivery%252C%2520and%2520Pt%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward multi-targeted platinum and ruthenium drugs-a new paradigm in cancer drug treatment regimens?</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFWjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1058-1137&author=R.+G.+Kennyauthor=C.+J.+Marmion&title=Toward+multi-targeted+platinum+and+ruthenium+drugs-a+new+paradigm+in+cancer+drug+treatment+regimens%3F&doi=10.1021%2Facs.chemrev.8b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?</span></div><div class="casAuthors">Kenny, Reece G.; Marmion, Celine J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1058-1137</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While medicinal inorg. chem. has been practiced for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chem. that the authors began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes.  The authors can now readily manipulate and fine-tune their properties.  This had led to a multitude of complexes with wide-ranging biomedical applications.  This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer.  With major advances in technologies and a deeper understanding of the human genome, the authors are now in a strong position to more fully understand carcinogenesis at a mol. level.  The authors can now also rationally design and develop drug mols. that can either selectively enhance or disrupt key biol. processes and, in doing so, optimize their therapeutic potential.  This has heralded a new era in drug design in which the authors are moving from a single- toward a multitargeted approach.  This approach lies at the very heart of medicinal inorg. chem.  In this review, the authors have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities assocd. with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens.  The authors have focused the attention on metallodrugs incorporating platinum and ruthenium ions given that complexes contg. these metal ions are already in clin. use or have advanced to clin. trials as anticancer agents.  The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins.  Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described.  A summary of advances in this field over the past decade or so will be provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGLyZAECkbVrVg90H21EOLACvtfcHk0liBeCqpPyo5bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFWjsw%253D%253D&md5=025d0c10a0e3e4ba6d9f138bf14ac4a6</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DR.%2BG.%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520multi-targeted%2520platinum%2520and%2520ruthenium%2520drugs-a%2520new%2520paradigm%2520in%2520cancer%2520drug%2520treatment%2520regimens%253F%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1058%26epage%3D1137%26doi%3D10.1021%2Facs.chemrev.8b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular processing of platinum anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+processing+of+platinum+anticancer+drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0liBeCqpPyo5bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520processing%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0lg-kHvTfnOh6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kelland, L.</span></span> <span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lg-kHvTfnOh6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Functionalization of platinum complexes for biomedical applications</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2622</span>– <span class="NLM_lpage">2631</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.5b00203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.5b00203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12ksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=2622-2631&author=X.+Wangauthor=X.+Wangauthor=Z.+Guo&title=Functionalization+of+platinum+complexes+for+biomedical+applications&doi=10.1021%2Facs.accounts.5b00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalization of Platinum Complexes for Biomedical Applications</span></div><div class="casAuthors">Wang, Xiaoyong; Wang, Xiaohui; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2622-2631</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Platinum-based anticancer drugs are the mainstay of chemotherapy regimens in clinic.  Nevertheless, the efficacy of platinum drugs is badly affected by serious systemic toxicities and drug resistance, and the pharmacokinetics of most platinum drugs is largely unknown.  In recent years, a keen interest in functionalizing platinum complexes with bioactive mols., targeting groups, photosensitizers, fluorophores, or nanomaterials has been sparked among chem. and biomedical researchers.  The motivation for functionalization comes from some of the following demands: to improve the tumor selectivity or minimize the systemic toxicity of the drugs, to enhance the cellular accumulation of the drugs, to overcome the tumor resistance to the drugs, to visualize the drug mols. in vitro or in vivo, to achieve a synergistic anticancer effect between different therapeutic modalities, or to add extra functionality to the drugs.  In this Account, we present different strategies being used for functionalizing platinum complexes, including conjugation with bisphosphonates, peptides, receptor-specific ligands, polymers, nanoparticles, magnetic resonance imaging contrast agents, metal chelators, or photosensitizers.  Among them, bisphosphonates, peptides, and receptor-specific ligands are used for actively targeted drug delivery, polymers and nanoparticles are for passively targeted drug delivery, magnetic resonance imaging contrast agents are for theranostic purposes, metal chelators are for the treatment or prevention of Alzheimer's disease (AD), and photosensitizers are for photodynamic therapy of cancers.  The rationales behind these designs are explained and justified at the mol. or cellular level, assocg. with the requirements for diagnosis, therapy, and visualization of biol. processes.  To illustrate the wide range of opportunities and challenges that are emerging in this realm, representative examples of targeted drug delivery systems, anticancer conjugates, anticancer theranostic agents, and anti-AD compds. relevant to functionalized platinum complexes are provided.  All the examples exhibit new potential of platinum complexes for future applications in biomedical areas.  The emphases of this Account are placed on the functionalization for targeted drug delivery and theranostic agents.  In the end, a general assessment of various strategies has been made according to their major shortcomings and defects.  The original information in this Account comes entirely from literature appearing since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEy28kth_dh7Vg90H21EOLACvtfcHk0lg-kHvTfnOh6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12ksLrO&md5=58a24fcee133388bcb4e9070625e7656</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.5b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.5b00203%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DFunctionalization%2520of%2520platinum%2520complexes%2520for%2520biomedical%2520applications%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D2622%26epage%3D2631%26doi%3D10.1021%2Facs.accounts.5b00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The platin-X series: activation, targeting, and delivery</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12992</span>– <span class="NLM_lpage">3004</span>, <span class="refDoi"> DOI: 10.1039/C6DT01738J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT01738J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27493131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12992-3004&author=U.+Basuauthor=B.+Banikauthor=R.+Wenauthor=R.+K.+Pathakauthor=S.+Dhar&title=The+platin-X+series%3A+activation%2C+targeting%2C+and+delivery&doi=10.1039%2FC6DT01738J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Platin-X series: activation, targeting, and delivery</span></div><div class="casAuthors">Basu, Uttara; Banik, Bhabatosh; Wen, Ru; Pathak, Rakesh K.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12992-13004</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorg. chem.  Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation.  Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append addnl. functional groups/ligands for prodrug activation, tumor targeting, or drug delivery.  The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs.  Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery.  In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnol.-based delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYcK59HMDWBbVg90H21EOLACvtfcHk0lg-kHvTfnOh6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J&md5=3d4894b6935545dceab775c94b75d38c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC6DT01738J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01738J%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DU.%26aulast%3DBanik%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520platin-X%2520series%253A%2520activation%252C%2520targeting%252C%2520and%2520delivery%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12992%26epage%3D3004%26doi%3D10.1039%2FC6DT01738J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span> <span> </span><span class="NLM_article-title">Recent advances in platinum (IV) complex-based delivery systems to improve platinum (II) anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1002/med.21360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fmed.21360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26280923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1268-1299&author=X.+Hanauthor=J.+Sunauthor=Y.+Wangauthor=Z.+He&title=Recent+advances+in+platinum+%28IV%29+complex-based+delivery+systems+to+improve+platinum+%28II%29+anticancer+therapy&doi=10.1002%2Fmed.21360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span></div><div class="casAuthors">Han, Xiaopeng; Sun, Jin; Wang, Yongjun; He, Zhonggui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1268-1299</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum (Pt) (II) derivs. play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors.  However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies.  The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) mols. under the reducing intracellular environment, and has demonstrated encouraging preclin. and clin. outcomes.  Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the i.v.-to-oral switch in cancer chemotherapy.  The overview briefly analyzes statuses of Pt (II) complex that are in clin. use, and then focuses on the development of Pt (IV) complexes.  Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoorUB6a37jSbVg90H21EOLACvtfcHk0liCkaz5fS0xpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI&md5=7c99c1bbe8eb959b26ae3c3fa649ba1d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.21360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21360%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26atitle%3DRecent%2520advances%2520in%2520platinum%2520%2528IV%2529%2520complex-based%2520delivery%2520systems%2520to%2520improve%2520platinum%2520%2528II%2529%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D1268%26epage%3D1299%26doi%3D10.1002%2Fmed.21360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunschweiger, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">A carbohydrate-linked cisplatin analogue having antitumor activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1768</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19990614)38:12<1768::AID-ANIE1768>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADyaK1MXktVCntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=1768&author=Y.+Chenauthor=M.+J.+Heegauthor=P.+G.+Braunschweigerauthor=W.+Xieauthor=P.+G.+Wang&title=A+carbohydrate-linked+cisplatin+analogue+having+antitumor+activity&doi=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">A carbohydrate-linked cisplatin analogue having antitumor activity</span></div><div class="casAuthors">Chen, Yongsheng; Heeg, Mary J.; Braunschweiger, Paul G.; Xie, Wenhua; Wang, Peng G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1768-1769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">The authors report on the synthesis, characterization, and cytotoxicity of a novel carbohydrate-linked cisplatin analog, cis-dichloro[(2-3-D-glucopyranosidyl)propane-l,3-diamine]platinum (I).  I was characterized by 1H and 13C NMR spectroscopy which confirms complex formation in water.  The x-ray crystal structure anal. of I reveals that there are two independent mols. in the crystal.  In both mols., the intact and unprotected β-D-glucopyranose moiety is connected to platinum through the 2-propane-1,3-diamine linker group, which acts as a neutral bidendate ligand and coordinates through the two amino groups.  The coordination about platinum is roughly square planar as expected, and the six-membered chelate ring is in a chair conformation as is the glucopyranose ring.  The in vitro antitumor activity of I shows that it is as active as cisplatin against human ovarian cancer cell A278OS and human melanoma cancer cell MeWo, but less active against human ovarian cancer cell A2780cP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo54HRm2aRFI7Vg90H21EOLACvtfcHk0liCkaz5fS0xpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVCntLg%253D&md5=c480614723cccb5078b2a6a808a6c1a6</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819990614%252938%253A12%253C1768%253A%253AAID-ANIE1768%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHeeg%26aufirst%3DM.%2BJ.%26aulast%3DBraunschweiger%26aufirst%3DP.%2BG.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DA%2520carbohydrate-linked%2520cisplatin%2520analogue%2520having%2520antitumor%2520activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1999%26volume%3D38%26spage%3D1768%26doi%3D10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">11830</span>– <span class="NLM_lpage">11838</span>, <span class="refDoi"> DOI: 10.1039/C6DT02207C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT02207C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27373800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGnsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=11830-11838&author=J.+Maauthor=Q.+Wangauthor=X.+Yangauthor=W.+Haoauthor=Z.+Huangauthor=J.+Zhangauthor=X.+Wangauthor=P.+Wang&title=Glycosylated+platinum%28iv%29+prodrugs+demonstrated+significant+therapeutic+efficacy+in+cancer+cells+and+minimized+side-effects&doi=10.1039%2FC6DT02207C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylated platinum(IV) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects</span></div><div class="casAuthors">Ma, Jing; Wang, Qingpeng; Yang, Xiande; Hao, Wenpei; Huang, Zhonglv; Zhang, Jiabao; Wang, Xin; Wang, Peng George</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11830-11838</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugates (A1-A5) of the Pt(IV) deriv. (A6) with amino groups from peracetyl glucose, rhamnose and mannose with a Pr amino or Et amino linker at the reducing end were synthesized and exhibited significant therapeutic efficacy in tumor cells, esp. for prostate cancer (PCa).  The antitumor activities are greatly affected by glycosyl groups.  Cytotoxic expts. in vitro indicated that the antitumor activities were increased by 5-fold when its Pt(IV) deriv. was conjugated to S18 (IC50 = 4.82 ± 0.45 μM) and by 12-fold when conjugated to S21 (IC50 = 1.9 ± 0.67 μM).  The mannose substituted Pt(IV) complexes A4 and A5 were also over an order of magnitude more potent towards HeLa, A549, MCF-7 and PC3 than cisplatin and oxaliplatin.  Importantly, the glycosylated Pt(IV) derivs. A4 and A5 displayed potential safety for clin. therapeutic exposure with IC50 of 84 μM and 169 μM compared with cisplatin (IC50 = 8 μM) to 3T3.  Cellular uptake and DNA platination are higher than cisplatin and oxaliplatin.  ESI-MS anal. of A5 binding to 5'-dGMP revealed that bifunctional DNA lesions were formed.  The antitumor activities in vivo showed that the MTD and LD50 for A4 and A5 are nearly 4-fold higher than that of oxaliplatin indicating the potential safety for the glycosylated Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3OOKQeJIPAbVg90H21EOLACvtfcHk0liCkaz5fS0xpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGnsLvO&md5=b982d491d8176b4dc24c43cc97621d07</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1039%2FC6DT02207C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT02207C%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DGlycosylated%2520platinum%2528iv%2529%2520prodrugs%2520demonstrated%2520significant%2520therapeutic%2520efficacy%2520in%2520cancer%2520cells%2520and%2520minimized%2520side-effects%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D11830%26epage%3D11838%26doi%3D10.1039%2FC6DT02207C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10366</span>– <span class="NLM_lpage">10374</span>, <span class="refDoi"> DOI: 10.1039/C6DT01562J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT01562J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27252024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot12jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=10366-10374&author=Q.+Wangauthor=Z.+Huangauthor=J.+Maauthor=X.+Luauthor=L.+Zhangauthor=X.+Wangauthor=P.+G.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+a+novel+series+of+glycosylated+platinum%28iv%29+complexes+as+antitumor+agents&doi=10.1039%2FC6DT01562J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a novel series of glycosylated platinum(IV) complexes as antitumor agents</span></div><div class="casAuthors">Wang, Qingpeng; Huang, Zhonglv; Ma, Jing; Lu, Xiaolin; Zhang, Li; Wang, Xin; Peng, George Wang</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10366-10374</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new series of glycosylated Pt(IV) complexes were designed, synthesized and evaluated for antitumor activities in vitro and in vivo.  The incorporation of glycosyl groups to the Pt(IV) system has much influence on the antitumor abilities.  Four lead compds. with activities comparable or even superior to cisplatin and oxaliplatin are screened out.  These Pt(IV) complexes could be reduced to release Pt(II) complexes and cause the death of tumor cells.  The apoptosis-inducing properties of these compds. are similar to cisplatin.  The accumulation of the glycosylated Pt(IV) complexes in cells and DNA is higher than cisplatin and oxaliplatin.  The in vivo assay demonstrates that the tested compds. inhibit the growth of HepG2 tumors with low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgpmOlnnEHmbVg90H21EOLACvtfcHk0lhzJ_fBAFOGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot12jt78%253D&md5=afb0024161b9623d4dfa664eb41a7366</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1039%2FC6DT01562J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01562J%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520series%2520of%2520glycosylated%2520platinum%2528iv%2529%2520complexes%2520as%2520antitumor%2520agents%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D10366%26epage%3D10374%26doi%3D10.1039%2FC6DT01562J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Glycosylated platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5736</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00433</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00433" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5736-5748&author=J.+Maauthor=Q.+Wangauthor=Z.+Huangauthor=X.+Yangauthor=Q.+Nieauthor=W.+Haoauthor=P.+G.+Wangauthor=X.+Wang&title=Glycosylated+platinum%28IV%29+complexes+as+substrates+for+glucose+transporters+%28GLUTs%29+and+organic+cation+transporters+%28OCTs%29+exhibited+cancer+targeting+and+human+serum+albumin+binding+properties+for+drug+delivery&doi=10.1021%2Facs.jmedchem.7b00433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery</span></div><div class="casAuthors">Ma, Jing; Wang, Qingpeng; Huang, Zhonglv; Yang, Xiande; Nie, Quandeng; Hao, Wenpei; Wang, Peng George; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5736-5748</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycosylated platinum(IV) complexes were synthesized as substrates for GLUTs and OCTs for the first time, and the cytotoxicity, and detailed mechanism were detd. in vitro and in vivo.  Galactoside Pt(IV), glucoside Pt(IV) and mannoside Pt(IV) were highly cytotoxic and showed specific cancer-targeting properties in vitro and in vivo.  Glycosylated platinum(IV) complexes 5, 6, 7 and 8 (IC50 0.24 μM-3.97 μM) had better antitumor activity of nearly 166-fold higher than the pos. controls cisplatin, oxaliplatin and satraplatin.  The presence of a hexadecanoic chain allowed binding with human serum albumin (HSA) for drug delivery, which not only enhanced the stability of the inert platinum(IV) prodrugs but also decreased their redn. by reductants present in human whole blood.  Their preferential accumulation in cancer cells compared to noncancerous cells (293T and 3T3 cells) suggested that they were potentially safe for clin. therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLg2UiwsXTgrVg90H21EOLACvtfcHk0lhzJ_fBAFOGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktbY%253D&md5=dbd924c79581b064cfa46733cc84eaf0</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00433%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DNie%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlycosylated%2520platinum%2528IV%2529%2520complexes%2520as%2520substrates%2520for%2520glucose%2520transporters%2520%2528GLUTs%2529%2520and%2520organic%2520cation%2520transporters%2520%2528OCTs%2529%2520exhibited%2520cancer%2520targeting%2520and%2520human%2520serum%2520albumin%2520binding%2520properties%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5736%26epage%3D5748%26doi%3D10.1021%2Facs.jmedchem.7b00433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.ejmech.2017.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=28147308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVGmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=45-55&author=J.+Maauthor=X.+Yangauthor=W.+Haoauthor=Z.+Huangauthor=X.+Wangauthor=P.+G.+Wang&title=Mono-functionalized+glycosylated+platinum%28IV%29+complexes+possessed+both+pH+and+redox+dual-responsive+properties%3A+exhibited+enhanced+safety+and+preferentially+accumulated+in+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2017.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo</span></div><div class="casAuthors">Ma, Jing; Yang, Xiande; Hao, Wenpei; Huang, Zhonglv; Wang, Xin; Wang, Peng George</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-55</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A serious of carbohydrate-conjugated platinum(IV) complexes in the form Pt(L2)(A2)(OH)R based on the clin. drug cisplatin and oxaliplatin were designed, synthesized and evaluated as antitumor agents in vitro and in vivo.  The conjugates possessing both pH and redox dual-responsive properties exhibited more potent cytotoxicity in seven different human cancer cell lines and lower toxicity to the normal 3T3 cells than cisplatin, oxaliplatin and even the reported bis-functionalized glycosylated platinum(IV) complexes indicating the enhanced safety of the sugar conjugates.  Cellular drug uptake and DNA platination were also superior to cisplatin, oxaliplatin and the reported bis-functionalized ones.  Peak current of B7 and B8 with the scan rate of 200mv/s at the concn. of 0.08 mM was 5-fold higher at pH 6.4 than the pH 7.4, indicating that carbohydrate-conjugated mono-functionalized platinum(IV) complexes possessed both pH and redox dual-responsive properties in the cancer cells.  The in vivo assays demonstrated that the Pt(IV) compds. could inhibit the growth of MCF-7 tumor and exert more safety than oxaliplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7wmUkHiGWH7Vg90H21EOLACvtfcHk0lhzJ_fBAFOGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVGmu74%253D&md5=1d29702c6ff32c318f6d83c1a163466c</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DMono-functionalized%2520glycosylated%2520platinum%2528IV%2529%2520complexes%2520possessed%2520both%2520pH%2520and%2520redox%2520dual-responsive%2520properties%253A%2520exhibited%2520enhanced%2520safety%2520and%2520preferentially%2520accumulated%2520in%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D128%26spage%3D45%26epage%3D55%26doi%3D10.1016%2Fj.ejmech.2017.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Protected and de-protected platinum(IV) glycoconjugates with GLUT1 and OCT2-mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">386</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3389%2Ffchem.2018.00386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30298127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1WlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=386&author=J.+Maauthor=H.+Liuauthor=Z.+Xiauthor=J.+Houauthor=Y.+Liauthor=J.+Niuauthor=T.+Liuauthor=S.+Biauthor=X.+Wangauthor=C.+Wangauthor=J.+Wangauthor=S.+Xieauthor=P.+G.+Wang&title=Protected+and+de-protected+platinum%28IV%29+glycoconjugates+with+GLUT1+and+OCT2-mediated+selective+cancer+targeting%3A+demonstrated+enhanced+transporter-mediated+cytotoxic+properties+in+vitro+and+in+vivo&doi=10.3389%2Ffchem.2018.00386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">Protected and de-protected platinum(IV) glycoconjugates with GLUT1 and OCT2-Mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo</span></div><div class="casAuthors">Ma, Jing; Liu, Hanfang; Xi, Zhuoqing; Hou, Jiuzhou; Li, Yingguang; Niu, Jie; Liu, Tong; Bi, Shuning; Wang, Xin; Wang, Chaojie; Wang, Jiajia; Xie, Songqiang; Wang, Peng G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">386</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Physiol. characteristics of human malignancies are increased glycolysis and overexpression of glucose transporters (GLUTs). 18Flurodeoxyglucose-positron emission tomog. (FDG-PET) has successfully developed as clin. modality for the diagnosis and staging of many cancers based on the Warburg effect.  To leverage this glucose transporter mediated metabolic disparity between normal and malignant cells, in the current report, protected, and de-protected glucose, mannose, galactose, rhamnose, maltose, and lactose-conjugated platinum(IV) complexes were designed and synthesized.  The suggested potential of facilitated i.v. to oral switching of glycosylated platinum(IV) prodrugs with cancer-targeting properties were evaluated for glucose transporter 1 (GLUT1) and org. cation transporter 2 (OCT2)-mediated selective properties in vitro and in vivo.  The cytotoxicity of 2d, 5d, and 6d were ∼23-fold greater than that of the pos. controls cisplatin, oxaliplatin, and satraplatin, resp.  The leading compd. 6d, the IC50 of which with the GLUT1 inhibitor 4,6-oethylidene-α-D-glucose (EDG) and phloretin (31.80 and 38.71 μM) are 36- and 44-folds higher, resp., than the 48 h IC50 (0.89 μM), is superior to the reported 5-8, exhibiting enhanced cancer targeting.  The compds. also showed reduced toxicity to normal cells (293T IC50 = 12.06 μM and 3T3 cells IC50 > 100 μM) and exhibited no cross-resistance to cisplatin.  Moreover, the encouraging selectivity of 6d for MCF-7 cells in vivo indicated that the pyranoside performs an important function in cancer targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOU1rG71vy_rVg90H21EOLACvtfcHk0lj1LjW5Vdpo4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1WlsL0%253D&md5=508046f05c910f59014fe883b25b9927</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00386%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXi%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DBi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DProtected%2520and%2520de-protected%2520platinum%2528IV%2529%2520glycoconjugates%2520with%2520GLUT1%2520and%2520OCT2-mediated%2520selective%2520cancer%2520targeting%253A%2520demonstrated%2520enhanced%2520transporter-mediated%2520cytotoxic%2520properties%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D386%26doi%3D10.3389%2Ffchem.2018.00386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.bmc.2019.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30852077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlOmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1639-1645&author=H.+Wangauthor=X.+Yangauthor=C.+Zhaoauthor=P.+G.+Wangauthor=X.+Wang&title=Glucose-conjugated+platinum%28IV%29+complexes+as+tumor-targeting+agents%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.bmc.2019.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation</span></div><div class="casAuthors">Wang, Haifeng; Yang, Xiande; Zhao, Caili; Wang, Peng George; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of glucose-conjugated Pt(IV) complexes that target tumor-specific glucose transporters (GLUTs) was designed, synthesized, and evaluated for their anticancer activities.  All six compds., namely, A1-A6, exhibited increased cytotoxicity that were almost six fold higher than that of oxaliplatin to MCF-7 cells.  These Pt(IV) complexes can be reduced to release Pt(II) complexes and cause the death of tumor cells.  Simultaneously, the glycosylated Pt(IV) complexes (30.21-91.33 μM) showed lower cytotoxicity that normal LO2 cells compared with cisplatin (5.25 μM) and oxaliplatin (8.34 μM).  The intervention of phlorizin as a GLUTs inhibitor increased the IC50 value of the glycosylated Pt(IV) complexes, thereby indicating the potential GLUT transportability.  The introduction of glucose moiety to Pt(IV) complexes can effectively enhance the Pt cellular uptake and DNA platination.  Results suggested glucose-conjugated Pt(IV) complexes had potential for further study as new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoantqNsI0OZLVg90H21EOLACvtfcHk0lj1LjW5Vdpo4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlOmsb0%253D&md5=76b4950efc459bdeca9416d9b04888bf</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlucose-conjugated%2520platinum%2528IV%2529%2520complexes%2520as%2520tumor-targeting%2520agents%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1639%26epage%3D1645%26doi%3D10.1016%2Fj.bmc.2019.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giljohann, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">14652</span>– <span class="NLM_lpage">14653</span>, <span class="refDoi"> DOI: 10.1021/ja9071282</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9071282" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=14652-14653&author=S.+Dharauthor=W.+L.+Danielauthor=D.+A.+Giljohannauthor=C.+A.+Mirkinauthor=S.+J.+Lippard&title=Polyvalent+oligonucleotide+gold+nanoparticle+conjugates+as+delivery+vehicles+for+platinum%28IV%29+warheads&doi=10.1021%2Fja9071282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads</span></div><div class="casAuthors">Dhar, Shanta; Daniel, Weston L.; Giljohann, David A.; Mirkin, Chad A.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">14652-14653</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amine-functionalized polyvalent oligonucleotide gold nanoparticles (DNA-Au NPs) were derivatized with a cisplatin prodrug, and the resulting DNA-Au NP conjugates were used to internalize multiple platinum centers.  A platinum(IV) complex, c,c,t-[Pt(NH3)2Cl2(OH)(O2CCH2CH2CO2H)], was tethered to the surface of DNA-Au NPs through amide linkages.  The platinum-tethered gold nanoparticles were taken into several cancer cells.  The drop in intracellular pH facilitated reductive release of cisplatin from the prodrug, which then formed 1,2-d(GpG) intrastrand crosslinks in the cell nuclei, as confirmed by an antibody specific for this adduct.  The cytotoxicity of the platinum(IV) complex increases significantly in several cancer cell lines when the complex is attached to the surface of the DNA-Au NPs and in some instances exceeds that of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4FDJuVSsfprVg90H21EOLACvtfcHk0lj1LjW5Vdpo4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurrM&md5=ab726464c915c4ba3785c9572f089c8f</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fja9071282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9071282%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DS.%26aulast%3DDaniel%26aufirst%3DW.%2BL.%26aulast%3DGiljohann%26aufirst%3DD.%2BA.%26aulast%3DMirkin%26aufirst%3DC.%2BA.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPolyvalent%2520oligonucleotide%2520gold%2520nanoparticle%2520conjugates%2520as%2520delivery%2520vehicles%2520for%2520platinum%2528IV%2529%2520warheads%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D14652%26epage%3D14653%26doi%3D10.1021%2Fja9071282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Negrerie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span> <span> </span><span class="NLM_article-title">Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2421</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1039/c3cc38589b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2Fc3cc38589b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=23420130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVClt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2421-2423&author=P.+Liuauthor=Y.+Luauthor=X.+Gaoauthor=R.+Liuauthor=D.+Zhang-Negrerieauthor=Y.+Shiauthor=Y.+Wangauthor=S.+Wangauthor=Q.+Gao&title=Highly+water-soluble+platinum%28II%29+complexes+as+GLUT+substrates+for+targeted+therapy%3A+improved+anticancer+efficacy+and+transporter-mediated+cytotoxic+properties&doi=10.1039%2Fc3cc38589b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties</span></div><div class="casAuthors">Liu, Pengxing; Lu, Yanhui; Gao, Xiangqian; Liu, Ran; Zhang-Negrerie, Daisy; Shi, Ying; Wang, Yiqiang; Wang, Songqing; Gao, Qingzhi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2421-2423</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Glucose-conjugated malonato Pt(II) R,R-cyclohexanediamine complexes are designed and synthesized to target tumor-specific active transporters, namely, glucose transporters (GLUTs).  The complexes exhibit much higher aq. soly. by 150 times, improved potency in cytotoxicities by 10 times, and increased therapeutic index by over 30 fold compared to the newest generation of clin. drugs oxaliplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbUs-f_ZR-LVg90H21EOLACvtfcHk0liWLItsPC5bQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVClt7w%253D&md5=dc9b30b67047b8b9797965e40eff516f</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1039%2Fc3cc38589b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc38589b%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DZhang-Negrerie%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DHighly%2520water-soluble%2520platinum%2528II%2529%2520complexes%2520as%2520GLUT%2520substrates%2520for%2520targeted%2520therapy%253A%2520improved%2520anticancer%2520efficacy%2520and%2520transporter-mediated%2520cytotoxic%2520properties%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D2421%26epage%3D2423%26doi%3D10.1039%2Fc3cc38589b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.-R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0liWLItsPC5bQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">7427</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1039/C4CC00419A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC4CC00419A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=24777030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=7427-7430&author=Q.+Chengauthor=H.+Shiauthor=H.+Wangauthor=Y.+Minauthor=J.+Wangauthor=Y.+Liu&title=The+ligation+of+aspirin+to+cisplatin+demonstrates+significant+synergistic+effects+on+tumor+cells&doi=10.1039%2FC4CC00419A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span></div><div class="casAuthors">Cheng, Qinqin; Shi, Hongdong; Wang, Hongxia; Min, Yuanzeng; Wang, Jun; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">7427-7430</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells.  Asplatin is highly accumulated in cancer cells and is activated upon the redn. by ascorbic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT52MltZpsqbVg90H21EOLACvtfcHk0liWLItsPC5bQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO&md5=5679afe1ad21bd6c6181aa0bd6d1f2fe</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1039%2FC4CC00419A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC00419A%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DThe%2520ligation%2520of%2520aspirin%2520to%2520cisplatin%2520demonstrates%2520significant%2520synergistic%2520effects%2520on%2520tumor%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D7427%26epage%3D7430%26doi%3D10.1039%2FC4CC00419A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The prodrug platin-A: simultaneous release of cisplatin and aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+prodrug+platin-A%3A+simultaneous+release+of+cisplatin+and+aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12eR"><div class="casContent"><span class="casTitleNuber">12e</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0liMQmuKot-rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520prodrug%2520platin-A%253A%2520simultaneous%2520release%2520of%2520cisplatin%2520and%2520aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12fR"><div class="casContent"><span class="casTitleNuber">12f</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0liMQmuKot-rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostrhunova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Křikavova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vančo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trávníček, Z.vn</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span> <span> </span><span class="NLM_article-title">A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">14478</span>– <span class="NLM_lpage">14482</span>, <span class="refDoi"> DOI: 10.1002/anie.201506533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201506533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26458068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1elurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=14478-14482&author=J.+Kasparkovaauthor=H.+Kostrhunovaauthor=O.+Novakovaauthor=R.+K%C5%99ikavovaauthor=J.+Van%C4%8Doauthor=Z.vn+Tr%C3%A1vn%C3%AD%C4%8Dekauthor=V.+Brabec&title=A+photoactivatable+platinum%28IV%29+complex+targeting+genomic+DNA+and+histone+deacetylases&doi=10.1002%2Fanie.201506533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12gR"><div class="casContent"><span class="casTitleNuber">12g</span><div class="casTitle"><span class="NLM_cas:atitle">A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases</span></div><div class="casAuthors">Kasparkova, Jana; Kostrhunova, Hana; Novakova, Olga; Krikavova, Radka; Vanco, Jan; Travnicek, Zdenek; Brabec, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14478-14482</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We report toxic effects of a photoactivatable platinum(IV) complex conjugated with suberoyl-bis-hydroxamic acid in tumor cells.  The conjugate exerts, after photoactivation, two functions: activity as both a platinum(II) anticancer drug and histone deacetylase (HDAC) inhibitor in cancer cells.  This approach relies on the use of a PtIV pro-drug, acting by two independent mechanisms of biol. action in a cooperative manner, which can be selectively photoactivated to a cytotoxic species in and around a tumor, thereby increasing selectivity towards cancer cells.  These results suggest that this strategy is a valuable route to design new platinum agents with higher efficacy for photodynamic anticancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFWLgeS4R17Vg90H21EOLACvtfcHk0liMQmuKot-rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1elurzF&md5=e4f315406af6835aae45931c24e91129</span></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506533%26sid%3Dliteratum%253Aachs%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DKostrhunova%26aufirst%3DH.%26aulast%3DNovakova%26aufirst%3DO.%26aulast%3DK%25C5%2599ikavova%26aufirst%3DR.%26aulast%3DVan%25C4%258Do%26aufirst%3DJ.%26aulast%3DTr%25C3%25A1vn%25C3%25AD%25C4%258Dek%26aufirst%3DZ.vn%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DA%2520photoactivatable%2520platinum%2528IV%2529%2520complex%2520targeting%2520genomic%2520DNA%2520and%2520histone%2520deacetylases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D14478%26epage%3D14482%26doi%3D10.1002%2Fanie.201506533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexselblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novohradsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuchlikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2381</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1039/C5SC04205D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC5SC04205D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29997781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2381-2391&author=R.+Raveendranauthor=J.+P.+Braudeauthor=E.+Wexselblattauthor=V.+Novohradskyauthor=O.+Stuchlikovaauthor=V.+Brabecauthor=V.+Gandinauthor=D.+Gibson&title=Pt%28iv%29+derivatives+of+cisplatin+and+oxaliplatin+with+phenylbutyrate+axial+ligands+are+potent+cytotoxic+agents+that+act+by+several+mechanisms+of+action&doi=10.1039%2FC5SC04205D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12hR"><div class="casContent"><span class="casTitleNuber">12h</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action</span></div><div class="casAuthors">Raveendran, Raji; Braude, Jeremy Phillip; Wexselblatt, Ezequiel; Novohradsky, Vojtech; Stuchlikova, Olga; Brabec, Viktor; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2381-2391</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Our study demonstrates that Pt(IV) deriv. of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)2(PhB)2Cl2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(IV) derivs. of cisplatin with either two hydroxido, two acetato or two valproato ligands.  The high potency of this compd. (and some others) is due to several factors including enhanced internalization, probably driven by "synergistic accumulation" of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity.  Ctc-[Pt(NH3)2(PhB)2Cl2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB.  Mechanistically, ctc-[Pt(NH3)2(PhB)2Cl2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway.  Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)2(PhB)2Cl2] may not depend of p53.  Pt(IV) derivs. of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs.  Ctc-[Pt(NH3)2(PhB)2Cl2] is significantly more potent than its valproate analog ctc-[Pt(NH3)2(VPA)2Cl2].  These compds. combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvxQyimpaX7Vg90H21EOLACvtfcHk0liMQmuKot-rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVOlsg%253D%253D&md5=0599753b615d64adcf6a4014defc1327</span></div><a href="/servlet/linkout?suffix=cit12h&amp;dbid=16384&amp;doi=10.1039%2FC5SC04205D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC04205D%26sid%3Dliteratum%253Aachs%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DWexselblatt%26aufirst%3DE.%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DStuchlikova%26aufirst%3DO.%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPt%2528iv%2529%2520derivatives%2520of%2520cisplatin%2520and%2520oxaliplatin%2520with%2520phenylbutyrate%2520axial%2520ligands%2520are%2520potent%2520cytotoxic%2520agents%2520that%2520act%2520by%2520several%2520mechanisms%2520of%2520action%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D2381%26epage%3D2391%26doi%3D10.1039%2FC5SC04205D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thiabaud, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arambula, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddik, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessler, J. L.</span></span> <span> </span><span class="NLM_article-title">Activation of platinum(IV) prodrugs by motexafin gadolinium as a redox mediator</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">12626</span>– <span class="NLM_lpage">12631</span>, <span class="refDoi"> DOI: 10.1002/anie.201604236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201604236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSqurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=12626-12631&author=G.+Thiabaudauthor=R.+McCallauthor=G.+Heauthor=J.+F.+Arambulaauthor=Z.+H.+Siddikauthor=J.+L.+Sessler&title=Activation+of+platinum%28IV%29+prodrugs+by+motexafin+gadolinium+as+a+redox+mediator&doi=10.1002%2Fanie.201604236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12iR"><div class="casContent"><span class="casTitleNuber">12i</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator</span></div><div class="casAuthors">Thiabaud, Gregory; McCall, Rebecca; He, Guangan; Arambula, Jonathan F.; Siddik, Zahid H.; Sessler, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12626-12631</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Water-sol. platinum(IV) prodrugs, which proved kinetically stable to redn. in the presence of physiol. concn. of ascorbate, were quickly reduced to their active form, oxaliplatin, when co-incubated with a macrocycle metallotexaphyrin (i.e., Motexafin Gadolinium (MGd)).  The redn. of PtIV to PtII promoted by MGd occurs in cell culture as well, leading to an increase in the antiproliferative activity of the PtIV species in question.  The mediated effect is proportional to the concn. of MGd and gives rise to an enhancement when the prodrug is relatively hydrophilic.  MGd is known to localize/accumulate preferentially in tumor tissues.  Thus, the present "activation by redn." approach may allow for the cancer-selective enhancement in the cytotoxicity of PtIV prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEZj9_gnwFvLVg90H21EOLACvtfcHk0liUcNnkrguryA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSqurbP&md5=6439e251e563a34966392a6c2e0cee78</span></div><a href="/servlet/linkout?suffix=cit12i&amp;dbid=16384&amp;doi=10.1002%2Fanie.201604236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201604236%26sid%3Dliteratum%253Aachs%26aulast%3DThiabaud%26aufirst%3DG.%26aulast%3DMcCall%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DArambula%26aufirst%3DJ.%2BF.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26aulast%3DSessler%26aufirst%3DJ.%2BL.%26atitle%3DActivation%2520of%2520platinum%2528IV%2529%2520prodrugs%2520by%2520motexafin%2520gadolinium%2520as%2520a%2520redox%2520mediator%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D12626%26epage%3D12631%26doi%3D10.1002%2Fanie.201604236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Biotin-tagged platinum(iv) complexes as targeted cytostatic agents against breast cancer cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9974</span>, <span class="refDoi"> DOI: 10.1039/C7CC05311H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC7CC05311H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=28831477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=9971-9974&author=N.+Muhammadauthor=N.+Sadiaauthor=C.+Zhuauthor=C.+Luoauthor=Z.+Guoauthor=X.+Wang&title=Biotin-tagged+platinum%28iv%29+complexes+as+targeted+cytostatic+agents+against+breast+cancer+cells&doi=10.1039%2FC7CC05311H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12jR"><div class="casContent"><span class="casTitleNuber">12j</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span></div><div class="casAuthors">Muhammad, Nafees; Sadia, Nasreen; Zhu, Chengcheng; Luo, Cheng; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">72</span>),
    <span class="NLM_cas:pages">9971-9974</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A biotin-guided platinumIV complex is highly cytotoxic against breast cancer cells but hypotoxic against mammary epithelial cells.  The mono-biotinylated PtIV complex is superior to the di-biotinylated one and hence a promising drug candidate for the targeted therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojsf_nE7HGsrVg90H21EOLACvtfcHk0liUcNnkrguryA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO&md5=e0003ab9a6a3ef976136f8ea223433e5</span></div><a href="/servlet/linkout?suffix=cit12j&amp;dbid=16384&amp;doi=10.1039%2FC7CC05311H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC05311H%26sid%3Dliteratum%253Aachs%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DSadia%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DBiotin-tagged%2520platinum%2528iv%2529%2520complexes%2520as%2520targeted%2520cytostatic%2520agents%2520against%2520breast%2520cancer%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D9971%26epage%3D9974%26doi%3D10.1039%2FC7CC05311H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AldrichWright, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">A quadruple-action platinum(IV) prodrug with anticancer activity against KRAS mutated cancer cell lines</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">11539</span>– <span class="NLM_lpage">11544</span>, <span class="refDoi"> DOI: 10.1002/anie.201706739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201706739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=11539-11544&author=E.+Petruzzellaauthor=J.+P.+Braudeauthor=J.+R.+AldrichWrightauthor=V.+Gandinauthor=D.+Gibson&title=A+quadruple-action+platinum%28IV%29+prodrug+with+anticancer+activity+against+KRAS+mutated+cancer+cell+lines&doi=10.1002%2Fanie.201706739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12kR"><div class="casContent"><span class="casTitleNuber">12k</span><div class="casTitle"><span class="NLM_cas:atitle">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines</span></div><div class="casAuthors">Petruzzella, Emanuele; Braude, Jeremy Phillip; Aldrich-Wright, Janice R.; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">11539-11544</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a novel PtIV prodrug that simultaneously releases four different bioactive moieties inside the cancer cell.  Its cytotoxicity against monolayer cultures (2D) and spheroid (3D) cancer cells is significantly better than cisplatin.  It is 200-450-fold more potent than cisplatin against KRAS mutated pancreatic and colon cancers and is 40-fold more selective towards KRAS mutated cells compared to non-cancerous.  This is important since RAS proteins play a role in regulating cell differentiation, proliferation, and survival and KRAS is mutated in 90 % of pancreatic adenocarcinomas, 45 % of colorectal cancers, and 35 % of lung adenocarcinomas.  The selectivity index, detd. by dividing the IC50 value in non-cancerous cells by that of a cancerous cell line, is two-fold better than cisplatin, attesting to preferential cytotoxicity towards neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQHgQHWGMgbVg90H21EOLACvtfcHk0lg6UHfYlfoffQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ&md5=4a9c4fcc8d6006775b09c9e4c246d175</span></div><a href="/servlet/linkout?suffix=cit12k&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706739%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DAldrichWright%26aufirst%3DJ.%2BR.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DA%2520quadruple-action%2520platinum%2528IV%2529%2520prodrug%2520with%2520anticancer%2520activity%2520against%2520KRAS%2520mutated%2520cancer%2520cell%2520lines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D11539%26epage%3D11544%26doi%3D10.1002%2Fanie.201706739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Monochalcoplatin: an actively transported, quickly reducible, and highly potent Pt(IV) anticancer prodrug</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9098</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1002/anie.201804314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201804314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=9098-9102&author=L.+Maauthor=N.+Wangauthor=R.+Maauthor=C.+Liauthor=Z.+Xuauthor=M.+K.+Tseauthor=G.+Zhu&title=Monochalcoplatin%3A+an+actively+transported%2C+quickly+reducible%2C+and+highly+potent+Pt%28IV%29+anticancer+prodrug&doi=10.1002%2Fanie.201804314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12lR"><div class="casContent"><span class="casTitleNuber">12l</span><div class="casTitle"><span class="NLM_cas:atitle">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug</span></div><div class="casAuthors">Ma, Lili; Wang, Na; Ma, Rong; Li, Cai; Xu, Zoufeng; Tse, Man-Kit; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">9098-9102</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recently, PtIV prodrugs have attracted much attention as the next generation of platinum-based antineoplastic drug candidates.  Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated PtIV prodrug that is among the most cytotoxic PtIV prodrugs to date.  Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin accumulates astonishingly effectively and rapidly in cancer cells, which is not ascribed to its lipophilicity.  The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin-sensitive and -resistant cells; these IC50 values are up to 422-fold higher than that of cisplatin.  A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter-mediated process.  Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model.  Our study implies a practical strategy for the design of more effective PtIV prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWzOjWinSirVg90H21EOLACvtfcHk0lg6UHfYlfoffQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ&md5=ef0e0d30da62acf13f0ceeb6729961c7</span></div><a href="/servlet/linkout?suffix=cit12l&amp;dbid=16384&amp;doi=10.1002%2Fanie.201804314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201804314%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DTse%26aufirst%3DM.%2BK.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DMonochalcoplatin%253A%2520an%2520actively%2520transported%252C%2520quickly%2520reducible%252C%2520and%2520highly%2520potent%2520Pt%2528IV%2529%2520anticancer%2520prodrug%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D9098%26epage%3D9102%26doi%3D10.1002%2Fanie.201804314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solazzo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4307</span>, <span class="refDoi"> DOI: 10.1039/C8SC00428E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC8SC00428E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29780561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4299-4307&author=E.+Petruzzellaauthor=R.+Sirotaauthor=I.+Solazzoauthor=V.+Gandinauthor=D.+Gibson&title=Triple+action+Pt%28iv%29+derivatives+of+cisplatin%3A+a+new+class+of+potent+anticancer+agents+that+overcome+resistance&doi=10.1039%2FC8SC00428E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12mR"><div class="casContent"><span class="casTitleNuber">12m</span><div class="casTitle"><span class="NLM_cas:atitle">Triple action Pt(IV) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance</span></div><div class="casAuthors">Petruzzella, Emanuele; Sirota, Roman; Solazzo, Irene; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4299-4307</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of triple action Pt(IV) prodrugs was designed to test the hypothesis that multi-action compds., where each bioactive moiety intervenes in several cellular processes, might be more effective than a single agent at killing cancer cells.  In particular, "triple action" Pt(IV) derivs. of cisplatin, where the axial ligands are inhibitors of cyclooxygenase (COXi), histone deacetylase (HDACi) or pyruvate dehydrogenase kinase (PDKi) were developed.  All compds., ctc-[Pt(NH3)2(COXi)(PDKi)Cl2], ctc-[Pt(NH3)2(COXi)(HDACi)Cl2] and ctc-[Pt(NH3)2(HDACi)(PDKi)Cl2], where COXi = aspirin or ibuprofen, PDKi = dichloroacetate and HDACi = valproate or phenylbutyrate, were significantly more cytotoxic than cisplatin against all cell lines of an inhouse panel of human cancer cells.  They were particularly effective against thyroid and pancreatic cancer cells in monolayer cytotoxicity tests.  Remarkably, in 3D spheroid cancer cell cultures, some triple action compds. showed an antitumor potency up to 50-fold higher than cisplatin against a KRAS mutated pancreatic cancer cell line (PSN-1 cells).  Std. biochem. assays classically employed to explore structure activity relationships of platinum drugs, such as cellular uptake and binding to potential biol. targets (DNA, HDAC, mitochondria, and COX), do not provide linear correlations with the overall cytotoxicity data.  We obsd. a preferential induction of ROS prodn. and of an anti-mitochondrial effect in cancer cells compared to rapidly dividing non-cancerous cells.  Thus, we propose that these new triple action Pt(IV) derivs. of cisplatin are a novel and interesting class of potent and selective cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJYZX5ATGxKbVg90H21EOLACvtfcHk0lg6UHfYlfoffQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOjs7o%253D&md5=439d568dae37ac7bb387b4b2055d1ecd</span></div><a href="/servlet/linkout?suffix=cit12m&amp;dbid=16384&amp;doi=10.1039%2FC8SC00428E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC00428E%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DSirota%26aufirst%3DR.%26aulast%3DSolazzo%26aufirst%3DI.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DTriple%2520action%2520Pt%2528iv%2529%2520derivatives%2520of%2520cisplatin%253A%2520a%2520new%2520class%2520of%2520potent%2520anticancer%2520agents%2520that%2520overcome%2520resistance%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D4299%26epage%3D4307%26doi%3D10.1039%2FC8SC00428E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Restraining cancer cells by dual metabolic inhibition with a mitochondrion-targeted platinum(II) complex</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4643</span>, <span class="refDoi"> DOI: 10.1002/anie.201900387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12n&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201900387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Kht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4638-4643&author=K.+Wangauthor=C.+Zhuauthor=Y.+Heauthor=Z.+Zhangauthor=W.+Zhouauthor=N.+Muhammadauthor=Y.+Guoauthor=X.+Wangauthor=Z.+Guo&title=Restraining+cancer+cells+by+dual+metabolic+inhibition+with+a+mitochondrion-targeted+platinum%28II%29+complex&doi=10.1002%2Fanie.201900387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12nR"><div class="casContent"><span class="casTitleNuber">12n</span><div class="casTitle"><span class="NLM_cas:atitle">Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion-Targeted Platinum(II) Complex</span></div><div class="casAuthors">Wang, Kun; Zhu, Chengcheng; He, Yafeng; Zhang, Zhenqin; Zhou, Wen; Muhammad, Nafees; Guo, Yan; Wang, Xiaoyong; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4638-4643</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer cells usually adapt metabolic phenotypes to chemotherapeutics.  A defensive strategy against this flexibility is to modulate signaling pathways relevant to cancer bioenergetics.  A triphenylphosphonium-modified terpyridine platinum(II) complex (TTP) was designed to inhibit thioredoxin reductase (TrxR) and multiple metabs. of cancer cells.  TTP exhibited enhanced cytotoxicity against cisplatin-insensitive human ovarian cancer cells in a caspase-3-independent manner and showed preferential inhibition to mitochondrial TrxR.  The morphol. and function of mitochondria were severely damaged, and the levels of mitochondrial and cellular reactive oxygen species were decreased.  As a result, TTP exerted strong inhibition to both mitochondrial and glycolytic bioenergetics, thus inducing cancer cells to enter a hypometabolic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMychFILZP_rVg90H21EOLACvtfcHk0li3bvKCDggDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Kht7o%253D&md5=53980c843fcfc333ad9d1943fa701faf</span></div><a href="/servlet/linkout?suffix=cit12n&amp;dbid=16384&amp;doi=10.1002%2Fanie.201900387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201900387%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DRestraining%2520cancer%2520cells%2520by%2520dual%2520metabolic%2520inhibition%2520with%2520a%2520mitochondrion-targeted%2520platinum%2528II%2529%2520complex%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D4638%26epage%3D4643%26doi%3D10.1002%2Fanie.201900387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3089</span>– <span class="NLM_lpage">3095</span>, <span class="refDoi"> DOI: 10.1039/C8SC04871A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC8SC04871A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30996891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVymtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3089-3095&author=Z.+Zhuauthor=Z.+Wangauthor=C.+Zhangauthor=Y.+Wangauthor=H.+Zhangauthor=Z.+Ganauthor=Z.+Guoauthor=X.+Wang&title=Mitochondrion-targeted+platinum+complexes+suppressing+lung+cancer+through+multiple+pathways+involving+energy+metabolism&doi=10.1039%2FC8SC04871A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12oR"><div class="casContent"><span class="casTitleNuber">12o</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism</span></div><div class="casAuthors">Zhu, Zhenzhu; Wang, Zenghui; Zhang, Changli; Wang, Yanjun; Zhang, Hongmei; Gan, Zhenji; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3089-3095</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mitochondria are potential therapeutic targets for anticancer drugs.  A series of mitochondrion-targeted monofunctional platinum complexes, [Pt(ortho-PPh3CH2Py)(NH3)2Cl](NO3)2 (OPT), [Pt(meta-PPh3CH2Py)(NH3)2Cl](NO3)2 (MPT), and [Pt(para-PPh3CH2Py)(NH3)2Cl](NO3)2 (PPT) (PPh3 = triphenylphosphonium, Py = pyridine), are studied in this article.  The antitumor activity and mechanism of action have been investigated in vitro and in vivo as well as on mol. levels.  OPT exhibits higher efficacy than cisplatin against A549 lung cancer cells; furthermore, it shows a strong inhibition towards the growth of non-small-cell lung cancer in nude mice.  The DNA binding ability of these complexes follows an order of PPT > OPT > MPT.  Cellular uptake and distribution studies show that OPT accumulates mainly in mitochondria, while MPT and PPT accumulate more preferentially in nuclei than in mitochondria.  As a result, OPT induces remarkable changes in the ultrastructure and membrane of mitochondria, leading to more radical mitochondrial dysfunctions than cisplatin.  The release of cytochrome c from mitochondria is more evident for cells treated with OPT than with cisplatin, though the apoptosis of A549 cells induced by OPT is similar to that induced by cisplatin.  Disruption to mitochondrial oxidative phosphorylation and glycolysis is involved in the antitumor mechanism of these compds.  The results indicate that in addn. to DNA binding, bioenergetic pathways also play crucial roles in the antitumor activity of mitochondrion-targeted monofunctional platinum complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohK1xe_5znVLVg90H21EOLACvtfcHk0li3bvKCDggDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVymtbs%253D&md5=5ac6d04499c4045cd8a9b9ac2c835df6</span></div><a href="/servlet/linkout?suffix=cit12o&amp;dbid=16384&amp;doi=10.1039%2FC8SC04871A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC04871A%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DMitochondrion-targeted%2520platinum%2520complexes%2520suppressing%2520lung%2520cancer%2520through%2520multiple%2520pathways%2520involving%2520energy%2520metabolism%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D3089%26epage%3D3095%26doi%3D10.1039%2FC8SC04871A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Babak, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorin, G.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8109</span>– <span class="NLM_lpage">8114</span>, <span class="refDoi"> DOI: 10.1002/anie.201903112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12p&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201903112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Wjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=8109-8114&author=M.+V.+Babakauthor=Y.+Zhiauthor=B.+Czarnyauthor=T.+B.+Tohauthor=L.+Hooiauthor=E.+K.+Chowauthor=W.+H.+Angauthor=D.+Gibsonauthor=G.+Pastorin&title=Dual-targeting+dual-action+platinum%28IV%29+platform+for+enhanced+anticancer+activity+and+reduced+nephrotoxicity&doi=10.1002%2Fanie.201903112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12pR"><div class="casContent"><span class="casTitleNuber">12p</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity</span></div><div class="casAuthors">Babak, Maria V.; Zhi, Yang; Czarny, Bertrand; Toh, Tan Boon; Hooi, Lissa; Chow, Edward Kai-Hua; Ang, Wee Han; Gibson, Dan; Pastorin, Giorgia</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8109-8114</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel and highly efficient dual-targeting platform was designed to ensure targeted in vivo delivery of dual-action PtIV prodrugs.  The dual targeting was established by liposomal encapsulation of PtIV complexes, thereby utilizing the enhanced permeability and retention (EPR) effect as the first stage of targeting to attain a high accumulation of the drug-loaded liposomes in the tumor.  After the release of the PtIV prodrug inside cancer cells, a second stage of targeting directed a portion of the PtIV prodrugs to the mitochondria.  Upon intracellular redn., these PtIV prodrugs released two bioactive mols., acting both on the mitochondrial and on the nuclear DNA.  Our PtIV system showed excellent activity in vitro and in vivo, characterized by a cytotoxicity in a low micromolar range and complete tumor remission, resp.  Notably, marked in vivo activity was accompanied by reduced kidney toxicity, highlighting the unique therapeutic potential of our novel dual-targeting dual-action platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMlkNaK-egdbVg90H21EOLACvtfcHk0li3bvKCDggDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Wjt70%253D&md5=b07046dd1a3652f581bfd530f1dc6d37</span></div><a href="/servlet/linkout?suffix=cit12p&amp;dbid=16384&amp;doi=10.1002%2Fanie.201903112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201903112%26sid%3Dliteratum%253Aachs%26aulast%3DBabak%26aufirst%3DM.%2BV.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DCzarny%26aufirst%3DB.%26aulast%3DToh%26aufirst%3DT.%2BB.%26aulast%3DHooi%26aufirst%3DL.%26aulast%3DChow%26aufirst%3DE.%2BK.%26aulast%3DAng%26aufirst%3DW.%2BH.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DPastorin%26aufirst%3DG.%26atitle%3DDual-targeting%2520dual-action%2520platinum%2528IV%2529%2520platform%2520for%2520enhanced%2520anticancer%2520activity%2520and%2520reduced%2520nephrotoxicity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D8109%26epage%3D8114%26doi%3D10.1002%2Fanie.201903112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12q"><span><span class="NLM_label">(q) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.canlet.2016.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27793693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=168-178&author=F.+Chenauthor=X.+Huangauthor=M.+Wuauthor=S.+Gouauthor=W.+Hu&title=A+CK2-targeted+Pt%28IV%29+prodrug+to+disrupt+DNA+damage+response&doi=10.1016%2Fj.canlet.2016.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12qR"><div class="casContent"><span class="casTitleNuber">12q</span><div class="casTitle"><span class="NLM_cas:atitle">A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response</span></div><div class="casAuthors">Chen, Feihong; Huang, Xiaochao; Wu, Mian; Gou, Shaohua; Hu, Weiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-178</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug, Cx-platin, contg. CX-4945 (a CK2 inhibitor) as an axial ligand was designed and prepd. by targeting CK2 to disrupt DNA damage response.  In vitro study indicated that Cx-platin had superior cytotoxicity to cisplatin against a no. of cancer cell lines with distinct CK2-expressed levels, caused CK2-overexpressed cancer cells death via suppressing CK2-mediated DNA damage repair and reversed cisplatin resistance.  Mechanistic investigation suggested that the potent antitumor activity of Cx-platin resulted from its major suppression of CK2-phosphorylated MDC1 to combine FHA domain of aprataxin to DNA double strand breaks (DSBs) caused by improved cellular uptakes of Pt and ATM deactivation.  Further in vivo tests exhibited that Cx-platin displayed high tumor inhibition rates, increased wt. gain, and hardly toxicity effects in contrast to cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxMYuJ3rPh7bVg90H21EOLACvtfcHk0lgN2JZ561U9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu7jI&md5=fb93fa80ba1c59f675622a6ad683ec97</span></div><a href="/servlet/linkout?suffix=cit12q&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DA%2520CK2-targeted%2520Pt%2528IV%2529%2520prodrug%2520to%2520disrupt%2520DNA%2520damage%2520response%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D168%26epage%3D178%26doi%3D10.1016%2Fj.canlet.2016.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12r"><span><span class="NLM_label">(r) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span> <span> </span><span class="NLM_article-title">A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6353</span>, <span class="refDoi"> DOI: 10.1039/C9CC02189B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC9CC02189B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=31065657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslKqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=6353&author=C.+Wuauthor=K.-J.+Wuauthor=J.-B.+Liuauthor=X.-M.+Zhouauthor=C.-H.+Leungauthor=D.-L.+Ma&title=A+dual-functional+molecular+strategy+for+in+situ+suppressing+and+visualizing+of+neuraminidase+in+aqueous+solution+using+iridium%28iii%29+complexes&doi=10.1039%2FC9CC02189B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12rR"><div class="casContent"><span class="casTitleNuber">12r</span><div class="casTitle"><span class="NLM_cas:atitle">A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(III) complexes</span></div><div class="casAuthors">Wu, Chun; Wu, Ke-Jia; Liu, Jin-Biao; Zhou, Xiao-Ming; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6353-6356</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We have designed for the first time a dual-functional luminescent probe and inhibitor of neuraminidase (NA), a key influenza target.  The lead iridium(III) complex exhibited enhanced inhibition against NA compared to the FDA-approved antiviral drug, oseltamivir, and could detect NA even in the presence of an autofluorescent background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-2mxBaV5r7bVg90H21EOLACvtfcHk0lgN2JZ561U9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslKqs78%253D&md5=37f9971d056e197210336cb465dcc953</span></div><a href="/servlet/linkout?suffix=cit12r&amp;dbid=16384&amp;doi=10.1039%2FC9CC02189B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC02189B%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DLiu%26aufirst%3DJ.-B.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DLeung%26aufirst%3DC.-H.%26aulast%3DMa%26aufirst%3DD.-L.%26atitle%3DA%2520dual-functional%2520molecular%2520strategy%2520for%2520in%2520situ%2520suppressing%2520and%2520visualizing%2520of%2520neuraminidase%2520in%2520aqueous%2520solution%2520using%2520iridium%2528iii%2529%2520complexes%26jtitle%3DChem.%2520Commun.%26date%3D2019%26volume%3D55%26spage%3D6353%26doi%3D10.1039%2FC9CC02189B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12s"><span><span class="NLM_label">(s) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">13091</span>, <span class="refDoi"> DOI: 10.1002/anie.201807305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12s&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201807305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12s&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=13091&author=G.-J.+Yangauthor=W.+Wangauthor=S.+W.+F.+Mokauthor=C.+Wuauthor=B.+Y.+K.+Lawauthor=X.-M.+Miaoauthor=K.-J.+Wuauthor=H.-J.+Zhongauthor=C.-Y.+Wongauthor=V.+K.+W.+Wongauthor=D.-L.+Maauthor=C.-H.+Leung&title=Selective+inhibition+of+lysine-specific+demethylase+5A+%28KDM5A%29+using+a+rhodium%28III%29+complex+for+triple-negative+breast+cancer+therapy&doi=10.1002%2Fanie.201807305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12sR"><div class="casContent"><span class="casTitleNuber">12s</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span></div><div class="casAuthors">Yang, Guan-Jun; Wang, Wanhe; Mok, Simon Wing Fai; Wu, Chun; Law, Betty Yuen Kwan; Miao, Xiang-Min; Wu, Ke-Jia; Zhong, Hai-Jing; Wong, Chun-Yuen; Wong, Vincent Kam Wai; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13091-13095</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 5A (KDM5A) has recently become a promising target for epigenetic therapy.  In this study, the authors designed and synthesized metal complexes bearing ligands with reported demethylase and p27 modulating activities.  The Rh(III) complex 1 (I) was identified as a direct, selective and potent inhibitor of KDM5A that directly abrogate KDM5A demethylase activity via antagonizing the KDM5A-tri-/di-methylated histone 3 protein-protein interaction (PPI) in vitro and in cellulo.  Complex 1 induced accumulation of H3K4me3 and H3K4me2 levels in cells, causing growth arrest at G1 phase in the triple-neg. breast cancer (TNBC) cell lines, MDA-MB-231 and 4T1.  Finally, 1 exhibited potent anti-tumor activity against TNBC xenografts in an in vivo mouse model, presumably via targeting of KDM5A and hence upregulating p27.  Moreover, complex 1 was less toxic compared with two clin. drugs, cisplatin and doxorubicin.  To the authors' knowledge, complex 1 is the first metal-based KDM5A inhibitor reported in the literature.  The authors anticipate that complex 1 may be used as a novel scaffold for the further development of more potent epigenetic agents against cancers, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUnhpINRuOrVg90H21EOLACvtfcHk0lgN2JZ561U9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM&md5=9a8f6097e7401592667690c255f1c9e6</span></div><a href="/servlet/linkout?suffix=cit12s&amp;dbid=16384&amp;doi=10.1002%2Fanie.201807305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201807305%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DB.%2BY.%2BK.%26aulast%3DMiao%26aufirst%3DX.-M.%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DWong%26aufirst%3DC.-Y.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DSelective%2520inhibition%2520of%2520lysine-specific%2520demethylase%25205A%2520%2528KDM5A%2529%2520using%2520a%2520rhodium%2528III%2529%2520complex%2520for%2520triple-negative%2520breast%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D13091%26doi%3D10.1002%2Fanie.201807305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12t"><span><span class="NLM_label">(t) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacque, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniforth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavros, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeted photoredox catalysis in cancer cells</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1041</span>, <span class="refDoi"> DOI: 10.1038/s41557-019-0328-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41557-019-0328-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=31548671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1041&author=H.+Huangauthor=S.+Banerjeeauthor=K.+Qiuauthor=P.+Zhangauthor=O.+Blacqueauthor=T.+Malcomsonauthor=M.+J.+Patersonauthor=G.+J.+Clarksonauthor=M.+Staniforthauthor=V.+G.+Stavrosauthor=G.+Gasserauthor=H.+Chaoauthor=P.+J.+Sadler&title=Targeted+photoredox+catalysis+in+cancer+cells&doi=10.1038%2Fs41557-019-0328-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12tR"><div class="casContent"><span class="casTitleNuber">12t</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted photoredox catalysis in cancer cells</span></div><div class="casAuthors">Huang, Huaiyi; Banerjee, Samya; Qiu, Kangqiang; Zhang, Pingyu; Blacque, Olivier; Malcomson, Thomas; Paterson, Martin J.; Clarkson, Guy J.; Staniforth, Michael; Stavros, Vasilios G.; Gasser, Gilles; Chao, Hui; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1041-1048</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hypoxic tumors are a major problem for cancer photodynamic therapy.  Here, we show that photoredox catalysis can provide an oxygen-independent mechanism of action to combat this problem.  We have designed a highly oxidative Ir(III) photocatalyst, [Ir(ttpy)(pq)Cl]PF6 ([1]PF6, where 'ttpy' represents 4'-(p-tolyl)-2,2':6',2''-terpyridine and 'pq' represents 3-phenylisoquinoline), which is phototoxic towards both normoxic and hypoxic cancer cells.  Complex 1 photocatalytically oxidizes 1,4-dihydronicotinamide adenine dinucleotide (NADH)-an important coenzyme in living cells-generating NAD• radicals with a high turnover frequency in biol. media.  Moreover, complex 1 and NADH synergistically photoreduce cytochrome c under hypoxia.  D. functional theory calcns. reveal π stacking in adducts of complex 1 and NADH, facilitating photoinduced single-electron transfer.  In cancer cells, complex 1 localizes in mitochondria and disrupts electron transport via NADH photocatalysis.  On light irradn., complex 1 induces NADH depletion, intracellular redox imbalance and immunogenic apoptotic cancer cell death.  This photocatalytic redox imbalance strategy offers a new approach for efficient cancer phototherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoZNCvl9_iQLVg90H21EOLACvtfcHk0lhkESByHSAb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgurfK&md5=b7774e96b85d9d648faa30c50bbea784</span></div><a href="/servlet/linkout?suffix=cit12t&amp;dbid=16384&amp;doi=10.1038%2Fs41557-019-0328-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-019-0328-4%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DBlacque%26aufirst%3DO.%26aulast%3DMalcomson%26aufirst%3DT.%26aulast%3DPaterson%26aufirst%3DM.%2BJ.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DStaniforth%26aufirst%3DM.%26aulast%3DStavros%26aufirst%3DV.%2BG.%26aulast%3DGasser%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DTargeted%2520photoredox%2520catalysis%2520in%2520cancer%2520cells%26jtitle%3DNat.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1041%26doi%3D10.1038%2Fs41557-019-0328-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray
Stewart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, A. E.</span></span> <span> </span><span class="NLM_article-title">Polyamine metabolism and cancer: treatments, challenges and opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0050-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41568-018-0050-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30181570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Gks7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=681-695&author=R.+A.+Caseroauthor=T.+Murray%0AStewartauthor=A.+E.+Pegg&title=Polyamine+metabolism+and+cancer%3A+treatments%2C+challenges+and+opportunities&doi=10.1038%2Fs41568-018-0050-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Polyamine metabolism and cancer: treatments, challenges and opportunities</span></div><div class="casAuthors">Casero, Jr, Robert A.; Murray Stewart, Tracy; Pegg, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">681-695</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Advances in our understanding of the metab. and mol. functions of polyamines and their alterations in cancer have led to resurgence in the interest of targeting polyamine metab. as an anticancer strategy.  Increasing knowledge of the interplay between polyamine metab. and other cancer-driving pathways, including the PTEN-PI3K-mTOR complex 1 (mTORC1), WNT signalling and RAS pathways, suggests potential combination therapies that will have considerable clin. promise.  Addnl., an expanding no. of promising clin. trials with agents targeting polyamines for both therapy and prevention are ongoing.  New insights into mol. mechanisms linking dysregulated polyamine catabolism and carcinogenesis suggest addnl. strategies that can be used for cancer prevention in at-risk individuals.  In addn., polyamine blocking therapy, a strategy that combines the inhibition of polyamine biosynthesis with the simultaneous blockade of polyamine transport, can be more effective than therapies based on polyamine depletion alone and may involve an antitumor immune response.  These findings open up new avenues of research into exploiting aberrant polyamine metab. for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQkeuH5QZMbVg90H21EOLACvtfcHk0lhkESByHSAb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Gks7nF&md5=9bcfc74df8e65e0ce8a53203770bd1f1</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0050-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0050-3%26sid%3Dliteratum%253Aachs%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DMurray%2BStewart%26aufirst%3DT.%26aulast%3DPegg%26aufirst%3DA.%2BE.%26atitle%3DPolyamine%2520metabolism%2520and%2520cancer%253A%2520treatments%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D681%26epage%3D695%26doi%3D10.1038%2Fs41568-018-0050-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">An overview of polyamine metabolism in pancreatic ductal adenocarcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">1976</span>, <span class="refDoi"> DOI: 10.1002/ijc.31155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fijc.31155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29134652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOnsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2018&pages=1968-1976&author=O.+Phanstiel&title=An+overview+of+polyamine+metabolism+in+pancreatic+ductal+adenocarcinoma&doi=10.1002%2Fijc.31155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of polyamine metabolism in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1968-1976</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%.  With current therapies only giving rise to modest life extension, new approaches are desperately needed.  Even though targeting polyamine metab. is a proven anticancer strategy, there are no reports, which thoroughly survey the literature describing the role of polyamine biosynthesis and transport in PDAC.  This review seeks to fill this void by describing what is currently known about polyamine metab. in PDAC and identifies new targets and opportunities to treat this disease.  Due to the pleiotropic effects that polyamines play in cells, this review covers diverse areas ranging from polyamine metab. (biosynthesis, catabolism and transport), as well as the potential role of polyamines in desmoplasia, autophagy and immune privilege.  Understanding these diverse roles provides the opportunity to design new therapies to treat this deadly cancer via polyamine depletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdSGr8c3DwEbVg90H21EOLACvtfcHk0lhkESByHSAb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOnsrbP&md5=3e6f4cd63716572b3cc9e90e545150cc</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fijc.31155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31155%26sid%3Dliteratum%253Aachs%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DAn%2520overview%2520of%2520polyamine%2520metabolism%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2018%26volume%3D142%26spage%3D1968%26epage%3D1976%26doi%3D10.1002%2Fijc.31155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marton, L. J.</span></span> <span> </span><span class="NLM_article-title">Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nrd2243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrd2243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=17464296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslyiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=373-90&author=R.+A.+Caseroauthor=L.+J.+Marton&title=Targeting+polyamine+metabolism+and+function+in+cancer+and+other+hyperproliferative+diseases&doi=10.1038%2Fnrd2243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases</span></div><div class="casAuthors">Casero, Robert A., Jr.; Marton, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-390</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polyamines spermidine and spermine and their diamine precursor putrescine are naturally occurring, polycationic alkylamines that are essential for eukaryotic cell growth.  The requirement for and the metab. of polyamines are frequently dysregulated in cancer and other hyperproliferative diseases, thus making polyamine function and metab. attractive targets for therapeutic intervention.  Recent advances in our understanding of polyamine function, metabolic regulation, and differences between normal cells and tumor cells with respect to polyamine biol., have reinforced the interest in this target-rich pathway for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJOs-U3gFu-7Vg90H21EOLACvtfcHk0lhkESByHSAb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslyiu7k%253D&md5=d04f6b516f8eea49c761e2f171747b58</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1038%2Fnrd2243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2243%26sid%3Dliteratum%253Aachs%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DMarton%26aufirst%3DL.%2BJ.%26atitle%3DTargeting%2520polyamine%2520metabolism%2520and%2520function%2520in%2520cancer%2520and%2520other%2520hyperproliferative%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D373%26epage%3D90%26doi%3D10.1038%2Fnrd2243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wason, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altomare, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of antimetastatic agents predicated upon dihydromotuporamine C and its carbocyclic derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4023</span>– <span class="NLM_lpage">4034</span>, <span class="refDoi"> DOI: 10.1021/jm401906v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401906v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4023-4034&author=A.+Muthauthor=V.+Pandeyauthor=N.+Kaurauthor=M.+Wasonauthor=C.+Bakerauthor=X.+Hanauthor=T.+R.+Johnsonauthor=D.+A.+Altomareauthor=O.+Phanstiel&title=Synthesis+and+biological+evaluation+of+antimetastatic+agents+predicated+upon+dihydromotuporamine+C+and+its+carbocyclic+derivatives&doi=10.1021%2Fjm401906v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Antimetastatic Agents Predicated upon Dihydromotuporamine C and Its Carbocyclic Derivatives</span></div><div class="casAuthors">Muth, Aaron; Pandey, Veethika; Kaur, Navneet; Wason, Melissa; Baker, Cheryl; Han, Xianlin; Johnson, Teresa R.; Altomare, Deborah A.; Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4023-4034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The motuporamines isolated from the sea sponge Xestospongia exigua are of biol. interest because of their unique antimigration and antiangiogenic properties.  Key bioactive features were found to be a satd. 15-membered heterocycle and a norspermidine motif.  This paper describes new analogs that modulate the cytotoxicity of this compd. class and have enhanced antimigration properties.  By movement of the polyamine chain outside the ring, new carbocycles were discovered that doubled the antimigration potency and reduced compd. toxicity by 133-fold.  Mice injected with metastatic human L3.6pl pancreatic cancer cells demonstrated significant redn. in liver metastases when treated with N1-(3-aminopropyl)-N3-(cyclopentadecylmethyl)propane-1,3-diamine (I) compared with dihydromotuporamine C (II).  Significant changes in specific ceramide populations (N16:0 and N22:1) were noted in L3.6pl cells treated with dihydromotuporamine C but not for the cyclopentadecylmethylnorspermidine deriv., which had lower toxicity.  Both compds. gave increased levels of specific low mol. wt. sphingomyelins, suggesting that they may act upon sphingomyelin processing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDD0zypqDEbVg90H21EOLACvtfcHk0lhJNvBhIshpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlSltbc%253D&md5=490cfc211e9f5a0f3443ccf95bffa9ef</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1021%2Fjm401906v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401906v%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DPandey%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DWason%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DJohnson%26aufirst%3DT.%2BR.%26aulast%3DAltomare%26aufirst%3DD.%2BA.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520antimetastatic%2520agents%2520predicated%2520upon%2520dihydromotuporamine%2520C%2520and%2520its%2520carbocyclic%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4023%26epage%3D4034%26doi%3D10.1021%2Fjm401906v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Skruber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Synthesis and bioevaluation of macrocycle-polyamine conjugates as cell migration inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8606</span>– <span class="NLM_lpage">8619</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2gsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8606-8619&author=K.+Skruberauthor=K.+J.+Chaplinauthor=O.+Phanstiel&title=Synthesis+and+bioevaluation+of+macrocycle-polyamine+conjugates+as+cell+migration+inhibitors&doi=10.1021%2Facs.jmedchem.7b01222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Bioevaluation of Macrocycle-Polyamine Conjugates as Cell Migration Inhibitors</span></div><div class="casAuthors">Skruber, Kristen; Chaplin, Kelvin J.; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8606-8619</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The motuporamines are natural products isolated from the New Guinea sea sponge Xestospongia exigua.  Dihydromotuporamine C contains a large macrocycle and an appended polyamine component and was shown to be both antimetastatic and cytotoxic to human L3.6pl pancreatic cancer cells.  A series of macrocycle-polyamine conjugates were prepd., and the sequence of the polyamine component was varied to optimize the antimigration properties (as measured in L3.6pl cells) of this mol. class.  A one-carbon spacer between the 15-membered carbocycle and the appended polyamine showed improved antimigration properties.  A survey of different polyamine sequences contg. two, three, or four carbon spacers revealed that the natural polyamine sequence (norspermidine, a 3,3-triamine) was superior in terms of inhibiting the migration of L3.6pl cells in vitro.  An investigation of the resp. ceramide and sphingomyelin populations in L3.6pl cells revealed that these mols. can modulate both ceramide and sphingomyelin pools in cells and inhibit cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLNuFxyknTrVg90H21EOLACvtfcHk0lhJNvBhIshpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2gsbrF&md5=e805e362a4e80c4ab7f7436f90cad317</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01222%26sid%3Dliteratum%253Aachs%26aulast%3DSkruber%26aufirst%3DK.%26aulast%3DChaplin%26aufirst%3DK.%2BJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520bioevaluation%2520of%2520macrocycle-polyamine%2520conjugates%2520as%2520cell%2520migration%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8606%26epage%3D8619%26doi%3D10.1021%2Facs.jmedchem.7b01222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shicora, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayene, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Development of polyamine transport ligands with improved metabolic stability and selectivity against specific human cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5819</span>– <span class="NLM_lpage">5828</span>, <span class="refDoi"> DOI: 10.1021/jm400496a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400496a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2msbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5819-5828&author=A.+Muthauthor=J.+Kamelauthor=N.+Kaurauthor=A.+C.+Shicoraauthor=I.+S.+Ayeneauthor=S.+K.+Gilmourauthor=O.+Phanstiel&title=Development+of+polyamine+transport+ligands+with+improved+metabolic+stability+and+selectivity+against+specific+human+cancers&doi=10.1021%2Fjm400496a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Polyamine Transport Ligands with Improved Metabolic Stability and Selectivity against Specific Human Cancers</span></div><div class="casAuthors">Muth, Aaron; Kamel, Joseph; Kaur, Navneet; Shicora, Allyson C.; Ayene, Iraimoudi S.; Gilmour, Susan K.; Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5819-5828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polyamine homeostasis is crit. for life and is accomplished via a balance of polyamine biosynthesis, degrdn., and transport.  Rapidly dividing cancer cells have been shown to have high polyamine transport activity compared to normal cells, likely due to their high requirement for polyamine metabolites.  The polyamine transport system (PTS) is a therapeutically relevant target, as it can provide selective drug delivery to cancer cells.  This report describes the synthesis and biol. evaluation of multimeric polyamine derivs. as efficient PTS ligands.  Arylmethyl-polyamine derivs. were synthesized to address two important concerns in PTS drug design: (a) PTS selectivity and (b) stability to amine oxidases.  N1,N1'-[Naphthalene-1,4-diylbis(methylene)]bis{N4-[4-(methylamino)butyl])butane-1,4-diamine}, 3b, was found to have an optimal balance between these parameters and demonstrated excellent targeting of melanoma (e.g., MALME-3M) and breast cancer cells (e.g., T47D) over other cancer cell lines.  These results provide a method to selectively target cancers via their intrinsic need for polyamine metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5w3QJ9zU5dbVg90H21EOLACvtfcHk0lhJNvBhIshpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2msbzF&md5=f6e19f2b781583e66a55a0da2d0b5981</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1021%2Fjm400496a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400496a%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DKamel%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DShicora%26aufirst%3DA.%2BC.%26aulast%3DAyene%26aufirst%3DI.%2BS.%26aulast%3DGilmour%26aufirst%3DS.%2BK.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520polyamine%2520transport%2520ligands%2520with%2520improved%2520metabolic%2520stability%2520and%2520selectivity%2520against%2520specific%2520human%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5819%26epage%3D5828%26doi%3D10.1021%2Fjm400496a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konate, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Defining the molecular requirements for the selective delivery of polyamine conjugates into cells containing active polyamine transporters</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5129</span>– <span class="NLM_lpage">5138</span>, <span class="refDoi"> DOI: 10.1021/jm030223a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030223a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot1Ojtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5129-5138&author=C.+Wangauthor=J.-G.+Delcrosauthor=L.+Cannonauthor=F.+Konateauthor=H.+Cariasauthor=J.+Biggerstaffauthor=R.+A.+Gardnerauthor=O.+Phanstiel&title=Defining+the+molecular+requirements+for+the+selective+delivery+of+polyamine+conjugates+into+cells+containing+active+polyamine+transporters&doi=10.1021%2Fjm030223a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Molecular Requirements for the Selective Delivery of Polyamine Conjugates into Cells Containing Active Polyamine Transporters</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Cannon, Laura; Konate, Fanta; Carias, Horacio; Biggerstaff, John; Gardner, Richard Andrew; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5129-5138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several N1-substituted polyamines contg. various spacer units between nitrogen centers were synthesized as their resp. HCl salts.  The N1-substituents included benzyl, naphthalen-1-ylmethyl, anthracen-9-ylmethyl, and pyren-1-ylmethyl.  The polyamine spacer units ranged from generic (4,4-triamine, 4,3-triamine, and diaminooctane) spacers to more exotic [2-(ethoxy)ethanoxy-contg. diamine, hydroxylated 4,3-triamine, and cyclohexylene-contg. triamine] spacers.  Two control compds. were also evaluated:N-(anthracen-9-ylmethyl)-butylamine and N-(anthracen-9-ylmethyl)-butanediamine.  Biol. activities in L1210 (murine leukemia), α-difluoromethylornithine (DFMO)-treated L1210, and Chinese hamster ovary (CHO) and its polyamine transport-deficient mutant (CHO-MG) cell lines were investigated via IC50 cytotoxicity detns. Ki values for spermidine uptake were also detd. in L1210 cells.  Of the series studied, the N1-benzyl-4,4-triamine deriv. (6) had significantly higher IC50 values (lower cytotoxicity) in the L1210, CHO, and CHO-MG cell lines.  A cellular debenzylation process was obsd. in L1210 cells with 6 and generated "free" homospermidine.  The size of the N1-arylmethyl substituent had direct bearing on the obsd. cytotoxicity in CHO-MG cells.  The N1-naphthalenylmethyl, N1-anthracenylmethyl, and N1-pyrenylmethyl 4,4-triamines had similar toxicity (IC50s: ∼0.5 μM) in CHO cells, which have an active polyamine transporter (PAT).  However, this series had IC50 values of >100 μM, 66.7 μM, and 15.5 μM, resp., in CHO-MG cells, which are PAT-deficient.  The obsd. lower cytotoxicity in the PAT-deficient CHO-MG cell line supported the premise that the conjugates use PAT for cellular entry.  In general, moderate affinities for the polyamine transporter were obsd. for the N-arylmethyl 4,4-triamine series with their L1210 Ki values all near 3 μM.  In summary, the 4,4-triamine motif was shown to facilitate entry of polyamine conjugates into cells contg. active polyamine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEbyVe-vZALVg90H21EOLACvtfcHk0lhjvQd5GSRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot1Ojtr8%253D&md5=df2bd3ad52a9a14ec1d5e821d1f66f72</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm030223a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030223a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DCannon%26aufirst%3DL.%26aulast%3DKonate%26aufirst%3DF.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DR.%2BA.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DDefining%2520the%2520molecular%2520requirements%2520for%2520the%2520selective%2520delivery%2520of%2520polyamine%2520conjugates%2520into%2520cells%2520containing%2520active%2520polyamine%2520transporters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5129%26epage%3D5138%26doi%3D10.1021%2Fjm030223a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm020598g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020598g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2672-2682&author=C.+Wangauthor=J.-G.+Delcrosauthor=J.+Biggerstaffauthor=O.+Phanstiel&title=Molecular+requirements+for+targeting+the+polyamine+transport+system.+Synthesis+and+biological+evaluation+of+polyamine-anthracene+conjugates&doi=10.1021%2Fjm020598g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Requirements for Targeting the Polyamine Transport System. Synthesis and Biological Evaluation of Polyamine-Anthracene Conjugates</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Biggerstaff, John; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2672-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of nine N1-(9-anthracenylmethyl)tetraamines (e.g., Ant-4,4,4-tetraamine) were synthesized and evaluated for cytotoxicity in L1210, α-difluoromethylornithine (DFMO)-treated L1210, Chinese hamster ovary (CHO), and CHO-MG cell lines.  Surprisingly, the 3,3,4- and 3,4,3-tetraamine motifs had the same or decreased cytotoxicity in DFMO-treated L1210 cells, whereas the rest of the tetraamine systems were usually more cytotoxic and gave lower IC50 values in this treated cell line.  The most sensitive derivs. to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogs, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, resp. Ki values for each of the anthracenylmethyl(Ant)-polyamine conjugates were detd. in L1210 cells and revealed that these systems are high-affinity ligands for the polyamine transporter (PAT).  Mixed results were obsd. in the CHO and CHO-MG assays.  The 4,4,4- and 5,4,4-tetraamine motifs were 3 times more toxic to CHO cells with active polyamine transporters.  For example, the Ant-4,4,4-tetraamine conjugate displayed IC50 values of 11 μM in CHO cells and 33 μM in CHO-MG cells, a PAT-deficient cell line.  This suggested that these derivs. used the PAT in part to access cells.  However, most of the other tetraamine derivs. had similar potencies in both the CHO and CHO-MG cell lines.  In terms of vector design, higher affinity for the PAT (lower Ki values) did not translate into higher potency for the tetraamine conjugate.  In contrast, the related triamine systems, which had micromolar Ki values in L1210 cells, were more efficacious and selective.  In one case, the 4,4-triamine motif imparted 150-fold higher potency in CHO cells than the CHO-MG mutant.  A deconvolution microscopy study in A375 melanoma cells revealed a rapid internalization of the Ant-4,4-triamine as fluorescent vesicles, whereas the Ant-4,4,4-tetraamine remained mostly at the cell surface.  These findings help define the key characteristics required for selective delivery of polyamine-drug conjugates into cell types with active polyamine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoooD6sQH5_LVg90H21EOLACvtfcHk0lhjvQd5GSRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVahuro%253D&md5=b30edf689e4567ba70c35da214472815</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm020598g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020598g%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DMolecular%2520requirements%2520for%2520targeting%2520the%2520polyamine%2520transport%2520system.%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520polyamine-anthracene%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2672%26epage%3D2682%26doi%3D10.1021%2Fjm020598g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as mo lecular recognition elements for the polyamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2663</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1021/jm030028w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030028w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2663-2671&author=C.+Wangauthor=J.-G.+Delcrosauthor=J.+Biggerstaffauthor=O.+Phanstiel&title=Synthesis+and+biological+evaluation+of+N1-%28anthracen-9-ylmethyl%29triamines+as+mo+lecular+recognition+elements+for+the+polyamine+transporter&doi=10.1021%2Fjm030028w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N1-(Anthracen-9-ylmethyl)triamines as Molecular Recognition Elements for the Polyamine Transporter</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Biggerstaff, John; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2663-2671</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient modular synthesis of N1-substituted triamines contg. different tether lengths between nitrogen centers was developed.  A series of N1-(9-anthracenylmethyl)triamines I (R = H, m = 3-5, n = 3-4; R = 4-MeC6H4SO2, m = 2-5, n = 4) were evaluated for biol. activity in L1210 (murine leukemia), α-difluoromethylornithine (DFMO)-treated L1210, Chinese hamster ovary (CHO), and CHO-MG cell lines.  All triamines I (R = H, m = 3-5, n = 3-4) had increased potency in DFMO-treated L1210 cells.  The 4,4- and 5,4-triamine systems I (R = H, m = n = 4; m = 5, n = 4) had the highest affinity for the polyamine transporter (PAT) with L1210 Ki values of 1.8 and 1.7 μM, resp.  This trend was also reflected in the CHO studies.  Surprisingly, the resp. 4,4- and 5,4-triamine systems had 150-fold and 38-fold higher cytotoxicity in CHO cells contg. active polyamine transporters.  Initial microscopy studies revealed the rapid formation of vesicular structures within A375 melanoma cells treated with the N1-(9-anthracenylmethyl)homospermidine (4,4-triamine) conjugate.  In summary, the 4,4- and 5,4-triamines were identified as selective vector motifs to ferry anthracene into cells via the PAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaq811vrP-LVg90H21EOLACvtfcHk0lhjvQd5GSRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVWrs7s%253D&md5=4756335fbe6450c2dfac5183f5e5e8d4</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm030028w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030028w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N1-%2528anthracen-9-ylmethyl%2529triamines%2520as%2520mo%2520lecular%2520recognition%2520elements%2520for%2520the%2520polyamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2663%26epage%3D2671%26doi%3D10.1021%2Fjm030028w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor conjugates with polyamine vectors and their molecular mechanisms</span>. <i>Expert Opin. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1517/17425247.2010.504205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1517%2F17425247.2010.504205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=20636185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCntLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1049-1061&author=S.+Xieauthor=J.+Wangauthor=Y.+Zhangauthor=C.+Wang&title=Antitumor+conjugates+with+polyamine+vectors+and+their+molecular+mechanisms&doi=10.1517%2F17425247.2010.504205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor conjugates with polyamine vectors and their molecular mechanisms</span></div><div class="casAuthors">Xie, Songqiang; Wang, Jianhong; Zhang, Yahong; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1049-1061</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: A polyamine conjugate is a special polyamine deriv. composed of polyamine vectors appended directly or by a linker to a cargo with specific biol. functions.  In recent years, extensive researches have emphasized the fact that polyamine conjugates acting as promising antitumor candidates are becoming increasingly important in the polyamine field.  Areas covered in this review: Two key subjects are illustrated in this review.  First, various drug-polyamine conjugates and relevant structure-activity relationships are discussed with a focus on the mol. recognition of polyamine transport system (PTS).  Second, the design of polyamine conjugates is following a rational mechanism-based strategy.  Therefore, it is critically important to understand the intrinsic properties of PTS on the cell membrane, enhanced pharmacol. effects of polyamine vector on cellular components, and resulting comprehensive signaling networks.  What the reader will gain: A general design strategy of polyamine conjugates as well as recent progress in both fundamental mechanism studies and preclin. therapies are provided for the readers.  Take home message: The multiple functions of polyamine moieties in objective conjugates furnish broad development space for more efficacious antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_QN8mZHcCrVg90H21EOLACvtfcHk0lj4-YImnTXPyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCntLnP&md5=134d791bed69b73f5dac62f8779724f8</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1517%2F17425247.2010.504205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.2010.504205%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DAntitumor%2520conjugates%2520with%2520polyamine%2520vectors%2520and%2520their%2520molecular%2520mechanisms%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2010%26volume%3D7%26spage%3D1049%26epage%3D1061%26doi%3D10.1517%2F17425247.2010.504205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span> <span> </span><span class="NLM_article-title">Nonhematotoxic naphthalene diimide modified by polyamine: synthesis and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3502</span>– <span class="NLM_lpage">3512</span>, <span class="refDoi"> DOI: 10.1021/jm300168w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300168w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFelu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3502-3512&author=Y.+X.+Wangauthor=X.+Zhangauthor=J.+Zhaoauthor=S.+Q.+Xieauthor=C.+J.+Wang&title=Nonhematotoxic+naphthalene+diimide+modified+by+polyamine%3A+synthesis+and+biological+evaluation&doi=10.1021%2Fjm300168w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14eR"><div class="casContent"><span class="casTitleNuber">14e</span><div class="casTitle"><span class="NLM_cas:atitle">Nonhematotoxic Naphthalene Diimide Modified by Polyamine: Synthesis and Biological Evaluation</span></div><div class="casAuthors">Wang, Yuxia; Zhang, Xingbo; Zhao, Jin; Xie, Songqiang; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3502-3512</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of up-regulating antitumor efficacy and down-regulating adverse effects, three types of arom. imide and diimides were designed to couple with different polyamines.  The in vitro assays revealed that two naphthalene diimide-polyamine conjugates could inhibit the growth of multiple cancer cell lines more potently than amonafide. 9f (I), the most potent compd., was verified to efficiently induce apoptosis via a ROS mediated mitochondrial pathway in a preliminary mechanistic study.  The comprehensive in vivo trials on three H22 tumor transplant models demonstrated that 9f improved the indexes in terms of inhibitive effect and lifespan extension and reduced the hematotoxicity which is one of main drawbacks of amonafide.  More importantly, the obviously elevated ability in preventing lung cancer metastasis was obsd., which increased the value of 9f as a promising lead compd.  This work supported that the versatile function of polyamines may endow some intriguing biol. features to the parent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rbHd3GIdC7Vg90H21EOLACvtfcHk0lj4-YImnTXPyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFelu7c%253D&md5=66b25bbb51f0570e0fe36421d5a3359e</span></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm300168w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300168w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26atitle%3DNonhematotoxic%2520naphthalene%2520diimide%2520modified%2520by%2520polyamine%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3502%26epage%3D3512%26doi%3D10.1021%2Fjm300168w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e328359affd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1097%2FCAD.0b013e328359affd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=23032518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslantLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=32-42&author=M.+Liauthor=Q.+Liauthor=Y.+H.+Zhangauthor=Z.+Y.+Tianauthor=H.+X.+Maauthor=J.+Zhaoauthor=S.+Q.+Xieauthor=C.+Wang&title=Antitumor+effects+and+preliminary+systemic+toxicity+of+ANISpm+in+vivo+and+in+vitro&doi=10.1097%2FCAD.0b013e328359affd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14fR"><div class="casContent"><span class="casTitleNuber">14f</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro</span></div><div class="casAuthors">Li, Ming; Li, Qian; Zhang, Ya-hong; Tian, Zhi-yong; Ma, Hong-xia; Zhao, Jin; Xie, Song-qiang; Wang, Chao-jie</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Polyamines as a vector to ferry toxic agents have attracted attention, and naphthalimide-polyamine conjugates show potent activity and tumor cell selectivity.  The present study was carried out to evaluate the antitumor effects and preliminary systemic toxicity of ANISpm, a novel 3-amino-naphthalimide-spermine conjugate.  The polyamine transport system recognition of ANISpm, supported by α-difluoromethylornithine (DFMO)/spermidine (Spd) expts., is in accordance with its potent cell selectivity between human hepatoma HepG2 cells and normal QSG7701 hepatocyte.  The antiproliferative effect is because of ANISpm-induced cell apoptosis, a common characteristic of both naphthalimide and polyamine analogs.  Various apoptotic assessment assays have shown that ANISpm can induce apoptosis through the PI3K/Akt signal pathway.  The apoptotic signaling cascade involves Akt inactivation, which results in a series of cellular events.  The downstream pathway includes Bad dephosphorylation, dissocn. of 14-3-3 and Bad, and binding to Bcl-xL, which triggers the disruption of the mitochondrial membrane, release of cytochrome c, and caspases' cascade activation.  Furthermore, the Akt/mTOR signal pathway is also involved in ANISpm-mediated cell-cycle arrest.  Additive DFMO or Spd, which only enhances or attenuates ANISpm-mediated cell apoptosis, resp., does not alter the signal pathway.  In addn., preliminary toxicol. evaluation showed that ANISpm had no obvious system toxicity at a dose of 2.5 mg/kg, which exerted potent antitumor activity in vivo, esp. hematotoxicity.  Thus, ANISpm merits further investigation as a potential chemotherapeutic agent against hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdAeGa8w_3CbVg90H21EOLACvtfcHk0lj4-YImnTXPyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslantLfK&md5=ae1af1913d657be6acb0b0081103c9e4</span></div><a href="/servlet/linkout?suffix=cit14f&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328359affd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328359affd%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DTian%26aufirst%3DZ.%2BY.%26aulast%3DMa%26aufirst%3DH.%2BX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DAntitumor%2520effects%2520and%2520preliminary%2520systemic%2520toxicity%2520of%2520ANISpm%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2013%26volume%3D24%26spage%3D32%26epage%3D42%26doi%3D10.1097%2FCAD.0b013e328359affd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.ejmech.2016.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27236067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVWhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=110-119&author=Q.+Liauthor=Y.+Zhaiauthor=W.+Luoauthor=Z.+Zhuauthor=X.+Zhangauthor=S.+Xieauthor=C.+Hongauthor=Y.+Wangauthor=Y.+Suauthor=J.+Zhaoauthor=C.+Wang&title=Synthesis+and+biological+properties+of+polyamine+modified+flavonoids+as+hepatocellular+carcinoma+inhibitors&doi=10.1016%2Fj.ejmech.2016.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14gR"><div class="casContent"><span class="casTitleNuber">14g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors</span></div><div class="casAuthors">Li, Qian; Zhai, Yangyang; Luo, Wen; Zhu, Zixin; Zhang, Xin; Xie, Songqiang; Hong, Chen; Wang, Yuxia; Su, Yabin; Zhao, Jin; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-119</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of polyamine conjugates of flavonoids with a naphthalene motif were synthesized and evaluated for their anti-hepatocellular carcinoma properties using in vitro and in vivo assays.  Compd. 8a displayed favorable selectivity between hepatocellular carcinoma cells and normal hepatocyte cells, and the combination of 8a with aspirin resulted in additive inhibition of in vitro tumor cell growth and migration.  The 8a-aspirin combination also inhibited H22 liver tumor growth and pulmonary metastasis and improved body wt. index in animal models.  Preliminary mechanistic studies indicated that 8a increased the expression of apoptosis-related proteins such as p-p38, p-JNK, p53 and Bcl-2, an effect that was further amplified by aspirin.  Therefore, a cocktail therapy of flavonoid-polyamine conjugates with aspirin has potential use as an antitumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXcJ8WScB97Vg90H21EOLACvtfcHk0lihg2-uufFMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVWhtrg%253D&md5=a37e727bb462c3f79e6cbfe78d2064ee</span></div><a href="/servlet/linkout?suffix=cit14g&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520properties%2520of%2520polyamine%2520modified%2520flavonoids%2520as%2520hepatocellular%2520carcinoma%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D110%26epage%3D119%26doi%3D10.1016%2Fj.ejmech.2016.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of mitochondria-targeted flavone-naphthalimide-polyamine conjugates with antimetastatic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2071</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2071-2083&author=F.+J.+Daiauthor=Q.+Liauthor=Y.+X.+Wangauthor=C.+C.+Geauthor=C.+Fengauthor=S.+Q.+Xieauthor=H.+Heauthor=X.+Xuauthor=C.+J.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+mitochondria-targeted+flavone-naphthalimide-polyamine+conjugates+with+antimetastatic+activity&doi=10.1021%2Facs.jmedchem.6b01846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14hR"><div class="casContent"><span class="casTitleNuber">14h</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity</span></div><div class="casAuthors">Dai, Fujun; Li, Qian; Wang, Yuxia; Ge, Chaochao; Feng, Chenyang; Xie, Songqiang; He, Haoying; Xu, Xiaojuan; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2071-2083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 90% of cancer-assocd. deaths result from disseminated tumors, indicating the ineffectiveness of current therapies and the imperative need of antimetastatic drugs.  A novel pharmacophore with flavonoid and naphthalimide moieties was constructed by using a fragment-based drug design and a series of eight flavone-naphthalimide-polyamine conjugates were synthesized.  In vitro evaluation revealed that compd. I with a homospermidine motif displayed better cell selectivity between cancerous and normal liver cells than amonafide did.  The in vivo assays on two hepatocellular carcinoma (HCC) models verified that I potently suppressed pulmonary metastasis with improved organ indexes compared to amonafide.  Various expts. showed that I as a potential fluorescent chem. probe could target the mitochondria.  Preliminary investigation into the mechanism of action of I indicated that it might harness a polyamine transporter for cell entrance, localize in the mitochondria, selectively cause reactive oxygen species (ROS) overprodn. in hepatoma cells instead of normal liver cells, and finally lead to HCC cell apoptosis and migration inhibition via multiple ROS-mediated signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnOVDRABi27Vg90H21EOLACvtfcHk0lihg2-uufFMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D&md5=de5add465c72748224b38fd9a153f131</span></div><a href="/servlet/linkout?suffix=cit14h&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01846%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DF.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DGe%26aufirst%3DC.%2BC.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520mitochondria-targeted%2520flavone-naphthalimide-polyamine%2520conjugates%2520with%2520antimetastatic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2071%26epage%3D2083%26doi%3D10.1021%2Facs.jmedchem.6b01846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of the polyamine conjugate with benzo[ cd]indol-2(1 H)-one as a lysosome-targeted antimetastatic agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6814</span>– <span class="NLM_lpage">6829</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00694</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00694" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6814-6829&author=J.+Liauthor=R.+Tianauthor=C.+Geauthor=Y.+Chenauthor=X.+Liuauthor=Y.+Wangauthor=Y.+Yangauthor=W.+Luoauthor=F.+Daiauthor=S.+Wangauthor=S.+Chenauthor=S.+Xieauthor=C.+Wang&title=Discovery+of+the+polyamine+conjugate+with+benzo%5B+cd%5Dindol-2%281+H%29-one+as+a+lysosome-targeted+antimetastatic+agent&doi=10.1021%2Facs.jmedchem.8b00694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14iR"><div class="casContent"><span class="casTitleNuber">14i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Polyamine Conjugate with Benzo[cd]indol-2(1H)-one as a Lysosome-Targeted Antimetastatic Agent</span></div><div class="casAuthors">Li, Jinghua; Tian, Runguo; Ge, Chaochao; Chen, Ying; liu, Xiaodan; Wang, Yuxia; Yang, Yacheng; Luo, Wen; Dai, Fujun; Wang, Senzhen; Chen, Shuai; Xie, Songqiang; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6814-6829</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polyamine derivs. have a promising prospect in dealing with disseminated tumor cells, a major obstacle in cancer therapy.  To develop a bifunctional polyamine deriv. that can serve as a fluorescent probe and an antimetastatic agent, three kinds of polyamine conjugates with benzo[cd]indol-2(1H)-one as a scaffold were designed and synthesized.  Compd. 5e was selected as a lead by in vitro screening.  Two animal models demonstrated that 5e inhibited pulmonary metastasis and tumor growth.  As a fluorescent probe, 5e might partially enter cells via a polyamine transporter and subsequently localize in the lysosome.  Mechanistic investigations demonstrated the interdependence of 5e-triggered apoptosis and autophagy.  Compd. 5e modulated the expression of LC3-II, p62, cathepsins, and the expression of caspases 3, caspase 8, Bcl-2, and p53.  The SSAT-mediated Akt/β-catenin pathways were also inhibited by 5e.  The dual features of 5e make it a worthwhile lead compd. for further structural optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpgNjuODdNLVg90H21EOLACvtfcHk0lihg2-uufFMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsbnI&md5=dd73db90492e94104a71a8dabdc46b5a</span></div><a href="/servlet/linkout?suffix=cit14i&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00694%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520the%2520polyamine%2520conjugate%2520with%2520benzo%255B%2520cd%255Dindol-2%25281%2520H%2529-one%2520as%2520a%2520lysosome-targeted%2520antimetastatic%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6814%26epage%3D6829%26doi%3D10.1021%2Facs.jmedchem.8b00694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span> <span> </span><span class="NLM_article-title">Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1092</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.18632%2Foncotarget.13582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27901475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvVGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1092-1109&author=C.+Wangauthor=P.+Ruanauthor=Y.+Zhaoauthor=X.+Liauthor=J.+Wangauthor=X.+Wuauthor=T.+Liuauthor=S.+Wangauthor=J.+Houauthor=W.+Liauthor=Q.+Liauthor=J.+Liauthor=F.+Daiauthor=D.+Fangauthor=C.+Wangauthor=S.+Xie&title=Spermidine%2Fspermine+N1-acetyltransferase+regulates+cell+growth+and+metastasis+via+AKT%2F%CE%B2-catenin+signaling+pathways+in+hepatocellular+and+colorectal+carcinoma+cells&doi=10.18632%2Foncotarget.13582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14jR"><div class="casContent"><span class="casTitleNuber">14j</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells</span></div><div class="casAuthors">Wang Cong; Ruan Ping; Zhao Ying; Li Xiaomin; Wang Jun; Wu Xiaoxiao; Liu Tong; Wang Shasha; Hou Jiuzhou; Li Wei; Fang Dong; Xie Songqiang; Li Qian; Li Jinghua; Dai Fujun; Wang Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1092-1109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common cancers across the world.  Therefore, identifying the potential molecular mechanisms that promote HCC and CRC progression and metastasis are urgently needed.  Spermidine/spermine N1-acetyltransferase (SSAT) is a catabolic enzyme that acetylates the high-order polyamines spermine and spermidine, thus decreasing the cellular content of polyamines.  Several publications have suggested that depletion of intracellular polyamines inhibited tumor progression and metastasis in various cancer cells.  However, whether and how SSAT regulates cell growth, migration and invasion in hepatocellular and colorectal carcinoma cells remains unclear.  In this study, depletion of polyamines mediated by SSAT not only attenuated the tumor cell proliferation but also dramatically inhibited cell migration and invasion in hepatocellular and colorectal carcinoma cells.  Subsequent investigations revealed introduction of SSAT into HepG2, SMMC7721 hepatocellular carcinoma cells and HCT116 colorectal carcinoma cells significantly suppressed p-AKT, p-GSK3β expression as well as β-catenin nuclear translocation, while inhibition of GSK3β activity or exogenous polyamines could restore SSAT-induced decreases in the protein expression of p-AKT, p-GSK3β and β-catenin.  Conversely, knockdown of SSAT in Bel7402 hepatocellular carcinoma cells and HT-29 colorectal carcinoma cells which expressed high levels of SSAT endogenously significantly promoted the expression of p-AKT, p-GSK3β as well as β-catenin nuclear translocation.  Taken together, our results indicated depletion of polyamines by SSAT significantly inhibited cell proliferation, migration and invasion through AKT/GSK3β/β-catenin signaling pathway in hepatocellular carcinoma and colorectal cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy24SyfiZNxD0O18WR3iAofW6udTcc2eb4pXpnoN_uZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvVGhug%253D%253D&md5=deacadffa9c604953b34a1930f6c9546</span></div><a href="/servlet/linkout?suffix=cit14j&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13582%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%26atitle%3DSpermidine%252Fspermine%2520N1-acetyltransferase%2520regulates%2520cell%2520growth%2520and%2520metastasis%2520via%2520AKT%252F%25CE%25B2-catenin%2520signaling%2520pathways%2520in%2520hepatocellular%2520and%2520colorectal%2520carcinoma%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1092%26epage%3D1109%26doi%3D10.18632%2Foncotarget.13582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span> <span> </span><span class="NLM_article-title">p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-0996-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41586-019-0996-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30842655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567&publication_year=2019&pages=253-256&author=L.+Liauthor=Y.+Maoauthor=L.+Zhaoauthor=L.+Liauthor=J.+Wuauthor=M.+Zhaoauthor=W.+Duauthor=L.+Yuauthor=P.+Jiang&title=p53+regulation+of+ammonia+metabolism+through+urea+cycle+controls+polyamine+biosynthesis&doi=10.1038%2Fs41586-019-0996-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis</span></div><div class="casAuthors">Li, Le; Mao, Youxiang; Zhao, Lina; Li, Lijia; Wu, Jinjun; Zhao, Mengjia; Du, Wenjing; Yu, Li; Jiang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">567</span>
        (<span class="NLM_cas:issue">7747</span>),
    <span class="NLM_cas:pages">253-256</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer cells exhibit altered and usually increased metabolic processes to meet their high biogenetic demands.  Under these conditions, ammonia is concomitantly produced by the increased metabolic processing.  However, it is unclear how tumor cells dispose of excess ammonia and what outcomes might be caused by the accumulation of ammonia.  Here we report that the tumor suppressor p53, the most frequently mutated gene in human tumors, regulates ammonia metab. by repressing the urea cycle.  Through transcriptional downregulation of CPS1, OTC and ARG1, p53 suppresses ureagenesis and elimination of ammonia in vitro and in vivo, leading to the inhibition of tumor growth.  Conversely, downregulation of these genes reciprocally activates p53 by MDM2-mediated mechanism(s).  Furthermore, the accumulation of ammonia causes a significant decline in mRNA translation of the polyamine biosynthetic rate-limiting enzyme ODC, thereby inhibiting the biosynthesis of polyamine and cell proliferation.  Together, these findings link p53 to ureagenesis and ammonia metab., and further reveal a role for ammonia in controlling polyamine biosynthesis and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF69TVb-Lx-LVg90H21EOLACvtfcHk0lhf4L561P-97g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurs%253D&md5=31e3f7a94ad9795604e12c26fa9143a5</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0996-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0996-7%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DP.%26atitle%3Dp53%2520regulation%2520of%2520ammonia%2520metabolism%2520through%2520urea%2520cycle%2520controls%2520polyamine%2520biosynthesis%26jtitle%3DNature%26date%3D2019%26volume%3D567%26spage%3D253%26epage%3D256%26doi%3D10.1038%2Fs41586-019-0996-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span> <span> </span><span class="NLM_article-title">Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E6806</span>– <span class="NLM_lpage">E6812</span>, <span class="refDoi"> DOI: 10.1073/pnas.1607152113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1073%2Fpnas.1607152113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27698118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Sitr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E6806-E6812&author=Y.+Ouauthor=S.+J.+Wangauthor=D.+Liauthor=B.+Chuauthor=W.+Gu&title=Activation+of+SAT1+engages+polyamine+metabolism+with+p53-mediated+ferroptotic+responses&doi=10.1073%2Fpnas.1607152113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses</span></div><div class="casAuthors">Ou, Yang; Wang, Shang-Jui; Li, Dawei; Chu, Bo; Gu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">E6806-E6812</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although p53-mediated cell-cycle arrest, senescence, and apoptosis remain crit. barriers to cancer development, the emerging role of p53 in cell metab., oxidative responses, and ferroptotic cell death has been a topic of great interest.  Nevertheless, it is unclear how p53 orchestrates its activities in multiple metabolic pathways into tumor suppressive effects.  Here, we identified the SAT1 (spermidine/spermine N1-acetyltransferase 1) gene as a transcription target of p53.  SAT1 is a rate-limiting enzyme in polyamine catabolism critically involved in the conversion of spermidine and spermine back to putrescine.  Surprisingly, we found that activation of SAT1 expression induces lipid peroxidn. and sensitizes cells to undergo ferroptosis upon reactive oxygen species (ROS)-induced stress, which also leads to suppression of tumor growth in xenograft tumor models.  Notably, SAT1 expression is down-regulated in human tumors, and CRISPR-cas9-mediated knockout of SAT1 expression partially abrogates p53-mediated ferroptosis.  Moreover, SAT1 induction is correlated with the expression levels of arachidonate 15-lipoxygenase (ALOX15), and SAT1-induced ferroptosis is significantly abrogated in the presence of PD146176, a specific inhibitor of ALOX15.  Thus, our findings uncover a metabolic target of p53 involved in ferroptotic cell death and provide insight into the regulation of polyamine metab. and ferroptosis-mediated tumor suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZFlA6cc7bLVg90H21EOLACvtfcHk0lhf4L561P-97g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Sitr7K&md5=a543ebc65f1b5bb49afde2a2f88d45e5</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1607152113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1607152113%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DActivation%2520of%2520SAT1%2520engages%2520polyamine%2520metabolism%2520with%2520p53-mediated%2520ferroptotic%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE6806%26epage%3DE6812%26doi%3D10.1073%2Fpnas.1607152113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8854</span>– <span class="NLM_lpage">8866</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.18632%2Foncotarget.12673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27750219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtlOjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8854-8866&author=A.+Eastman&title=Improving+anticancer+drug+development+begins+with+cell+culture%3A+misinformation+perpetrated+by+the+misuse+of+cytotoxicity+assays&doi=10.18632%2Foncotarget.12673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays</span></div><div class="casAuthors">Eastman Alan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">8854-8866</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The high failure rate of anticancer drug discovery and development has consumed billions of dollars annually.  While many explanations have been provided, I believe that misinformation arising from inappropriate cell-based screens has been completely over-looked.  Most cell culture experiments are irrelevant to how drugs are subsequently administered to patients.  Usually, drug development focuses on growth inhibition rather than cell killing.  Drugs are selected based on continuous incubation of cells, then frequently administered to the patient as a bolus.  Target identification and validation is often performed by gene suppression that inevitably mimics continuous target inhibition.  Drug concentrations in vitro frequently far exceed in vivo concentrations.  Studies of drug synergy are performed at sub-optimal concentrations.  And the focus on a limited number of cell lines can misrepresent the potential efficacy in a patient population.  The intent of this review is to encourage more appropriate experimental design and data interpretation, and to improve drug development in the area of cell-based assays.  Application of these principles should greatly enhance the successful translation of novel drugs to the patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReT51ZB6VkgHELvajU9pjPfW6udTcc2eYIhSl2o3nLIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtlOjtA%253D%253D&md5=cc8ee6536db13f7c09d01553fd81a641</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12673%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DImproving%2520anticancer%2520drug%2520development%2520begins%2520with%2520cell%2520culture%253A%2520misinformation%2520perpetrated%2520by%2520the%2520misuse%2520of%2520cytotoxicity%2520assays%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D8854%26epage%3D8866%26doi%3D10.18632%2Foncotarget.12673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzayans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span> <span> </span><span class="NLM_article-title">Do Multiwell Plate High Throughput Assays Measure Loss of Cell Viability Following Exposure to Genotoxic Agents?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1679</span>, <span class="refDoi"> DOI: 10.3390/ijms18081679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3390%2Fijms18081679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1679&author=R.+Mirzayansauthor=B.+Andraisauthor=D.+Murray&title=Do+Multiwell+Plate+High+Throughput+Assays+Measure+Loss+of+Cell+Viability+Following+Exposure+to+Genotoxic+Agents%3F&doi=10.3390%2Fijms18081679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Do multiwell plate high throughput assays measure loss of cell viability following exposure to genotoxic agents?</span></div><div class="casAuthors">Mirzayans, Razmik; Andrais, Bonnie; Murray, David</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1679/1-1679/10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cell-based assays in multiwell plates are widely used for radiosensitivity and chemosensitivity assessment with different mammalian cell types.  Despite their relative ease of performance, such assays lack specificity as they do not distinguish between the cytostatic (reversible/sustained growth arrest) and cytotoxic (loss of viability) effects of genotoxic agents.  We recently reported studies with solid tumor-derived cell lines demonstrating that radiosensitivity as measured by multiwell plate colorimetric (e.g., XTT) and fluorimetric (e.g., CellTiter-Blue) assays reflects growth arrest but not loss of viability.  Herein we report similar observations with cancer cell lines expressing wild-type p53 (A549 lung carcinoma) or mutant p53 (MDA-MB-231 breast carcinoma) after treatment with the chemotherapeutic drug cisplatin.  Importantly, we show that treatment of cancer cells with concns. of cisplatin that result in 50% effect (i.e., IC50) in multiwell plate assays trigger the emergence of growth arrested cells that exhibit highly enlarged morphol., remain viable and adherent to the culture dish, and metabolize the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to its formazan deriv.  The emergence of markedly enlarged viable cells complicates the interpretation of chemosensitivity data obtained with multiwell plate high throughput assays.  Relying solely on IC50 values could be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1IIZMjmkGLVg90H21EOLACvtfcHk0lidQBwVrhEgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7zE&md5=9a70f03a7e7fed08005584df4b62b8dc</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.3390%2Fijms18081679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081679%26sid%3Dliteratum%253Aachs%26aulast%3DMirzayans%26aufirst%3DR.%26aulast%3DAndrais%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DD.%26atitle%3DDo%2520Multiwell%2520Plate%2520High%2520Throughput%2520Assays%2520Measure%2520Loss%2520of%2520Cell%2520Viability%2520Following%2520Exposure%2520to%2520Genotoxic%2520Agents%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1679%26doi%3D10.3390%2Fijms18081679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massague, J.</span></span> <span> </span><span class="NLM_article-title">Metastasis: from dissemination to organ-specific colonization</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1038/nrc2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=19308067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=274-284&author=D.+X.+Nguyenauthor=P.+D.+Bosauthor=J.+Massague&title=Metastasis%3A+from+dissemination+to+organ-specific+colonization&doi=10.1038%2Fnrc2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metastasis: from dissemination to organ-specific colonization</span></div><div class="casAuthors">Nguyen, Don X.; Bos, Paula D.; Massague, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">274-284</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis to distant organs is an ominous feature of most malignant tumors but the natural history of this process varies in different cancers.  The cellular origin, intrinsic properties of the tumor, tissue affinities and circulation patterns det. not only the sites of tumor spread, but also the temporal course and severity of metastasis to vital organs.  Striking disparities in the natural progression of different cancers raise important questions about the evolution of metastatic traits, the genetic determinants of these properties and the mechanisms that lead to the selection of metastatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8Sj9LL_MPLVg90H21EOLACvtfcHk0lidQBwVrhEgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSrsr4%253D&md5=c9a4a69159de28fe6477154df4d8ade8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrc2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2622%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BX.%26aulast%3DBos%26aufirst%3DP.%2BD.%26aulast%3DMassague%26aufirst%3DJ.%26atitle%3DMetastasis%253A%2520from%2520dissemination%2520to%2520organ-specific%2520colonization%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D274%26epage%3D284%26doi%3D10.1038%2Fnrc2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">GammaH2AX and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/nrc2523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=19005492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=957-967&author=W.+M.+Bonnerauthor=C.+E.+Redonauthor=J.+S.+Dickeyauthor=A.+J.+Nakamuraauthor=O.+A.+Sedelnikovaauthor=S.+Solierauthor=Y.+Pommier&title=GammaH2AX+and+cancer&doi=10.1038%2Fnrc2523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">γH2AX and cancer</span></div><div class="casAuthors">Bonner, William M.; Redon, Christophe E.; Dickey, Jennifer S.; Nakamura, Asako J.; Sedelnikova, Olga A.; Solier, Stephanie; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone H2AX phosphorylation on a serine four residues from the carboxyl terminus (producing γH2AX) is a sensitive marker for DNA double-strand breaks (DSBs).  DSBs may lead to cancer but, paradoxically, are also used to kill cancer cells.  Using γH2AX detection to det. the extent of DSB induction may help to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvJ8vnkfC0bVg90H21EOLACvtfcHk0lidQBwVrhEgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK&md5=b0a83efe87f2823e79146ba8a2edf808</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc2523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2523%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DDickey%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DSedelnikova%26aufirst%3DO.%2BA.%26aulast%3DSolier%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DGammaH2AX%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D957%26epage%3D967%26doi%3D10.1038%2Fnrc2523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">The ATP-dependent glutathione S-conjugate export pump</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(92)90489-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2F0968-0004%2892%2990489-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1455517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1992&pages=463-468&issue=11&author=T.+Ishikawa&title=The+ATP-dependent+glutathione+S-conjugate+export+pump&doi=10.1016%2F0968-0004%2892%2990489-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ATP-dependent glutathione S-conjugate export pump</span></div><div class="casAuthors">Ishikawa, Toshihisa</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">463-8</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    </div><div class="casAbstract">A review, with 34 refs., on the physiol. significance of the ATP-dependent glutathione S-conjugate pump (GS-X pump) with respect to the metab. of endo- and xenobiotics, as well as its potential role in the modulation of the proliferation of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ejhB8FHearVg90H21EOLACvtfcHk0ljDjbuXVLE4Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVSltQ%253D%253D&md5=806cd4e5ac20363c655a808a82072e3e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2892%2990489-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252892%252990489-V%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DThe%2520ATP-dependent%2520glutathione%2520S-conjugate%2520export%2520pump%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1992%26volume%3D17%26issue%3D11%26spage%3D463%26epage%3D468%26doi%3D10.1016%2F0968-0004%2892%2990489-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species (ROS) accumulation induced by mononaphthalimide-spermidine leads to intrinsic and AIF-mediated apoptosis in HeLa cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.3892/or.2011.1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3892%2For.2011.1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=21290091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1099-1107&issue=4&author=L.+Yangauthor=J.+Zhaoauthor=Y.+Zhuauthor=Z.+Tianauthor=C.+Wang&title=Reactive+oxygen+species+%28ROS%29+accumulation+induced+by+mononaphthalimide-spermidine+leads+to+intrinsic+and+AIF-mediated+apoptosis+in+HeLa+cells&doi=10.3892%2For.2011.1173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species (ROS) accumulation induced by mononaphthalimide-spermidine leads to intrinsic and AIF-mediated apoptosis in HeLa cells</span></div><div class="casAuthors">Yang, Lianhe; Zhao, Jin; Zhu, Yanqin; Tian, Zhiyong; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1099-1107</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Developing polyamine conjugates having the potential of transporting naphthalimide selectively into tumor cells is attractive.  However, the evaluation of their cytotoxic mechanism has not been comprehensive.  This study focused on the effects of mononaphthalimide spermidine (MNISpd) conjugate on apoptosis induction and the relationship between MNISpd-induced apoptosis and reactive oxygen species (ROS) in HeLa cells.  Our findings indicated that 9 μM MNISpd induced apoptosis in HeLa cells during a 48-h period.  MNISpd induced apoptosis in HeLa cells following cytochrome c release, elevation of caspase 3/9 activity, apoptosis-inducing factor (AIF) translocation and up-/down-regulation of Bax/Bcl-2 protein expression, resp., and these effects were completely antagonized by pre-incubation with 10 mM NAC for 2 h.  MNISpd induced significant ROS accumulation following up-regulation of polyamine oxidase (PAO) activity and complex variations in glutathione levels.  It is concluded that MNISpd-induced apoptosis is related to intrinsic caspase-dependent and AIF-mediated caspase-independent apoptosis pathways in HeLa cells.  MNISpd-induced apoptosis correlates to MNISpd-induced ROS prodn. resulting from GSH (reduced form of glutathione) pool depletion, and PAO is likely to be the source of ROS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgdG1pmQgW7Vg90H21EOLACvtfcHk0ljDjbuXVLE4Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFWltbg%253D&md5=cd9732f40d7820a6255861aa43b4fa95</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3892%2For.2011.1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2011.1173%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DReactive%2520oxygen%2520species%2520%2528ROS%2529%2520accumulation%2520induced%2520by%2520mononaphthalimide-spermidine%2520leads%2520to%2520intrinsic%2520and%2520AIF-mediated%2520apoptosis%2520in%2520HeLa%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2011%26volume%3D25%26issue%3D4%26spage%3D1099%26epage%3D1107%26doi%3D10.3892%2For.2011.1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e','cit11f','cit11g'],'ref12':['cit12a','cit12b','cit12c','cit12d','cit12e','cit12f','cit12g','cit12h','cit12i','cit12j','cit12k','cit12l','cit12m','cit12n','cit12o','cit12p','cit12q','cit12r','cit12s','cit12t'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f'],'ref14':['cit14a','cit14b','cit14c','cit14d','cit14e','cit14f','cit14g','cit14h','cit14i','cit14j'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenting  Li</span>, <span class="hlFld-ContribAuthor ">Lingyun  Wang</span>, <span class="hlFld-ContribAuthor ">Tianlei  Sun</span>, <span class="hlFld-ContribAuthor ">Hao  Tang</span>, <span class="hlFld-ContribAuthor ">Brian  Bui</span>, <span class="hlFld-ContribAuthor ">Derong  Cao</span>, <span class="hlFld-ContribAuthor ">Ruibing  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of nanoparticles combining polyamine detection with photodynamic therapy. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2021,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-021-02317-5" title="DOI URL">https://doi.org/10.1038/s42003-021-02317-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-021-02317-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-021-02317-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DCharacterization%252Bof%252Bnanoparticles%252Bcombining%252Bpolyamine%252Bdetection%252Bwith%252Bphotodynamic%252Btherapy%26aulast%3DLi%26aufirst%3DWenting%26date%3D2021%26date%3D2021%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin  Rioux</span>, <span class="hlFld-ContribAuthor ">Aline  Pinon</span>, <span class="hlFld-ContribAuthor ">Aurélie  Gamond</span>, <span class="hlFld-ContribAuthor ">Frédérique  Martin</span>, <span class="hlFld-ContribAuthor ">Aurélie  Laurent</span>, <span class="hlFld-ContribAuthor ">Yves  Champavier</span>, <span class="hlFld-ContribAuthor ">Caroline  Barette</span>, <span class="hlFld-ContribAuthor ">Bertrand  Liagre</span>, <span class="hlFld-ContribAuthor ">Catherine  Fagnère</span>, <span class="hlFld-ContribAuthor ">Vincent  Sol</span>, <span class="hlFld-ContribAuthor ">Christelle  Pouget</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of chalcone-polyamine conjugates as novel vectorized agents in colorectal and prostate cancer chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113586. <a href="https://doi.org/10.1016/j.ejmech.2021.113586" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113586%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bchalcone-polyamine%252Bconjugates%252Bas%252Bnovel%252Bvectorized%252Bagents%252Bin%252Bcolorectal%252Band%252Bprostate%252Bcancer%252Bchemotherapy%26aulast%3DRioux%26aufirst%3DBenjamin%26date%3D2021%26volume%3D222%26spage%3D113586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Linrong  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Yue</span>, <span class="hlFld-ContribAuthor ">Zhansheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Shihao  Su</span>, <span class="hlFld-ContribAuthor ">Yutong  Chen</span>, <span class="hlFld-ContribAuthor ">Lu  Yu</span>, <span class="hlFld-ContribAuthor ">Pengfei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruijuan  Ma</span>, <span class="hlFld-ContribAuthor ">Yingguang  Li</span>, <span class="hlFld-ContribAuthor ">Yinxia  Ma</span>, <span class="hlFld-ContribAuthor ">Huinan  Jia</span>, <span class="hlFld-ContribAuthor ">Chaojie  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Wang</span>, <span class="hlFld-ContribAuthor ">Songqiang  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113469. <a href="https://doi.org/10.1016/j.ejmech.2021.113469" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113469%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnaphthalimide-polyamine%252Bconjugate%252Bpreferentially%252Baccumulates%252Bin%252Bhepatic%252Bcarcinoma%252Bmetastases%252Bas%252Ba%252Blysosome-targeted%252Bantimetastatic%252Bagent%26aulast%3DMa%26aufirst%3DJing%26date%3D2021%26volume%3D221%26spage%3D113469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Ravera</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Gabano</span>, <span class="hlFld-ContribAuthor ">Ilaria  Zanellato</span>, <span class="hlFld-ContribAuthor ">Beatrice  Rangone</span>, <span class="hlFld-ContribAuthor ">Elena  Perin</span>, <span class="hlFld-ContribAuthor ">Beatrice  Ferrari</span>, <span class="hlFld-ContribAuthor ">Maria Grazia  Bottone</span>, <span class="hlFld-ContribAuthor ">Domenico  Osella</span>. </span><span class="cited-content_cbyCitation_article-title">Cis,cis,trans
              -[Pt
              IV
              Cl
              2
              (NH
              3
              )
              2
              (perillato)
              2
              ], a dual-action prodrug with excellent cytotoxic and antimetastatic activity. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2021,</strong> <em>50 </em>
                                    (9)
                                     , 3161-3177. <a href="https://doi.org/10.1039/D0DT04051G" title="DOI URL">https://doi.org/10.1039/D0DT04051G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT04051G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT04051G%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DCis%25252Ccis%25252Ctrans%252B-%25255BPt%252BIV%252BCl%252B2%252B%252528NH%252B3%252B%252529%252B2%252B%252528perillato%252529%252B2%252B%25255D%25252C%252Ba%252Bdual-action%252Bprodrug%252Bwith%252Bexcellent%252Bcytotoxic%252Band%252Bantimetastatic%252Bactivity%26aulast%3DRavera%26aufirst%3DMauro%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D9%26spage%3D3161%26epage%3D3177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anil K.  Gorle</span>, <span class="hlFld-ContribAuthor ">Thomas  Haselhorst</span>, <span class="hlFld-ContribAuthor ">Samantha J.  Katner</span>, <span class="hlFld-ContribAuthor ">Arun V.  Everest‐Dass</span>, <span class="hlFld-ContribAuthor ">James D.  Hampton</span>, <span class="hlFld-ContribAuthor ">Erica J.  Peterson</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Koblinski</span>, <span class="hlFld-ContribAuthor ">Eriko  Katsuta</span>, <span class="hlFld-ContribAuthor ">Kazuaki  Takabe</span>, <span class="hlFld-ContribAuthor ">Mark  Itzstein</span>, <span class="hlFld-ContribAuthor ">Susan J.  Berners‐Price</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Farrell</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational Modulation of Iduronic Acid‐Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound and Implications for Development of Antimetastatic Platinum Drugs. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (6)
                                     , 3320-3326. <a href="https://doi.org/10.1002/ange.202013749" title="DOI URL">https://doi.org/10.1002/ange.202013749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202013749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202013749%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DConformational%252BModulation%252Bof%252BIduronic%252BAcid%2525E2%252580%252590Containing%252BSulfated%252BGlycosaminoglycans%252Bby%252Ba%252BPolynuclear%252BPlatinum%252BCompound%252Band%252BImplications%252Bfor%252BDevelopment%252Bof%252BAntimetastatic%252BPlatinum%252BDrugs%26aulast%3DGorle%26aufirst%3DAnil%2BK.%26date%3D2021%26date%3D2020%26volume%3D133%26issue%3D6%26spage%3D3320%26epage%3D3326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anil K.  Gorle</span>, <span class="hlFld-ContribAuthor ">Thomas  Haselhorst</span>, <span class="hlFld-ContribAuthor ">Samantha J.  Katner</span>, <span class="hlFld-ContribAuthor ">Arun V.  Everest‐Dass</span>, <span class="hlFld-ContribAuthor ">James D.  Hampton</span>, <span class="hlFld-ContribAuthor ">Erica J.  Peterson</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Koblinski</span>, <span class="hlFld-ContribAuthor ">Eriko  Katsuta</span>, <span class="hlFld-ContribAuthor ">Kazuaki  Takabe</span>, <span class="hlFld-ContribAuthor ">Mark  Itzstein</span>, <span class="hlFld-ContribAuthor ">Susan J.  Berners‐Price</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Farrell</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational Modulation of Iduronic Acid‐Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound and Implications for Development of Antimetastatic Platinum Drugs. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (6)
                                     , 3283-3289. <a href="https://doi.org/10.1002/anie.202013749" title="DOI URL">https://doi.org/10.1002/anie.202013749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202013749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202013749%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DConformational%252BModulation%252Bof%252BIduronic%252BAcid%2525E2%252580%252590Containing%252BSulfated%252BGlycosaminoglycans%252Bby%252Ba%252BPolynuclear%252BPlatinum%252BCompound%252Band%252BImplications%252Bfor%252BDevelopment%252Bof%252BAntimetastatic%252BPlatinum%252BDrugs%26aulast%3DGorle%26aufirst%3DAnil%2BK.%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D6%26spage%3D3283%26epage%3D3289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingguang  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Yue</span>, <span class="hlFld-ContribAuthor ">Linrong  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Niu</span>, <span class="hlFld-ContribAuthor ">Hanfang  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Songqiang  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104011. <a href="https://doi.org/10.1016/j.bioorg.2020.104011" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252BPt%252528IV%252529-based%252Bmononitro-naphthalimide%252Bconjugate%252Bwith%252Bminimized%252Bside-effects%252Btargeting%252BDNA%252Bdamage%252Bresponse%252Bvia%252Ba%252Bdual-DNA-damage%252Bapproach%252Bto%252Bovercome%252Bcisplatin%252Bresistance%26aulast%3DLi%26aufirst%3DYingguang%26date%3D2020%26volume%3D101%26spage%3D104011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengyi  Zhao</span>, <span class="hlFld-ContribAuthor ">Wen  Lu</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Xu</span>, <span class="hlFld-ContribAuthor ">Jingjing  Zhang</span>, <span class="hlFld-ContribAuthor ">Xu  Sun</span>, <span class="hlFld-ContribAuthor ">Shilong  Yang</span>, <span class="hlFld-ContribAuthor ">Mengyi  Zhou</span>, <span class="hlFld-ContribAuthor ">Fan  Su</span>, <span class="hlFld-ContribAuthor ">Feng  Lin</span>, <span class="hlFld-ContribAuthor ">Fuliang  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and high antiproliferative activity of dehydroabietylamine pyridine derivatives in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2020,</strong> <em>477 </em>
                                    (12)
                                     , 2383-2399. <a href="https://doi.org/10.1042/BCJ20200337" title="DOI URL">https://doi.org/10.1042/BCJ20200337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20200337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20200337%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DSynthesis%252Band%252Bhigh%252Bantiproliferative%252Bactivity%252Bof%252Bdehydroabietylamine%252Bpyridine%252Bderivatives%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DZhao%26aufirst%3DFengyi%26date%3D2020%26date%3D2020%26volume%3D477%26issue%3D12%26spage%3D2383%26epage%3D2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Yingguang  Li</span>, <span class="hlFld-ContribAuthor ">Linrong  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Yue</span>, <span class="hlFld-ContribAuthor ">Hanfang  Liu</span>, <span class="hlFld-ContribAuthor ">Jiajia  Wang</span>, <span class="hlFld-ContribAuthor ">Zhuoqing  Xi</span>, <span class="hlFld-ContribAuthor ">Man  Shi</span>, <span class="hlFld-ContribAuthor ">Sihan  Zhao</span>, <span class="hlFld-ContribAuthor ">Qi  Ma</span>, <span class="hlFld-ContribAuthor ">Sitong  Liu</span>, <span class="hlFld-ContribAuthor ">Shudi  Guo</span>, <span class="hlFld-ContribAuthor ">Jianing  Liu</span>, <span class="hlFld-ContribAuthor ">Lili  Hou</span>, <span class="hlFld-ContribAuthor ">Chaojie  Wang</span>, <span class="hlFld-ContribAuthor ">Peng George  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Tian</span>, <span class="hlFld-ContribAuthor ">Songqiang  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">A Polyamine-Based Dinitro-Naphthalimide Conjugate as Substrates for Polyamine Transporters Preferentially Accumulates in Cancer Cells and Minimizes Side Effects in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00166" title="DOI URL">https://doi.org/10.3389/fchem.2020.00166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00166%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DA%252BPolyamine-Based%252BDinitro-Naphthalimide%252BConjugate%252Bas%252BSubstrates%252Bfor%252BPolyamine%252BTransporters%252BPreferentially%252BAccumulates%252Bin%252BCancer%252BCells%252Band%252BMinimizes%252BSide%252BEffects%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DMa%26aufirst%3DJing%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zuojie  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Zhifang  Liu</span>, <span class="hlFld-ContribAuthor ">Qingpeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yanna  Zhao</span>, <span class="hlFld-ContribAuthor ">Jinjian  Wei</span>, <span class="hlFld-ContribAuthor ">Min  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengping  Wang</span>, <span class="hlFld-ContribAuthor ">Dacheng  Li</span>, <span class="hlFld-ContribAuthor ">Jun  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2020,</strong> <em>151 </em>
                                    (3)
                                     , 353-367. <a href="https://doi.org/10.1007/s00706-020-02561-1" title="DOI URL">https://doi.org/10.1007/s00706-020-02561-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-020-02561-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-020-02561-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bmono%252Bnaphthalimide%252Bplatinum%252528IV%252529%252Bderivatives%252Bas%252Bantitumor%252Bagents%252Bwith%252Bdual%252BDNA%252Bdamage%252Bmechanism%26aulast%3DLi%26aufirst%3DZuojie%26date%3D2020%26date%3D2020%26volume%3D151%26issue%3D3%26spage%3D353%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of homospermidineplatin (<b>4a</b>), Pt(IV) prodrugs without polyamine modified (<b>6a</b>), and the released polyamine ligand <b>8a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> antimetastatic activity of <b>4a</b>, <b>6a</b>, cisplatin, and oxaliplatin in 4T1 breast carcinoma tumors every 2 days for a total of four treatments. (A) Body weight of mice during treatment with <b>4a</b>, <b>6a</b>, cisplatin, oxaliplatin, and a control group for 14 days. (B) Statistics of lung metastasis nodules from mice after treatment with <b>4a</b>, <b>6a</b>, cisplatin, oxaliplatin, and a control group for 14 days. (C) Representative images of pulmonary metastasis from mice treated with control, <b>6a</b> (14 mg/kg, 4.8 mg of Pt/kg), oxaliplatin (5 mg/kg, 2.46 mg of Pt/kg), cisplatin (5 mg/kg, 3.26 mg of Pt/kg), <b>4a1</b> (5 mg/kg, 1.20 mg of Pt/kg), <b>4a2</b> (10 mg/kg, 2.40 mg of Pt/kg), and <b>4a3</b> (20 mg/kg, 4.80 mg of Pt/kg) by intravenous delivery once every 2 days (<i>n</i> = 8 mice per group). **<i>P</i> < 0.01; ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> antitumor activity of <b>4a</b>, polyamine ligand <b>8a</b>, <b>6a</b> without polyamine modified, cisplatin, and oxaliplatin in 4T1 breast carcinoma tumors. Eight mice each received the vehicle, cisplatin (5 mg/kg, 3.26 mg of Pt/kg), oxaliplatin (5 mg/kg, 2.46 mg of Pt/kg), cisplatin and polyamine ligand (1:1, 5 mg of cisplatin/kg + 5 mg of polyamine ligand/kg), <b>4a</b> (5 mg/kg, 1.20 mg of Pt/kg; 10 mg/kg, 2.40 mg of Pt/kg; 20 mg/kg, 4.80 mg of Pt/kg), <b>6a</b> (14 mg/kg, 4.8 mg of Pt/kg), or <b>8a</b> (20 mg/kg) intravenously (i.v.) every 2 days for a total of four treatments. (A) Body weight of the mice during treatment. (B) Tumor weight in each group at the end of the experiment. (C) Tumor growth as a function of time. (D) Images of the tumors at the end of the experiment. Definitions: first horizontal line, control group; second line, polyamine ligand <b>8a</b> group; third line, <b>6a</b> group; fourth line, oxaliplatin group (5 mg/kg, 2.46 mg of Pt/kg); fifth line, cisplatin and polyamine ligand group; sixth line, cisplatin group (5 mg/kg, 3.26 mg of Pt/kg); seventh line, <b>4a</b> group (5 mg/kg, 1.20 mg of Pt/kg); eighth line, <b>4a</b> group (10 mg/kg, 2.40 mg of Pt/kg); ninth line, <b>4a</b> group (20 mg/kg, 4.80 mg of Pt/kg). **<i>P</i> < 0.01; ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cellular uptake and distribution following an 8 h incubation with 10 μM <b>4a</b> in A549 and A549cisR cells. (A) Accumulation of Pt in A549 and A549cisR cells upon 10 μM treatment for 8 h. (B) Platination levels of nuclear DNA extracts from A549 and A549cisR cells after an 8 h incubation with 10 μM tested compounds. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of different concentrations of <b>4a</b> and cisplatin on p53 protein and gene expression in A549cisR cells. (A) Effect of <b>4a</b> and cisplatin on p53 protein in A549cisR cells after a 24 h treatment. (B) qRT-PCR analysis of the p53 transcriptional level was performed with total RNAs purified from A549cisR cells treated with <b>4a</b> and cisplatin after 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of different concentrations of (A) <b>4a</b> and (B) cisplatin on SSAT expression in A549cisR cells after a 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of (A) <b>4a</b> and (B) cisplatin on β-catenin expression in A549cisR cells at 10 μM after a 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>4a</b> affects polyamine metabolism and function by upregulating PAO and ROS and downregulating GSH and GSH-Px. (A) Effect of <b>4a</b>, <b>8a</b>, cisplatin, and <b>6a</b> on PAO expression in A549cisR cells at 10 μM after a 24 h treatment. (B) Effect of <b>4a</b>, cisplatin, and <b>6a</b> on PAO expression in A549 cells at 10 μM after a 24 h treatment. (C) Effect of <b>4a</b>, cisplatin, and <b>6a</b> on ROS expression in A549cisR cells at 10 μM after a 24 h treatment: yellow, homospermidineplatin <b>4a</b>; green, cisplatin; red, control group. (D and E) GSH and GSH-Px expression in A549 and A549cisR cells after a 24 h treatment with <b>4a</b>, <b>8a</b>, <b>6a</b>, and cisplatin, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of <b>4a</b>, <b>6a</b>, and cisplatin on polyamine metabolism and function. Polyamine (Put, Spd, and Spm) concentrations in (A) A549 and (B) A549cisR cells after a 24 h treatment with or without <b>4a</b>. Cisplatin and <b>6a</b> are the reference drugs. ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/medium/jm9b01641_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Proposed mechanism of action for polyamine-Pt(IV) prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01641/20191219/images/large/jm9b01641_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01641&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 19 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruix, J.</span></span> <span> </span><span class="NLM_article-title">Bruix, Hepatocellular carcinoma</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1255</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)61347-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2FS0140-6736%2811%2961347-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=22353262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC38vjslOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1245-1255&author=A.+Fornerauthor=J.+M+Llovetauthor=J.+Bruix&title=Bruix%2C+Hepatocellular+carcinoma&doi=10.1016%2FS0140-6736%2811%2961347-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocellular carcinoma</span></div><div class="casAuthors">Forner Alejandro; Llovet Josep M; Bruix Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9822</span>),
    <span class="NLM_cas:pages">1245-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death.  Patients with cirrhosis are at highest risk of developing this malignant disease, and ultrasonography every 6 months is recommended.  Surveillance with ultrasonography allows diagnosis at early stages when the tumour might be curable by resection, liver transplantation, or ablation, and 5-year survival higher than 50% can be achieved.  Patients with small solitary tumours and very well preserved liver function are the best candidates for surgical resection.  Liver transplantation is most beneficial for individuals who are not good candidates for resection, especially those within Milano criteria (solitary tumour ≤5 cm and up to three nodules ≤3 cm).  Donor shortage greatly limits its applicability.  Percutaneous ablation is the most frequently used treatment but its effectiveness is limited by tumour size and localisation.  In asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread not amenable to curative treatments, chemoembolisation can provide survival benefit.  Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer.  Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOX8RK_5ylfwWRJ3OJdH_qfW6udTcc2eb-I8RpFwrYzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjslOhuw%253D%253D&md5=9c13d87d11d47ff8555b73abbaad5558</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961347-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961347-0%26sid%3Dliteratum%253Aachs%26aulast%3DForner%26aufirst%3DA.%26aulast%3DLlovet%26aufirst%3DJ.%2BM%26aulast%3DBruix%26aufirst%3DJ.%26atitle%3DBruix%252C%2520Hepatocellular%2520carcinoma%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1245%26epage%3D1255%26doi%3D10.1016%2FS0140-6736%2811%2961347-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">miR-187–3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.canlet.2016.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27544906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2016&pages=380-390&author=C.+Douauthor=Z.+Liuauthor=M.+Xuauthor=Y.+Jiaauthor=Y.+Wangauthor=Q.+Liauthor=W.+Yangauthor=X.+Zhengauthor=K.+Tuauthor=Q.+Liu&title=miR-187%E2%80%933p+inhibits+the+metastasis+and+epithelial-mesenchymal+transition+of+hepatocellular+carcinoma+by+targeting+S100A4&doi=10.1016%2Fj.canlet.2016.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4</span></div><div class="casAuthors">Dou, Changwei; Liu, Zhikui; Xu, Meng; Jia, Yuli; Wang, Yufeng; Li, Qing; Yang, Wei; Zheng, Xin; Tu, Kangsheng; Liu, Qingguang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">380-390</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MiR-187-3p, a novel cancer-related microRNA, was previously reported to play promoting or suppressive roles in different malignancies.  However, the expression level, biol. function, and underlying mechanisms of miR-187-3p in hepatocellular carcinoma (HCC) remain unknown.  This study demonstrated that miR-187-3p was significantly down-regulated in HCC tissues and cell lines, and was assocd. with advanced TNM stage and metastasis in HCC.  Functional studies confirmed that miR-187-3p could inhibit the metastasis of HCC both in vitro and in vivo.  Moreover, we proved that miR-187-3p could prevent the epithelial-mesenchymal transition (EMT) of HCC cells.  Mech., S100A4 was a direct downstream target of miR-187-3p, and mediated the functional influence of miR-187-3p in HCC.  Furthermore, miR-187-3p and S100A4 expression was evidently correlated with adverse clin. features and poor prognosis of HCC.  Lastly, we showed that hypoxia was responsible for the significantly decreased level of miR-187-3p in HCC, and miR-187-3p was involved in the promoting effects of hypoxia on the metastasis and EMT of HCC cells.  Taken together, miR-187-3p inhibits the metastasis and EMT in HCC by targeting S100A4. miR-187-3p can serve as a prognostic indicator and a promising therapeutic target for HCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRH2rv97Fj7Vg90H21EOLACvtfcHk0li1KeABOTGeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7fL&md5=a8950572421a81f6bdd6f1b442c1d6f8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DmiR-187%25E2%2580%25933p%2520inhibits%2520the%2520metastasis%2520and%2520epithelial-mesenchymal%2520transition%2520of%2520hepatocellular%2520carcinoma%2520by%2520targeting%2520S100A4%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D381%26spage%3D380%26epage%3D390%26doi%3D10.1016%2Fj.canlet.2016.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valastyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tumor metastasis: molecular insights and evolving paradigms</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.cell.2011.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=22000009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=275-292&author=S.+Valastyanauthor=R.+A.+Weinberg&title=Tumor+metastasis%3A+molecular+insights+and+evolving+paradigms&doi=10.1016%2Fj.cell.2011.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Metastasis: Molecular Insights and Evolving Paradigms</span></div><div class="casAuthors">Valastyan, Scott; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-292</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Metastases represent the end products of a multistep cell-biol. process termed the invasion-metastasis cascade, which involves dissemination of cancer cells to anatomically distant organ sites and their subsequent adaptation to foreign tissue microenvironments.  Each of these events is driven by the acquisition of genetic and/or epigenetic alterations within tumor cells and the co-option of nonneoplastic stromal cells, which together endow incipient metastatic cells with traits needed to generate macroscopic metastases.  Recent advances provide provocative insights into these cell-biol. and mol. changes, which have implications regarding the steps of the invasion-metastasis cascade that appear amenable to therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqOPVKwPqtbVg90H21EOLACvtfcHk0li1KeABOTGeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3N&md5=fa62d15c6b61bf90cfcdc1d51bbe98b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DValastyan%26aufirst%3DS.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTumor%2520metastasis%253A%2520molecular%2520insights%2520and%2520evolving%2520paradigms%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D275%26epage%3D292%26doi%3D10.1016%2Fj.cell.2011.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, A. M.</span></span> <span> </span><span class="NLM_article-title">Cancer metastases: so close and so far</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">djv236</span>, <span class="refDoi"> DOI: 10.1093/jnci/djv236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1093%2Fjnci%2Fdjv236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26283653" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&pages=djv236&author=C.+Sonnenscheinauthor=A.+M.+Soto&title=Cancer+metastases%3A+so+close+and+so+far&doi=10.1093%2Fjnci%2Fdjv236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv236%26sid%3Dliteratum%253Aachs%26aulast%3DSonnenschein%26aufirst%3DC.%26aulast%3DSoto%26aufirst%3DA.%2BM.%26atitle%3DCancer%2520metastases%253A%2520so%2520close%2520and%2520so%2520far%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2015%26volume%3D107%26spage%3Ddjv236%26doi%3D10.1093%2Fjnci%2Fdjv236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ran, S.</span></span> <span> </span><span class="NLM_article-title">The role of TLR4 in chemotherapy-driven metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2410</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1158%2F0008-5472.CAN-14-3525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=25998620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2405-2410&author=S.+Ran&title=The+role+of+TLR4+in+chemotherapy-driven+metastasis&doi=10.1158%2F0008-5472.CAN-14-3525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of TLR4 in Chemotherapy-Driven Metastasis</span></div><div class="casAuthors">Ran, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2405-2410</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tumor resistance to cytotoxic drugs is one of the main obstacles to successful cancer therapy.  Emerging evidence suggests that chemoresistance is promoted by substances released from dead and damaged cells that activate the host repair program orchestrated by Toll-like receptor-4 (TLR4).  TLR4 is often overexpressed in malignant and tumor-infiltrating immune cells.  In addn. to endogenous ligands released by therapy-induced tumor destruction, TLR4 is directly activated by paclitaxel, one of the most commonly used chemotherapeutic drugs against various human cancers.  TLR4 activation promotes local and systemic inflammation, leading to induction of multiple circuits that create a regenerative environment favoring local recurrence and metastasis.  Of particular importance is TLR4-mediated recruitment of endothelial progenitors derived from immature myeloid cells.  These cells play a major role in rebuilding tumor-assocd. lymphatic and blood vessels, thereby promoting lymphatic and hematogenous metastasis.  The latter is further enhanced by the premetastatic niche generated by mobilization of myeloid provascular cells to distant organs.  This review summarizes the recent evidence demonstrating that paclitaxel and other clin. used anticancer drugs actively induce metastasis even while shrinking the primary tumor.  Better understanding of the mechanisms underlying TLR4-dependent chemotherapy-driven metastasis might be the key to overcoming challenges of cancer eradication.  Cancer Res; 75(12); 2405-10. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWGx96uNFs8LVg90H21EOLACvtfcHk0li1KeABOTGeAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtb0%253D&md5=1e974998a7963b99bb052f145a097475</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3525%26sid%3Dliteratum%253Aachs%26aulast%3DRan%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520TLR4%2520in%2520chemotherapy-driven%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D2405%26epage%3D2410%26doi%3D10.1158%2F0008-5472.CAN-14-3525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The Next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+generation+of+platinum+drugs%3A+targeted+Pt%28II%29+agents%2C+nanoparticle+delivery%2C+and+Pt%28IV%29+prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0ljtLDA4izxzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520generation%2520of%2520platinum%2520drugs%253A%2520targeted%2520Pt%2528II%2529%2520agents%252C%2520nanoparticle%2520delivery%252C%2520and%2520Pt%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward multi-targeted platinum and ruthenium drugs-a new paradigm in cancer drug treatment regimens?</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFWjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1058-1137&author=R.+G.+Kennyauthor=C.+J.+Marmion&title=Toward+multi-targeted+platinum+and+ruthenium+drugs-a+new+paradigm+in+cancer+drug+treatment+regimens%3F&doi=10.1021%2Facs.chemrev.8b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?</span></div><div class="casAuthors">Kenny, Reece G.; Marmion, Celine J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1058-1137</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While medicinal inorg. chem. has been practiced for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chem. that the authors began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes.  The authors can now readily manipulate and fine-tune their properties.  This had led to a multitude of complexes with wide-ranging biomedical applications.  This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer.  With major advances in technologies and a deeper understanding of the human genome, the authors are now in a strong position to more fully understand carcinogenesis at a mol. level.  The authors can now also rationally design and develop drug mols. that can either selectively enhance or disrupt key biol. processes and, in doing so, optimize their therapeutic potential.  This has heralded a new era in drug design in which the authors are moving from a single- toward a multitargeted approach.  This approach lies at the very heart of medicinal inorg. chem.  In this review, the authors have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities assocd. with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens.  The authors have focused the attention on metallodrugs incorporating platinum and ruthenium ions given that complexes contg. these metal ions are already in clin. use or have advanced to clin. trials as anticancer agents.  The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins.  Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described.  A summary of advances in this field over the past decade or so will be provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGLyZAECkbVrVg90H21EOLACvtfcHk0ljtLDA4izxzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFWjsw%253D%253D&md5=025d0c10a0e3e4ba6d9f138bf14ac4a6</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DR.%2BG.%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520multi-targeted%2520platinum%2520and%2520ruthenium%2520drugs-a%2520new%2520paradigm%2520in%2520cancer%2520drug%2520treatment%2520regimens%253F%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1058%26epage%3D1137%26doi%3D10.1021%2Facs.chemrev.8b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular processing of platinum anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+processing+of+platinum+anticancer+drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0ljtLDA4izxzCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520processing%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0lhigjE9PKqndQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kelland, L.</span></span> <span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0liEMY2pbcPTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Functionalization of platinum complexes for biomedical applications</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2622</span>– <span class="NLM_lpage">2631</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.5b00203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.5b00203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12ksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=2622-2631&author=X.+Wangauthor=X.+Wangauthor=Z.+Guo&title=Functionalization+of+platinum+complexes+for+biomedical+applications&doi=10.1021%2Facs.accounts.5b00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalization of Platinum Complexes for Biomedical Applications</span></div><div class="casAuthors">Wang, Xiaoyong; Wang, Xiaohui; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2622-2631</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Platinum-based anticancer drugs are the mainstay of chemotherapy regimens in clinic.  Nevertheless, the efficacy of platinum drugs is badly affected by serious systemic toxicities and drug resistance, and the pharmacokinetics of most platinum drugs is largely unknown.  In recent years, a keen interest in functionalizing platinum complexes with bioactive mols., targeting groups, photosensitizers, fluorophores, or nanomaterials has been sparked among chem. and biomedical researchers.  The motivation for functionalization comes from some of the following demands: to improve the tumor selectivity or minimize the systemic toxicity of the drugs, to enhance the cellular accumulation of the drugs, to overcome the tumor resistance to the drugs, to visualize the drug mols. in vitro or in vivo, to achieve a synergistic anticancer effect between different therapeutic modalities, or to add extra functionality to the drugs.  In this Account, we present different strategies being used for functionalizing platinum complexes, including conjugation with bisphosphonates, peptides, receptor-specific ligands, polymers, nanoparticles, magnetic resonance imaging contrast agents, metal chelators, or photosensitizers.  Among them, bisphosphonates, peptides, and receptor-specific ligands are used for actively targeted drug delivery, polymers and nanoparticles are for passively targeted drug delivery, magnetic resonance imaging contrast agents are for theranostic purposes, metal chelators are for the treatment or prevention of Alzheimer's disease (AD), and photosensitizers are for photodynamic therapy of cancers.  The rationales behind these designs are explained and justified at the mol. or cellular level, assocg. with the requirements for diagnosis, therapy, and visualization of biol. processes.  To illustrate the wide range of opportunities and challenges that are emerging in this realm, representative examples of targeted drug delivery systems, anticancer conjugates, anticancer theranostic agents, and anti-AD compds. relevant to functionalized platinum complexes are provided.  All the examples exhibit new potential of platinum complexes for future applications in biomedical areas.  The emphases of this Account are placed on the functionalization for targeted drug delivery and theranostic agents.  In the end, a general assessment of various strategies has been made according to their major shortcomings and defects.  The original information in this Account comes entirely from literature appearing since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEy28kth_dh7Vg90H21EOLACvtfcHk0liEMY2pbcPTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12ksLrO&md5=58a24fcee133388bcb4e9070625e7656</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.5b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.5b00203%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DFunctionalization%2520of%2520platinum%2520complexes%2520for%2520biomedical%2520applications%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D2622%26epage%3D2631%26doi%3D10.1021%2Facs.accounts.5b00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The platin-X series: activation, targeting, and delivery</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12992</span>– <span class="NLM_lpage">3004</span>, <span class="refDoi"> DOI: 10.1039/C6DT01738J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT01738J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27493131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12992-3004&author=U.+Basuauthor=B.+Banikauthor=R.+Wenauthor=R.+K.+Pathakauthor=S.+Dhar&title=The+platin-X+series%3A+activation%2C+targeting%2C+and+delivery&doi=10.1039%2FC6DT01738J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Platin-X series: activation, targeting, and delivery</span></div><div class="casAuthors">Basu, Uttara; Banik, Bhabatosh; Wen, Ru; Pathak, Rakesh K.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12992-13004</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorg. chem.  Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation.  Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append addnl. functional groups/ligands for prodrug activation, tumor targeting, or drug delivery.  The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs.  Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery.  In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnol.-based delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYcK59HMDWBbVg90H21EOLACvtfcHk0liEMY2pbcPTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J&md5=3d4894b6935545dceab775c94b75d38c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC6DT01738J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01738J%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DU.%26aulast%3DBanik%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520platin-X%2520series%253A%2520activation%252C%2520targeting%252C%2520and%2520delivery%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12992%26epage%3D3004%26doi%3D10.1039%2FC6DT01738J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span> <span> </span><span class="NLM_article-title">Recent advances in platinum (IV) complex-based delivery systems to improve platinum (II) anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1002/med.21360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fmed.21360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26280923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1268-1299&author=X.+Hanauthor=J.+Sunauthor=Y.+Wangauthor=Z.+He&title=Recent+advances+in+platinum+%28IV%29+complex-based+delivery+systems+to+improve+platinum+%28II%29+anticancer+therapy&doi=10.1002%2Fmed.21360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span></div><div class="casAuthors">Han, Xiaopeng; Sun, Jin; Wang, Yongjun; He, Zhonggui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1268-1299</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum (Pt) (II) derivs. play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors.  However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies.  The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) mols. under the reducing intracellular environment, and has demonstrated encouraging preclin. and clin. outcomes.  Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the i.v.-to-oral switch in cancer chemotherapy.  The overview briefly analyzes statuses of Pt (II) complex that are in clin. use, and then focuses on the development of Pt (IV) complexes.  Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoorUB6a37jSbVg90H21EOLACvtfcHk0li0JFGGFLNekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI&md5=7c99c1bbe8eb959b26ae3c3fa649ba1d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.21360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21360%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26atitle%3DRecent%2520advances%2520in%2520platinum%2520%2528IV%2529%2520complex-based%2520delivery%2520systems%2520to%2520improve%2520platinum%2520%2528II%2529%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D1268%26epage%3D1299%26doi%3D10.1002%2Fmed.21360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunschweiger, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">A carbohydrate-linked cisplatin analogue having antitumor activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1768</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19990614)38:12<1768::AID-ANIE1768>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADyaK1MXktVCntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=1768&author=Y.+Chenauthor=M.+J.+Heegauthor=P.+G.+Braunschweigerauthor=W.+Xieauthor=P.+G.+Wang&title=A+carbohydrate-linked+cisplatin+analogue+having+antitumor+activity&doi=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">A carbohydrate-linked cisplatin analogue having antitumor activity</span></div><div class="casAuthors">Chen, Yongsheng; Heeg, Mary J.; Braunschweiger, Paul G.; Xie, Wenhua; Wang, Peng G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1768-1769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">The authors report on the synthesis, characterization, and cytotoxicity of a novel carbohydrate-linked cisplatin analog, cis-dichloro[(2-3-D-glucopyranosidyl)propane-l,3-diamine]platinum (I).  I was characterized by 1H and 13C NMR spectroscopy which confirms complex formation in water.  The x-ray crystal structure anal. of I reveals that there are two independent mols. in the crystal.  In both mols., the intact and unprotected β-D-glucopyranose moiety is connected to platinum through the 2-propane-1,3-diamine linker group, which acts as a neutral bidendate ligand and coordinates through the two amino groups.  The coordination about platinum is roughly square planar as expected, and the six-membered chelate ring is in a chair conformation as is the glucopyranose ring.  The in vitro antitumor activity of I shows that it is as active as cisplatin against human ovarian cancer cell A278OS and human melanoma cancer cell MeWo, but less active against human ovarian cancer cell A2780cP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo54HRm2aRFI7Vg90H21EOLACvtfcHk0li0JFGGFLNekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVCntLg%253D&md5=c480614723cccb5078b2a6a808a6c1a6</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819990614%252938%253A12%253C1768%253A%253AAID-ANIE1768%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHeeg%26aufirst%3DM.%2BJ.%26aulast%3DBraunschweiger%26aufirst%3DP.%2BG.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DA%2520carbohydrate-linked%2520cisplatin%2520analogue%2520having%2520antitumor%2520activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1999%26volume%3D38%26spage%3D1768%26doi%3D10.1002%2F%28SICI%291521-3773%2819990614%2938%3A12%3C1768%3A%3AAID-ANIE1768%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">11830</span>– <span class="NLM_lpage">11838</span>, <span class="refDoi"> DOI: 10.1039/C6DT02207C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT02207C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27373800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGnsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=11830-11838&author=J.+Maauthor=Q.+Wangauthor=X.+Yangauthor=W.+Haoauthor=Z.+Huangauthor=J.+Zhangauthor=X.+Wangauthor=P.+Wang&title=Glycosylated+platinum%28iv%29+prodrugs+demonstrated+significant+therapeutic+efficacy+in+cancer+cells+and+minimized+side-effects&doi=10.1039%2FC6DT02207C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylated platinum(IV) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects</span></div><div class="casAuthors">Ma, Jing; Wang, Qingpeng; Yang, Xiande; Hao, Wenpei; Huang, Zhonglv; Zhang, Jiabao; Wang, Xin; Wang, Peng George</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11830-11838</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugates (A1-A5) of the Pt(IV) deriv. (A6) with amino groups from peracetyl glucose, rhamnose and mannose with a Pr amino or Et amino linker at the reducing end were synthesized and exhibited significant therapeutic efficacy in tumor cells, esp. for prostate cancer (PCa).  The antitumor activities are greatly affected by glycosyl groups.  Cytotoxic expts. in vitro indicated that the antitumor activities were increased by 5-fold when its Pt(IV) deriv. was conjugated to S18 (IC50 = 4.82 ± 0.45 μM) and by 12-fold when conjugated to S21 (IC50 = 1.9 ± 0.67 μM).  The mannose substituted Pt(IV) complexes A4 and A5 were also over an order of magnitude more potent towards HeLa, A549, MCF-7 and PC3 than cisplatin and oxaliplatin.  Importantly, the glycosylated Pt(IV) derivs. A4 and A5 displayed potential safety for clin. therapeutic exposure with IC50 of 84 μM and 169 μM compared with cisplatin (IC50 = 8 μM) to 3T3.  Cellular uptake and DNA platination are higher than cisplatin and oxaliplatin.  ESI-MS anal. of A5 binding to 5'-dGMP revealed that bifunctional DNA lesions were formed.  The antitumor activities in vivo showed that the MTD and LD50 for A4 and A5 are nearly 4-fold higher than that of oxaliplatin indicating the potential safety for the glycosylated Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3OOKQeJIPAbVg90H21EOLACvtfcHk0li0JFGGFLNekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGnsLvO&md5=b982d491d8176b4dc24c43cc97621d07</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1039%2FC6DT02207C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT02207C%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DGlycosylated%2520platinum%2528iv%2529%2520prodrugs%2520demonstrated%2520significant%2520therapeutic%2520efficacy%2520in%2520cancer%2520cells%2520and%2520minimized%2520side-effects%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D11830%26epage%3D11838%26doi%3D10.1039%2FC6DT02207C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10366</span>– <span class="NLM_lpage">10374</span>, <span class="refDoi"> DOI: 10.1039/C6DT01562J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC6DT01562J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27252024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot12jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=10366-10374&author=Q.+Wangauthor=Z.+Huangauthor=J.+Maauthor=X.+Luauthor=L.+Zhangauthor=X.+Wangauthor=P.+G.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+a+novel+series+of+glycosylated+platinum%28iv%29+complexes+as+antitumor+agents&doi=10.1039%2FC6DT01562J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a novel series of glycosylated platinum(IV) complexes as antitumor agents</span></div><div class="casAuthors">Wang, Qingpeng; Huang, Zhonglv; Ma, Jing; Lu, Xiaolin; Zhang, Li; Wang, Xin; Peng, George Wang</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10366-10374</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new series of glycosylated Pt(IV) complexes were designed, synthesized and evaluated for antitumor activities in vitro and in vivo.  The incorporation of glycosyl groups to the Pt(IV) system has much influence on the antitumor abilities.  Four lead compds. with activities comparable or even superior to cisplatin and oxaliplatin are screened out.  These Pt(IV) complexes could be reduced to release Pt(II) complexes and cause the death of tumor cells.  The apoptosis-inducing properties of these compds. are similar to cisplatin.  The accumulation of the glycosylated Pt(IV) complexes in cells and DNA is higher than cisplatin and oxaliplatin.  The in vivo assay demonstrates that the tested compds. inhibit the growth of HepG2 tumors with low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgpmOlnnEHmbVg90H21EOLACvtfcHk0li0JFGGFLNekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot12jt78%253D&md5=afb0024161b9623d4dfa664eb41a7366</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1039%2FC6DT01562J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01562J%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520series%2520of%2520glycosylated%2520platinum%2528iv%2529%2520complexes%2520as%2520antitumor%2520agents%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D10366%26epage%3D10374%26doi%3D10.1039%2FC6DT01562J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Glycosylated platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5736</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00433</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00433" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5736-5748&author=J.+Maauthor=Q.+Wangauthor=Z.+Huangauthor=X.+Yangauthor=Q.+Nieauthor=W.+Haoauthor=P.+G.+Wangauthor=X.+Wang&title=Glycosylated+platinum%28IV%29+complexes+as+substrates+for+glucose+transporters+%28GLUTs%29+and+organic+cation+transporters+%28OCTs%29+exhibited+cancer+targeting+and+human+serum+albumin+binding+properties+for+drug+delivery&doi=10.1021%2Facs.jmedchem.7b00433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery</span></div><div class="casAuthors">Ma, Jing; Wang, Qingpeng; Huang, Zhonglv; Yang, Xiande; Nie, Quandeng; Hao, Wenpei; Wang, Peng George; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5736-5748</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycosylated platinum(IV) complexes were synthesized as substrates for GLUTs and OCTs for the first time, and the cytotoxicity, and detailed mechanism were detd. in vitro and in vivo.  Galactoside Pt(IV), glucoside Pt(IV) and mannoside Pt(IV) were highly cytotoxic and showed specific cancer-targeting properties in vitro and in vivo.  Glycosylated platinum(IV) complexes 5, 6, 7 and 8 (IC50 0.24 μM-3.97 μM) had better antitumor activity of nearly 166-fold higher than the pos. controls cisplatin, oxaliplatin and satraplatin.  The presence of a hexadecanoic chain allowed binding with human serum albumin (HSA) for drug delivery, which not only enhanced the stability of the inert platinum(IV) prodrugs but also decreased their redn. by reductants present in human whole blood.  Their preferential accumulation in cancer cells compared to noncancerous cells (293T and 3T3 cells) suggested that they were potentially safe for clin. therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLg2UiwsXTgrVg90H21EOLACvtfcHk0ljQOB-qI6m0BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktbY%253D&md5=dbd924c79581b064cfa46733cc84eaf0</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00433%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DNie%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlycosylated%2520platinum%2528IV%2529%2520complexes%2520as%2520substrates%2520for%2520glucose%2520transporters%2520%2528GLUTs%2529%2520and%2520organic%2520cation%2520transporters%2520%2528OCTs%2529%2520exhibited%2520cancer%2520targeting%2520and%2520human%2520serum%2520albumin%2520binding%2520properties%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5736%26epage%3D5748%26doi%3D10.1021%2Facs.jmedchem.7b00433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.ejmech.2017.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=28147308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVGmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=45-55&author=J.+Maauthor=X.+Yangauthor=W.+Haoauthor=Z.+Huangauthor=X.+Wangauthor=P.+G.+Wang&title=Mono-functionalized+glycosylated+platinum%28IV%29+complexes+possessed+both+pH+and+redox+dual-responsive+properties%3A+exhibited+enhanced+safety+and+preferentially+accumulated+in+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2017.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo</span></div><div class="casAuthors">Ma, Jing; Yang, Xiande; Hao, Wenpei; Huang, Zhonglv; Wang, Xin; Wang, Peng George</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-55</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A serious of carbohydrate-conjugated platinum(IV) complexes in the form Pt(L2)(A2)(OH)R based on the clin. drug cisplatin and oxaliplatin were designed, synthesized and evaluated as antitumor agents in vitro and in vivo.  The conjugates possessing both pH and redox dual-responsive properties exhibited more potent cytotoxicity in seven different human cancer cell lines and lower toxicity to the normal 3T3 cells than cisplatin, oxaliplatin and even the reported bis-functionalized glycosylated platinum(IV) complexes indicating the enhanced safety of the sugar conjugates.  Cellular drug uptake and DNA platination were also superior to cisplatin, oxaliplatin and the reported bis-functionalized ones.  Peak current of B7 and B8 with the scan rate of 200mv/s at the concn. of 0.08 mM was 5-fold higher at pH 6.4 than the pH 7.4, indicating that carbohydrate-conjugated mono-functionalized platinum(IV) complexes possessed both pH and redox dual-responsive properties in the cancer cells.  The in vivo assays demonstrated that the Pt(IV) compds. could inhibit the growth of MCF-7 tumor and exert more safety than oxaliplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7wmUkHiGWH7Vg90H21EOLACvtfcHk0ljQOB-qI6m0BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVGmu74%253D&md5=1d29702c6ff32c318f6d83c1a163466c</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DMono-functionalized%2520glycosylated%2520platinum%2528IV%2529%2520complexes%2520possessed%2520both%2520pH%2520and%2520redox%2520dual-responsive%2520properties%253A%2520exhibited%2520enhanced%2520safety%2520and%2520preferentially%2520accumulated%2520in%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D128%26spage%3D45%26epage%3D55%26doi%3D10.1016%2Fj.ejmech.2017.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Protected and de-protected platinum(IV) glycoconjugates with GLUT1 and OCT2-mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">386</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3389%2Ffchem.2018.00386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30298127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1WlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=386&author=J.+Maauthor=H.+Liuauthor=Z.+Xiauthor=J.+Houauthor=Y.+Liauthor=J.+Niuauthor=T.+Liuauthor=S.+Biauthor=X.+Wangauthor=C.+Wangauthor=J.+Wangauthor=S.+Xieauthor=P.+G.+Wang&title=Protected+and+de-protected+platinum%28IV%29+glycoconjugates+with+GLUT1+and+OCT2-mediated+selective+cancer+targeting%3A+demonstrated+enhanced+transporter-mediated+cytotoxic+properties+in+vitro+and+in+vivo&doi=10.3389%2Ffchem.2018.00386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">Protected and de-protected platinum(IV) glycoconjugates with GLUT1 and OCT2-Mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo</span></div><div class="casAuthors">Ma, Jing; Liu, Hanfang; Xi, Zhuoqing; Hou, Jiuzhou; Li, Yingguang; Niu, Jie; Liu, Tong; Bi, Shuning; Wang, Xin; Wang, Chaojie; Wang, Jiajia; Xie, Songqiang; Wang, Peng G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">386</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Physiol. characteristics of human malignancies are increased glycolysis and overexpression of glucose transporters (GLUTs). 18Flurodeoxyglucose-positron emission tomog. (FDG-PET) has successfully developed as clin. modality for the diagnosis and staging of many cancers based on the Warburg effect.  To leverage this glucose transporter mediated metabolic disparity between normal and malignant cells, in the current report, protected, and de-protected glucose, mannose, galactose, rhamnose, maltose, and lactose-conjugated platinum(IV) complexes were designed and synthesized.  The suggested potential of facilitated i.v. to oral switching of glycosylated platinum(IV) prodrugs with cancer-targeting properties were evaluated for glucose transporter 1 (GLUT1) and org. cation transporter 2 (OCT2)-mediated selective properties in vitro and in vivo.  The cytotoxicity of 2d, 5d, and 6d were ∼23-fold greater than that of the pos. controls cisplatin, oxaliplatin, and satraplatin, resp.  The leading compd. 6d, the IC50 of which with the GLUT1 inhibitor 4,6-oethylidene-α-D-glucose (EDG) and phloretin (31.80 and 38.71 μM) are 36- and 44-folds higher, resp., than the 48 h IC50 (0.89 μM), is superior to the reported 5-8, exhibiting enhanced cancer targeting.  The compds. also showed reduced toxicity to normal cells (293T IC50 = 12.06 μM and 3T3 cells IC50 > 100 μM) and exhibited no cross-resistance to cisplatin.  Moreover, the encouraging selectivity of 6d for MCF-7 cells in vivo indicated that the pyranoside performs an important function in cancer targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOU1rG71vy_rVg90H21EOLACvtfcHk0ljQOB-qI6m0BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1WlsL0%253D&md5=508046f05c910f59014fe883b25b9927</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00386%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXi%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DBi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DProtected%2520and%2520de-protected%2520platinum%2528IV%2529%2520glycoconjugates%2520with%2520GLUT1%2520and%2520OCT2-mediated%2520selective%2520cancer%2520targeting%253A%2520demonstrated%2520enhanced%2520transporter-mediated%2520cytotoxic%2520properties%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D386%26doi%3D10.3389%2Ffchem.2018.00386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.bmc.2019.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30852077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlOmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1639-1645&author=H.+Wangauthor=X.+Yangauthor=C.+Zhaoauthor=P.+G.+Wangauthor=X.+Wang&title=Glucose-conjugated+platinum%28IV%29+complexes+as+tumor-targeting+agents%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.bmc.2019.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation</span></div><div class="casAuthors">Wang, Haifeng; Yang, Xiande; Zhao, Caili; Wang, Peng George; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of glucose-conjugated Pt(IV) complexes that target tumor-specific glucose transporters (GLUTs) was designed, synthesized, and evaluated for their anticancer activities.  All six compds., namely, A1-A6, exhibited increased cytotoxicity that were almost six fold higher than that of oxaliplatin to MCF-7 cells.  These Pt(IV) complexes can be reduced to release Pt(II) complexes and cause the death of tumor cells.  Simultaneously, the glycosylated Pt(IV) complexes (30.21-91.33 μM) showed lower cytotoxicity that normal LO2 cells compared with cisplatin (5.25 μM) and oxaliplatin (8.34 μM).  The intervention of phlorizin as a GLUTs inhibitor increased the IC50 value of the glycosylated Pt(IV) complexes, thereby indicating the potential GLUT transportability.  The introduction of glucose moiety to Pt(IV) complexes can effectively enhance the Pt cellular uptake and DNA platination.  Results suggested glucose-conjugated Pt(IV) complexes had potential for further study as new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoantqNsI0OZLVg90H21EOLACvtfcHk0liNL5lqAab75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlOmsb0%253D&md5=76b4950efc459bdeca9416d9b04888bf</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlucose-conjugated%2520platinum%2528IV%2529%2520complexes%2520as%2520tumor-targeting%2520agents%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1639%26epage%3D1645%26doi%3D10.1016%2Fj.bmc.2019.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giljohann, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">14652</span>– <span class="NLM_lpage">14653</span>, <span class="refDoi"> DOI: 10.1021/ja9071282</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9071282" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=14652-14653&author=S.+Dharauthor=W.+L.+Danielauthor=D.+A.+Giljohannauthor=C.+A.+Mirkinauthor=S.+J.+Lippard&title=Polyvalent+oligonucleotide+gold+nanoparticle+conjugates+as+delivery+vehicles+for+platinum%28IV%29+warheads&doi=10.1021%2Fja9071282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads</span></div><div class="casAuthors">Dhar, Shanta; Daniel, Weston L.; Giljohann, David A.; Mirkin, Chad A.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">14652-14653</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amine-functionalized polyvalent oligonucleotide gold nanoparticles (DNA-Au NPs) were derivatized with a cisplatin prodrug, and the resulting DNA-Au NP conjugates were used to internalize multiple platinum centers.  A platinum(IV) complex, c,c,t-[Pt(NH3)2Cl2(OH)(O2CCH2CH2CO2H)], was tethered to the surface of DNA-Au NPs through amide linkages.  The platinum-tethered gold nanoparticles were taken into several cancer cells.  The drop in intracellular pH facilitated reductive release of cisplatin from the prodrug, which then formed 1,2-d(GpG) intrastrand crosslinks in the cell nuclei, as confirmed by an antibody specific for this adduct.  The cytotoxicity of the platinum(IV) complex increases significantly in several cancer cell lines when the complex is attached to the surface of the DNA-Au NPs and in some instances exceeds that of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4FDJuVSsfprVg90H21EOLACvtfcHk0liNL5lqAab75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurrM&md5=ab726464c915c4ba3785c9572f089c8f</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fja9071282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9071282%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DS.%26aulast%3DDaniel%26aufirst%3DW.%2BL.%26aulast%3DGiljohann%26aufirst%3DD.%2BA.%26aulast%3DMirkin%26aufirst%3DC.%2BA.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPolyvalent%2520oligonucleotide%2520gold%2520nanoparticle%2520conjugates%2520as%2520delivery%2520vehicles%2520for%2520platinum%2528IV%2529%2520warheads%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D14652%26epage%3D14653%26doi%3D10.1021%2Fja9071282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Negrerie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span> <span> </span><span class="NLM_article-title">Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2421</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1039/c3cc38589b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2Fc3cc38589b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=23420130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVClt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2421-2423&author=P.+Liuauthor=Y.+Luauthor=X.+Gaoauthor=R.+Liuauthor=D.+Zhang-Negrerieauthor=Y.+Shiauthor=Y.+Wangauthor=S.+Wangauthor=Q.+Gao&title=Highly+water-soluble+platinum%28II%29+complexes+as+GLUT+substrates+for+targeted+therapy%3A+improved+anticancer+efficacy+and+transporter-mediated+cytotoxic+properties&doi=10.1039%2Fc3cc38589b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties</span></div><div class="casAuthors">Liu, Pengxing; Lu, Yanhui; Gao, Xiangqian; Liu, Ran; Zhang-Negrerie, Daisy; Shi, Ying; Wang, Yiqiang; Wang, Songqing; Gao, Qingzhi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2421-2423</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Glucose-conjugated malonato Pt(II) R,R-cyclohexanediamine complexes are designed and synthesized to target tumor-specific active transporters, namely, glucose transporters (GLUTs).  The complexes exhibit much higher aq. soly. by 150 times, improved potency in cytotoxicities by 10 times, and increased therapeutic index by over 30 fold compared to the newest generation of clin. drugs oxaliplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbUs-f_ZR-LVg90H21EOLACvtfcHk0liNL5lqAab75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVClt7w%253D&md5=dc9b30b67047b8b9797965e40eff516f</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1039%2Fc3cc38589b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc38589b%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DZhang-Negrerie%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DHighly%2520water-soluble%2520platinum%2528II%2529%2520complexes%2520as%2520GLUT%2520substrates%2520for%2520targeted%2520therapy%253A%2520improved%2520anticancer%2520efficacy%2520and%2520transporter-mediated%2520cytotoxic%2520properties%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D2421%26epage%3D2423%26doi%3D10.1039%2Fc3cc38589b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.-R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lgqBvaqYgQ96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">7427</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1039/C4CC00419A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC4CC00419A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=24777030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=7427-7430&author=Q.+Chengauthor=H.+Shiauthor=H.+Wangauthor=Y.+Minauthor=J.+Wangauthor=Y.+Liu&title=The+ligation+of+aspirin+to+cisplatin+demonstrates+significant+synergistic+effects+on+tumor+cells&doi=10.1039%2FC4CC00419A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span></div><div class="casAuthors">Cheng, Qinqin; Shi, Hongdong; Wang, Hongxia; Min, Yuanzeng; Wang, Jun; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">7427-7430</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells.  Asplatin is highly accumulated in cancer cells and is activated upon the redn. by ascorbic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT52MltZpsqbVg90H21EOLACvtfcHk0lgqBvaqYgQ96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO&md5=5679afe1ad21bd6c6181aa0bd6d1f2fe</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1039%2FC4CC00419A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC00419A%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DThe%2520ligation%2520of%2520aspirin%2520to%2520cisplatin%2520demonstrates%2520significant%2520synergistic%2520effects%2520on%2520tumor%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D7427%26epage%3D7430%26doi%3D10.1039%2FC4CC00419A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The prodrug platin-A: simultaneous release of cisplatin and aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+prodrug+platin-A%3A+simultaneous+release+of+cisplatin+and+aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12eR"><div class="casContent"><span class="casTitleNuber">12e</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0lgqBvaqYgQ96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520prodrug%2520platin-A%253A%2520simultaneous%2520release%2520of%2520cisplatin%2520and%2520aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12fR"><div class="casContent"><span class="casTitleNuber">12f</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0lg-VdFoJyzUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostrhunova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Křikavova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vančo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trávníček, Z.vn</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span> <span> </span><span class="NLM_article-title">A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">14478</span>– <span class="NLM_lpage">14482</span>, <span class="refDoi"> DOI: 10.1002/anie.201506533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201506533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=26458068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1elurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=14478-14482&author=J.+Kasparkovaauthor=H.+Kostrhunovaauthor=O.+Novakovaauthor=R.+K%C5%99ikavovaauthor=J.+Van%C4%8Doauthor=Z.vn+Tr%C3%A1vn%C3%AD%C4%8Dekauthor=V.+Brabec&title=A+photoactivatable+platinum%28IV%29+complex+targeting+genomic+DNA+and+histone+deacetylases&doi=10.1002%2Fanie.201506533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12gR"><div class="casContent"><span class="casTitleNuber">12g</span><div class="casTitle"><span class="NLM_cas:atitle">A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases</span></div><div class="casAuthors">Kasparkova, Jana; Kostrhunova, Hana; Novakova, Olga; Krikavova, Radka; Vanco, Jan; Travnicek, Zdenek; Brabec, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14478-14482</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We report toxic effects of a photoactivatable platinum(IV) complex conjugated with suberoyl-bis-hydroxamic acid in tumor cells.  The conjugate exerts, after photoactivation, two functions: activity as both a platinum(II) anticancer drug and histone deacetylase (HDAC) inhibitor in cancer cells.  This approach relies on the use of a PtIV pro-drug, acting by two independent mechanisms of biol. action in a cooperative manner, which can be selectively photoactivated to a cytotoxic species in and around a tumor, thereby increasing selectivity towards cancer cells.  These results suggest that this strategy is a valuable route to design new platinum agents with higher efficacy for photodynamic anticancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFWLgeS4R17Vg90H21EOLACvtfcHk0lg-VdFoJyzUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1elurzF&md5=e4f315406af6835aae45931c24e91129</span></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506533%26sid%3Dliteratum%253Aachs%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DKostrhunova%26aufirst%3DH.%26aulast%3DNovakova%26aufirst%3DO.%26aulast%3DK%25C5%2599ikavova%26aufirst%3DR.%26aulast%3DVan%25C4%258Do%26aufirst%3DJ.%26aulast%3DTr%25C3%25A1vn%25C3%25AD%25C4%258Dek%26aufirst%3DZ.vn%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DA%2520photoactivatable%2520platinum%2528IV%2529%2520complex%2520targeting%2520genomic%2520DNA%2520and%2520histone%2520deacetylases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D14478%26epage%3D14482%26doi%3D10.1002%2Fanie.201506533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexselblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novohradsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuchlikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2381</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1039/C5SC04205D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC5SC04205D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29997781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2381-2391&author=R.+Raveendranauthor=J.+P.+Braudeauthor=E.+Wexselblattauthor=V.+Novohradskyauthor=O.+Stuchlikovaauthor=V.+Brabecauthor=V.+Gandinauthor=D.+Gibson&title=Pt%28iv%29+derivatives+of+cisplatin+and+oxaliplatin+with+phenylbutyrate+axial+ligands+are+potent+cytotoxic+agents+that+act+by+several+mechanisms+of+action&doi=10.1039%2FC5SC04205D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12hR"><div class="casContent"><span class="casTitleNuber">12h</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action</span></div><div class="casAuthors">Raveendran, Raji; Braude, Jeremy Phillip; Wexselblatt, Ezequiel; Novohradsky, Vojtech; Stuchlikova, Olga; Brabec, Viktor; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2381-2391</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Our study demonstrates that Pt(IV) deriv. of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)2(PhB)2Cl2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(IV) derivs. of cisplatin with either two hydroxido, two acetato or two valproato ligands.  The high potency of this compd. (and some others) is due to several factors including enhanced internalization, probably driven by "synergistic accumulation" of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity.  Ctc-[Pt(NH3)2(PhB)2Cl2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB.  Mechanistically, ctc-[Pt(NH3)2(PhB)2Cl2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway.  Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)2(PhB)2Cl2] may not depend of p53.  Pt(IV) derivs. of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs.  Ctc-[Pt(NH3)2(PhB)2Cl2] is significantly more potent than its valproate analog ctc-[Pt(NH3)2(VPA)2Cl2].  These compds. combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvxQyimpaX7Vg90H21EOLACvtfcHk0lg-VdFoJyzUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVOlsg%253D%253D&md5=0599753b615d64adcf6a4014defc1327</span></div><a href="/servlet/linkout?suffix=cit12h&amp;dbid=16384&amp;doi=10.1039%2FC5SC04205D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC04205D%26sid%3Dliteratum%253Aachs%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DWexselblatt%26aufirst%3DE.%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DStuchlikova%26aufirst%3DO.%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPt%2528iv%2529%2520derivatives%2520of%2520cisplatin%2520and%2520oxaliplatin%2520with%2520phenylbutyrate%2520axial%2520ligands%2520are%2520potent%2520cytotoxic%2520agents%2520that%2520act%2520by%2520several%2520mechanisms%2520of%2520action%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D2381%26epage%3D2391%26doi%3D10.1039%2FC5SC04205D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thiabaud, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arambula, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddik, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessler, J. L.</span></span> <span> </span><span class="NLM_article-title">Activation of platinum(IV) prodrugs by motexafin gadolinium as a redox mediator</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">12626</span>– <span class="NLM_lpage">12631</span>, <span class="refDoi"> DOI: 10.1002/anie.201604236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201604236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSqurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=12626-12631&author=G.+Thiabaudauthor=R.+McCallauthor=G.+Heauthor=J.+F.+Arambulaauthor=Z.+H.+Siddikauthor=J.+L.+Sessler&title=Activation+of+platinum%28IV%29+prodrugs+by+motexafin+gadolinium+as+a+redox+mediator&doi=10.1002%2Fanie.201604236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12iR"><div class="casContent"><span class="casTitleNuber">12i</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator</span></div><div class="casAuthors">Thiabaud, Gregory; McCall, Rebecca; He, Guangan; Arambula, Jonathan F.; Siddik, Zahid H.; Sessler, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12626-12631</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Water-sol. platinum(IV) prodrugs, which proved kinetically stable to redn. in the presence of physiol. concn. of ascorbate, were quickly reduced to their active form, oxaliplatin, when co-incubated with a macrocycle metallotexaphyrin (i.e., Motexafin Gadolinium (MGd)).  The redn. of PtIV to PtII promoted by MGd occurs in cell culture as well, leading to an increase in the antiproliferative activity of the PtIV species in question.  The mediated effect is proportional to the concn. of MGd and gives rise to an enhancement when the prodrug is relatively hydrophilic.  MGd is known to localize/accumulate preferentially in tumor tissues.  Thus, the present "activation by redn." approach may allow for the cancer-selective enhancement in the cytotoxicity of PtIV prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEZj9_gnwFvLVg90H21EOLACvtfcHk0lhOsuJBNbRmsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSqurbP&md5=6439e251e563a34966392a6c2e0cee78</span></div><a href="/servlet/linkout?suffix=cit12i&amp;dbid=16384&amp;doi=10.1002%2Fanie.201604236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201604236%26sid%3Dliteratum%253Aachs%26aulast%3DThiabaud%26aufirst%3DG.%26aulast%3DMcCall%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DArambula%26aufirst%3DJ.%2BF.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26aulast%3DSessler%26aufirst%3DJ.%2BL.%26atitle%3DActivation%2520of%2520platinum%2528IV%2529%2520prodrugs%2520by%2520motexafin%2520gadolinium%2520as%2520a%2520redox%2520mediator%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D12626%26epage%3D12631%26doi%3D10.1002%2Fanie.201604236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Biotin-tagged platinum(iv) complexes as targeted cytostatic agents against breast cancer cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9974</span>, <span class="refDoi"> DOI: 10.1039/C7CC05311H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC7CC05311H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=28831477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=9971-9974&author=N.+Muhammadauthor=N.+Sadiaauthor=C.+Zhuauthor=C.+Luoauthor=Z.+Guoauthor=X.+Wang&title=Biotin-tagged+platinum%28iv%29+complexes+as+targeted+cytostatic+agents+against+breast+cancer+cells&doi=10.1039%2FC7CC05311H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12jR"><div class="casContent"><span class="casTitleNuber">12j</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span></div><div class="casAuthors">Muhammad, Nafees; Sadia, Nasreen; Zhu, Chengcheng; Luo, Cheng; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">72</span>),
    <span class="NLM_cas:pages">9971-9974</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A biotin-guided platinumIV complex is highly cytotoxic against breast cancer cells but hypotoxic against mammary epithelial cells.  The mono-biotinylated PtIV complex is superior to the di-biotinylated one and hence a promising drug candidate for the targeted therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojsf_nE7HGsrVg90H21EOLACvtfcHk0lhOsuJBNbRmsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO&md5=e0003ab9a6a3ef976136f8ea223433e5</span></div><a href="/servlet/linkout?suffix=cit12j&amp;dbid=16384&amp;doi=10.1039%2FC7CC05311H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC05311H%26sid%3Dliteratum%253Aachs%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DSadia%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DBiotin-tagged%2520platinum%2528iv%2529%2520complexes%2520as%2520targeted%2520cytostatic%2520agents%2520against%2520breast%2520cancer%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D9971%26epage%3D9974%26doi%3D10.1039%2FC7CC05311H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AldrichWright, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">A quadruple-action platinum(IV) prodrug with anticancer activity against KRAS mutated cancer cell lines</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">11539</span>– <span class="NLM_lpage">11544</span>, <span class="refDoi"> DOI: 10.1002/anie.201706739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201706739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=11539-11544&author=E.+Petruzzellaauthor=J.+P.+Braudeauthor=J.+R.+AldrichWrightauthor=V.+Gandinauthor=D.+Gibson&title=A+quadruple-action+platinum%28IV%29+prodrug+with+anticancer+activity+against+KRAS+mutated+cancer+cell+lines&doi=10.1002%2Fanie.201706739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12kR"><div class="casContent"><span class="casTitleNuber">12k</span><div class="casTitle"><span class="NLM_cas:atitle">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines</span></div><div class="casAuthors">Petruzzella, Emanuele; Braude, Jeremy Phillip; Aldrich-Wright, Janice R.; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">11539-11544</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a novel PtIV prodrug that simultaneously releases four different bioactive moieties inside the cancer cell.  Its cytotoxicity against monolayer cultures (2D) and spheroid (3D) cancer cells is significantly better than cisplatin.  It is 200-450-fold more potent than cisplatin against KRAS mutated pancreatic and colon cancers and is 40-fold more selective towards KRAS mutated cells compared to non-cancerous.  This is important since RAS proteins play a role in regulating cell differentiation, proliferation, and survival and KRAS is mutated in 90 % of pancreatic adenocarcinomas, 45 % of colorectal cancers, and 35 % of lung adenocarcinomas.  The selectivity index, detd. by dividing the IC50 value in non-cancerous cells by that of a cancerous cell line, is two-fold better than cisplatin, attesting to preferential cytotoxicity towards neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQHgQHWGMgbVg90H21EOLACvtfcHk0lhOsuJBNbRmsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ&md5=4a9c4fcc8d6006775b09c9e4c246d175</span></div><a href="/servlet/linkout?suffix=cit12k&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706739%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DAldrichWright%26aufirst%3DJ.%2BR.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DA%2520quadruple-action%2520platinum%2528IV%2529%2520prodrug%2520with%2520anticancer%2520activity%2520against%2520KRAS%2520mutated%2520cancer%2520cell%2520lines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D11539%26epage%3D11544%26doi%3D10.1002%2Fanie.201706739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Monochalcoplatin: an actively transported, quickly reducible, and highly potent Pt(IV) anticancer prodrug</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9098</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1002/anie.201804314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201804314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=9098-9102&author=L.+Maauthor=N.+Wangauthor=R.+Maauthor=C.+Liauthor=Z.+Xuauthor=M.+K.+Tseauthor=G.+Zhu&title=Monochalcoplatin%3A+an+actively+transported%2C+quickly+reducible%2C+and+highly+potent+Pt%28IV%29+anticancer+prodrug&doi=10.1002%2Fanie.201804314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12lR"><div class="casContent"><span class="casTitleNuber">12l</span><div class="casTitle"><span class="NLM_cas:atitle">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug</span></div><div class="casAuthors">Ma, Lili; Wang, Na; Ma, Rong; Li, Cai; Xu, Zoufeng; Tse, Man-Kit; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">9098-9102</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recently, PtIV prodrugs have attracted much attention as the next generation of platinum-based antineoplastic drug candidates.  Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated PtIV prodrug that is among the most cytotoxic PtIV prodrugs to date.  Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin accumulates astonishingly effectively and rapidly in cancer cells, which is not ascribed to its lipophilicity.  The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin-sensitive and -resistant cells; these IC50 values are up to 422-fold higher than that of cisplatin.  A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter-mediated process.  Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model.  Our study implies a practical strategy for the design of more effective PtIV prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWzOjWinSirVg90H21EOLACvtfcHk0lhOsuJBNbRmsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ&md5=ef0e0d30da62acf13f0ceeb6729961c7</span></div><a href="/servlet/linkout?suffix=cit12l&amp;dbid=16384&amp;doi=10.1002%2Fanie.201804314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201804314%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DTse%26aufirst%3DM.%2BK.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DMonochalcoplatin%253A%2520an%2520actively%2520transported%252C%2520quickly%2520reducible%252C%2520and%2520highly%2520potent%2520Pt%2528IV%2529%2520anticancer%2520prodrug%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D9098%26epage%3D9102%26doi%3D10.1002%2Fanie.201804314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solazzo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4307</span>, <span class="refDoi"> DOI: 10.1039/C8SC00428E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC8SC00428E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29780561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4299-4307&author=E.+Petruzzellaauthor=R.+Sirotaauthor=I.+Solazzoauthor=V.+Gandinauthor=D.+Gibson&title=Triple+action+Pt%28iv%29+derivatives+of+cisplatin%3A+a+new+class+of+potent+anticancer+agents+that+overcome+resistance&doi=10.1039%2FC8SC00428E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12mR"><div class="casContent"><span class="casTitleNuber">12m</span><div class="casTitle"><span class="NLM_cas:atitle">Triple action Pt(IV) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance</span></div><div class="casAuthors">Petruzzella, Emanuele; Sirota, Roman; Solazzo, Irene; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4299-4307</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of triple action Pt(IV) prodrugs was designed to test the hypothesis that multi-action compds., where each bioactive moiety intervenes in several cellular processes, might be more effective than a single agent at killing cancer cells.  In particular, "triple action" Pt(IV) derivs. of cisplatin, where the axial ligands are inhibitors of cyclooxygenase (COXi), histone deacetylase (HDACi) or pyruvate dehydrogenase kinase (PDKi) were developed.  All compds., ctc-[Pt(NH3)2(COXi)(PDKi)Cl2], ctc-[Pt(NH3)2(COXi)(HDACi)Cl2] and ctc-[Pt(NH3)2(HDACi)(PDKi)Cl2], where COXi = aspirin or ibuprofen, PDKi = dichloroacetate and HDACi = valproate or phenylbutyrate, were significantly more cytotoxic than cisplatin against all cell lines of an inhouse panel of human cancer cells.  They were particularly effective against thyroid and pancreatic cancer cells in monolayer cytotoxicity tests.  Remarkably, in 3D spheroid cancer cell cultures, some triple action compds. showed an antitumor potency up to 50-fold higher than cisplatin against a KRAS mutated pancreatic cancer cell line (PSN-1 cells).  Std. biochem. assays classically employed to explore structure activity relationships of platinum drugs, such as cellular uptake and binding to potential biol. targets (DNA, HDAC, mitochondria, and COX), do not provide linear correlations with the overall cytotoxicity data.  We obsd. a preferential induction of ROS prodn. and of an anti-mitochondrial effect in cancer cells compared to rapidly dividing non-cancerous cells.  Thus, we propose that these new triple action Pt(IV) derivs. of cisplatin are a novel and interesting class of potent and selective cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJYZX5ATGxKbVg90H21EOLACvtfcHk0li5C1EiSTqfJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOjs7o%253D&md5=439d568dae37ac7bb387b4b2055d1ecd</span></div><a href="/servlet/linkout?suffix=cit12m&amp;dbid=16384&amp;doi=10.1039%2FC8SC00428E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC00428E%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DSirota%26aufirst%3DR.%26aulast%3DSolazzo%26aufirst%3DI.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DTriple%2520action%2520Pt%2528iv%2529%2520derivatives%2520of%2520cisplatin%253A%2520a%2520new%2520class%2520of%2520potent%2520anticancer%2520agents%2520that%2520overcome%2520resistance%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D4299%26epage%3D4307%26doi%3D10.1039%2FC8SC00428E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Restraining cancer cells by dual metabolic inhibition with a mitochondrion-targeted platinum(II) complex</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4643</span>, <span class="refDoi"> DOI: 10.1002/anie.201900387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12n&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201900387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Kht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4638-4643&author=K.+Wangauthor=C.+Zhuauthor=Y.+Heauthor=Z.+Zhangauthor=W.+Zhouauthor=N.+Muhammadauthor=Y.+Guoauthor=X.+Wangauthor=Z.+Guo&title=Restraining+cancer+cells+by+dual+metabolic+inhibition+with+a+mitochondrion-targeted+platinum%28II%29+complex&doi=10.1002%2Fanie.201900387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12nR"><div class="casContent"><span class="casTitleNuber">12n</span><div class="casTitle"><span class="NLM_cas:atitle">Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion-Targeted Platinum(II) Complex</span></div><div class="casAuthors">Wang, Kun; Zhu, Chengcheng; He, Yafeng; Zhang, Zhenqin; Zhou, Wen; Muhammad, Nafees; Guo, Yan; Wang, Xiaoyong; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4638-4643</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer cells usually adapt metabolic phenotypes to chemotherapeutics.  A defensive strategy against this flexibility is to modulate signaling pathways relevant to cancer bioenergetics.  A triphenylphosphonium-modified terpyridine platinum(II) complex (TTP) was designed to inhibit thioredoxin reductase (TrxR) and multiple metabs. of cancer cells.  TTP exhibited enhanced cytotoxicity against cisplatin-insensitive human ovarian cancer cells in a caspase-3-independent manner and showed preferential inhibition to mitochondrial TrxR.  The morphol. and function of mitochondria were severely damaged, and the levels of mitochondrial and cellular reactive oxygen species were decreased.  As a result, TTP exerted strong inhibition to both mitochondrial and glycolytic bioenergetics, thus inducing cancer cells to enter a hypometabolic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMychFILZP_rVg90H21EOLACvtfcHk0li5C1EiSTqfJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Kht7o%253D&md5=53980c843fcfc333ad9d1943fa701faf</span></div><a href="/servlet/linkout?suffix=cit12n&amp;dbid=16384&amp;doi=10.1002%2Fanie.201900387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201900387%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DRestraining%2520cancer%2520cells%2520by%2520dual%2520metabolic%2520inhibition%2520with%2520a%2520mitochondrion-targeted%2520platinum%2528II%2529%2520complex%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D4638%26epage%3D4643%26doi%3D10.1002%2Fanie.201900387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3089</span>– <span class="NLM_lpage">3095</span>, <span class="refDoi"> DOI: 10.1039/C8SC04871A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC8SC04871A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30996891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVymtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3089-3095&author=Z.+Zhuauthor=Z.+Wangauthor=C.+Zhangauthor=Y.+Wangauthor=H.+Zhangauthor=Z.+Ganauthor=Z.+Guoauthor=X.+Wang&title=Mitochondrion-targeted+platinum+complexes+suppressing+lung+cancer+through+multiple+pathways+involving+energy+metabolism&doi=10.1039%2FC8SC04871A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12oR"><div class="casContent"><span class="casTitleNuber">12o</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism</span></div><div class="casAuthors">Zhu, Zhenzhu; Wang, Zenghui; Zhang, Changli; Wang, Yanjun; Zhang, Hongmei; Gan, Zhenji; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3089-3095</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mitochondria are potential therapeutic targets for anticancer drugs.  A series of mitochondrion-targeted monofunctional platinum complexes, [Pt(ortho-PPh3CH2Py)(NH3)2Cl](NO3)2 (OPT), [Pt(meta-PPh3CH2Py)(NH3)2Cl](NO3)2 (MPT), and [Pt(para-PPh3CH2Py)(NH3)2Cl](NO3)2 (PPT) (PPh3 = triphenylphosphonium, Py = pyridine), are studied in this article.  The antitumor activity and mechanism of action have been investigated in vitro and in vivo as well as on mol. levels.  OPT exhibits higher efficacy than cisplatin against A549 lung cancer cells; furthermore, it shows a strong inhibition towards the growth of non-small-cell lung cancer in nude mice.  The DNA binding ability of these complexes follows an order of PPT > OPT > MPT.  Cellular uptake and distribution studies show that OPT accumulates mainly in mitochondria, while MPT and PPT accumulate more preferentially in nuclei than in mitochondria.  As a result, OPT induces remarkable changes in the ultrastructure and membrane of mitochondria, leading to more radical mitochondrial dysfunctions than cisplatin.  The release of cytochrome c from mitochondria is more evident for cells treated with OPT than with cisplatin, though the apoptosis of A549 cells induced by OPT is similar to that induced by cisplatin.  Disruption to mitochondrial oxidative phosphorylation and glycolysis is involved in the antitumor mechanism of these compds.  The results indicate that in addn. to DNA binding, bioenergetic pathways also play crucial roles in the antitumor activity of mitochondrion-targeted monofunctional platinum complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohK1xe_5znVLVg90H21EOLACvtfcHk0li5C1EiSTqfJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVymtbs%253D&md5=5ac6d04499c4045cd8a9b9ac2c835df6</span></div><a href="/servlet/linkout?suffix=cit12o&amp;dbid=16384&amp;doi=10.1039%2FC8SC04871A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC04871A%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DMitochondrion-targeted%2520platinum%2520complexes%2520suppressing%2520lung%2520cancer%2520through%2520multiple%2520pathways%2520involving%2520energy%2520metabolism%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D3089%26epage%3D3095%26doi%3D10.1039%2FC8SC04871A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Babak, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorin, G.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8109</span>– <span class="NLM_lpage">8114</span>, <span class="refDoi"> DOI: 10.1002/anie.201903112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12p&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201903112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Wjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=8109-8114&author=M.+V.+Babakauthor=Y.+Zhiauthor=B.+Czarnyauthor=T.+B.+Tohauthor=L.+Hooiauthor=E.+K.+Chowauthor=W.+H.+Angauthor=D.+Gibsonauthor=G.+Pastorin&title=Dual-targeting+dual-action+platinum%28IV%29+platform+for+enhanced+anticancer+activity+and+reduced+nephrotoxicity&doi=10.1002%2Fanie.201903112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12pR"><div class="casContent"><span class="casTitleNuber">12p</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity</span></div><div class="casAuthors">Babak, Maria V.; Zhi, Yang; Czarny, Bertrand; Toh, Tan Boon; Hooi, Lissa; Chow, Edward Kai-Hua; Ang, Wee Han; Gibson, Dan; Pastorin, Giorgia</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8109-8114</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel and highly efficient dual-targeting platform was designed to ensure targeted in vivo delivery of dual-action PtIV prodrugs.  The dual targeting was established by liposomal encapsulation of PtIV complexes, thereby utilizing the enhanced permeability and retention (EPR) effect as the first stage of targeting to attain a high accumulation of the drug-loaded liposomes in the tumor.  After the release of the PtIV prodrug inside cancer cells, a second stage of targeting directed a portion of the PtIV prodrugs to the mitochondria.  Upon intracellular redn., these PtIV prodrugs released two bioactive mols., acting both on the mitochondrial and on the nuclear DNA.  Our PtIV system showed excellent activity in vitro and in vivo, characterized by a cytotoxicity in a low micromolar range and complete tumor remission, resp.  Notably, marked in vivo activity was accompanied by reduced kidney toxicity, highlighting the unique therapeutic potential of our novel dual-targeting dual-action platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMlkNaK-egdbVg90H21EOLACvtfcHk0ljZScRhpLgoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Wjt70%253D&md5=b07046dd1a3652f581bfd530f1dc6d37</span></div><a href="/servlet/linkout?suffix=cit12p&amp;dbid=16384&amp;doi=10.1002%2Fanie.201903112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201903112%26sid%3Dliteratum%253Aachs%26aulast%3DBabak%26aufirst%3DM.%2BV.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DCzarny%26aufirst%3DB.%26aulast%3DToh%26aufirst%3DT.%2BB.%26aulast%3DHooi%26aufirst%3DL.%26aulast%3DChow%26aufirst%3DE.%2BK.%26aulast%3DAng%26aufirst%3DW.%2BH.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DPastorin%26aufirst%3DG.%26atitle%3DDual-targeting%2520dual-action%2520platinum%2528IV%2529%2520platform%2520for%2520enhanced%2520anticancer%2520activity%2520and%2520reduced%2520nephrotoxicity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D8109%26epage%3D8114%26doi%3D10.1002%2Fanie.201903112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12q"><span><span class="NLM_label">(q) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.canlet.2016.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27793693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12q&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=168-178&author=F.+Chenauthor=X.+Huangauthor=M.+Wuauthor=S.+Gouauthor=W.+Hu&title=A+CK2-targeted+Pt%28IV%29+prodrug+to+disrupt+DNA+damage+response&doi=10.1016%2Fj.canlet.2016.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12qR"><div class="casContent"><span class="casTitleNuber">12q</span><div class="casTitle"><span class="NLM_cas:atitle">A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response</span></div><div class="casAuthors">Chen, Feihong; Huang, Xiaochao; Wu, Mian; Gou, Shaohua; Hu, Weiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-178</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug, Cx-platin, contg. CX-4945 (a CK2 inhibitor) as an axial ligand was designed and prepd. by targeting CK2 to disrupt DNA damage response.  In vitro study indicated that Cx-platin had superior cytotoxicity to cisplatin against a no. of cancer cell lines with distinct CK2-expressed levels, caused CK2-overexpressed cancer cells death via suppressing CK2-mediated DNA damage repair and reversed cisplatin resistance.  Mechanistic investigation suggested that the potent antitumor activity of Cx-platin resulted from its major suppression of CK2-phosphorylated MDC1 to combine FHA domain of aprataxin to DNA double strand breaks (DSBs) caused by improved cellular uptakes of Pt and ATM deactivation.  Further in vivo tests exhibited that Cx-platin displayed high tumor inhibition rates, increased wt. gain, and hardly toxicity effects in contrast to cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxMYuJ3rPh7bVg90H21EOLACvtfcHk0ljZScRhpLgoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu7jI&md5=fb93fa80ba1c59f675622a6ad683ec97</span></div><a href="/servlet/linkout?suffix=cit12q&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DA%2520CK2-targeted%2520Pt%2528IV%2529%2520prodrug%2520to%2520disrupt%2520DNA%2520damage%2520response%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D168%26epage%3D178%26doi%3D10.1016%2Fj.canlet.2016.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12r"><span><span class="NLM_label">(r) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span> <span> </span><span class="NLM_article-title">A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6353</span>, <span class="refDoi"> DOI: 10.1039/C9CC02189B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1039%2FC9CC02189B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=31065657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12r&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslKqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=6353&author=C.+Wuauthor=K.-J.+Wuauthor=J.-B.+Liuauthor=X.-M.+Zhouauthor=C.-H.+Leungauthor=D.-L.+Ma&title=A+dual-functional+molecular+strategy+for+in+situ+suppressing+and+visualizing+of+neuraminidase+in+aqueous+solution+using+iridium%28iii%29+complexes&doi=10.1039%2FC9CC02189B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12rR"><div class="casContent"><span class="casTitleNuber">12r</span><div class="casTitle"><span class="NLM_cas:atitle">A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(III) complexes</span></div><div class="casAuthors">Wu, Chun; Wu, Ke-Jia; Liu, Jin-Biao; Zhou, Xiao-Ming; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6353-6356</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We have designed for the first time a dual-functional luminescent probe and inhibitor of neuraminidase (NA), a key influenza target.  The lead iridium(III) complex exhibited enhanced inhibition against NA compared to the FDA-approved antiviral drug, oseltamivir, and could detect NA even in the presence of an autofluorescent background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-2mxBaV5r7bVg90H21EOLACvtfcHk0ljZScRhpLgoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslKqs78%253D&md5=37f9971d056e197210336cb465dcc953</span></div><a href="/servlet/linkout?suffix=cit12r&amp;dbid=16384&amp;doi=10.1039%2FC9CC02189B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC02189B%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DLiu%26aufirst%3DJ.-B.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DLeung%26aufirst%3DC.-H.%26aulast%3DMa%26aufirst%3DD.-L.%26atitle%3DA%2520dual-functional%2520molecular%2520strategy%2520for%2520in%2520situ%2520suppressing%2520and%2520visualizing%2520of%2520neuraminidase%2520in%2520aqueous%2520solution%2520using%2520iridium%2528iii%2529%2520complexes%26jtitle%3DChem.%2520Commun.%26date%3D2019%26volume%3D55%26spage%3D6353%26doi%3D10.1039%2FC9CC02189B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12s"><span><span class="NLM_label">(s) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">13091</span>, <span class="refDoi"> DOI: 10.1002/anie.201807305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12s&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fanie.201807305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12s&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=13091&author=G.-J.+Yangauthor=W.+Wangauthor=S.+W.+F.+Mokauthor=C.+Wuauthor=B.+Y.+K.+Lawauthor=X.-M.+Miaoauthor=K.-J.+Wuauthor=H.-J.+Zhongauthor=C.-Y.+Wongauthor=V.+K.+W.+Wongauthor=D.-L.+Maauthor=C.-H.+Leung&title=Selective+inhibition+of+lysine-specific+demethylase+5A+%28KDM5A%29+using+a+rhodium%28III%29+complex+for+triple-negative+breast+cancer+therapy&doi=10.1002%2Fanie.201807305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12sR"><div class="casContent"><span class="casTitleNuber">12s</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span></div><div class="casAuthors">Yang, Guan-Jun; Wang, Wanhe; Mok, Simon Wing Fai; Wu, Chun; Law, Betty Yuen Kwan; Miao, Xiang-Min; Wu, Ke-Jia; Zhong, Hai-Jing; Wong, Chun-Yuen; Wong, Vincent Kam Wai; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13091-13095</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 5A (KDM5A) has recently become a promising target for epigenetic therapy.  In this study, the authors designed and synthesized metal complexes bearing ligands with reported demethylase and p27 modulating activities.  The Rh(III) complex 1 (I) was identified as a direct, selective and potent inhibitor of KDM5A that directly abrogate KDM5A demethylase activity via antagonizing the KDM5A-tri-/di-methylated histone 3 protein-protein interaction (PPI) in vitro and in cellulo.  Complex 1 induced accumulation of H3K4me3 and H3K4me2 levels in cells, causing growth arrest at G1 phase in the triple-neg. breast cancer (TNBC) cell lines, MDA-MB-231 and 4T1.  Finally, 1 exhibited potent anti-tumor activity against TNBC xenografts in an in vivo mouse model, presumably via targeting of KDM5A and hence upregulating p27.  Moreover, complex 1 was less toxic compared with two clin. drugs, cisplatin and doxorubicin.  To the authors' knowledge, complex 1 is the first metal-based KDM5A inhibitor reported in the literature.  The authors anticipate that complex 1 may be used as a novel scaffold for the further development of more potent epigenetic agents against cancers, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUnhpINRuOrVg90H21EOLACvtfcHk0lg-X6mTlwSnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM&md5=9a8f6097e7401592667690c255f1c9e6</span></div><a href="/servlet/linkout?suffix=cit12s&amp;dbid=16384&amp;doi=10.1002%2Fanie.201807305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201807305%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DB.%2BY.%2BK.%26aulast%3DMiao%26aufirst%3DX.-M.%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DWong%26aufirst%3DC.-Y.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DSelective%2520inhibition%2520of%2520lysine-specific%2520demethylase%25205A%2520%2528KDM5A%2529%2520using%2520a%2520rhodium%2528III%2529%2520complex%2520for%2520triple-negative%2520breast%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D13091%26doi%3D10.1002%2Fanie.201807305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12t"><span><span class="NLM_label">(t) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacque, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniforth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavros, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeted photoredox catalysis in cancer cells</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1041</span>, <span class="refDoi"> DOI: 10.1038/s41557-019-0328-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41557-019-0328-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=31548671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12t&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1041&author=H.+Huangauthor=S.+Banerjeeauthor=K.+Qiuauthor=P.+Zhangauthor=O.+Blacqueauthor=T.+Malcomsonauthor=M.+J.+Patersonauthor=G.+J.+Clarksonauthor=M.+Staniforthauthor=V.+G.+Stavrosauthor=G.+Gasserauthor=H.+Chaoauthor=P.+J.+Sadler&title=Targeted+photoredox+catalysis+in+cancer+cells&doi=10.1038%2Fs41557-019-0328-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12tR"><div class="casContent"><span class="casTitleNuber">12t</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted photoredox catalysis in cancer cells</span></div><div class="casAuthors">Huang, Huaiyi; Banerjee, Samya; Qiu, Kangqiang; Zhang, Pingyu; Blacque, Olivier; Malcomson, Thomas; Paterson, Martin J.; Clarkson, Guy J.; Staniforth, Michael; Stavros, Vasilios G.; Gasser, Gilles; Chao, Hui; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1041-1048</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hypoxic tumors are a major problem for cancer photodynamic therapy.  Here, we show that photoredox catalysis can provide an oxygen-independent mechanism of action to combat this problem.  We have designed a highly oxidative Ir(III) photocatalyst, [Ir(ttpy)(pq)Cl]PF6 ([1]PF6, where 'ttpy' represents 4'-(p-tolyl)-2,2':6',2''-terpyridine and 'pq' represents 3-phenylisoquinoline), which is phototoxic towards both normoxic and hypoxic cancer cells.  Complex 1 photocatalytically oxidizes 1,4-dihydronicotinamide adenine dinucleotide (NADH)-an important coenzyme in living cells-generating NAD• radicals with a high turnover frequency in biol. media.  Moreover, complex 1 and NADH synergistically photoreduce cytochrome c under hypoxia.  D. functional theory calcns. reveal π stacking in adducts of complex 1 and NADH, facilitating photoinduced single-electron transfer.  In cancer cells, complex 1 localizes in mitochondria and disrupts electron transport via NADH photocatalysis.  On light irradn., complex 1 induces NADH depletion, intracellular redox imbalance and immunogenic apoptotic cancer cell death.  This photocatalytic redox imbalance strategy offers a new approach for efficient cancer phototherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoZNCvl9_iQLVg90H21EOLACvtfcHk0lg-X6mTlwSnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgurfK&md5=b7774e96b85d9d648faa30c50bbea784</span></div><a href="/servlet/linkout?suffix=cit12t&amp;dbid=16384&amp;doi=10.1038%2Fs41557-019-0328-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-019-0328-4%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DBlacque%26aufirst%3DO.%26aulast%3DMalcomson%26aufirst%3DT.%26aulast%3DPaterson%26aufirst%3DM.%2BJ.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DStaniforth%26aufirst%3DM.%26aulast%3DStavros%26aufirst%3DV.%2BG.%26aulast%3DGasser%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DH.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DTargeted%2520photoredox%2520catalysis%2520in%2520cancer%2520cells%26jtitle%3DNat.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1041%26doi%3D10.1038%2Fs41557-019-0328-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray
Stewart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, A. E.</span></span> <span> </span><span class="NLM_article-title">Polyamine metabolism and cancer: treatments, challenges and opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0050-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41568-018-0050-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30181570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Gks7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=681-695&author=R.+A.+Caseroauthor=T.+Murray%0AStewartauthor=A.+E.+Pegg&title=Polyamine+metabolism+and+cancer%3A+treatments%2C+challenges+and+opportunities&doi=10.1038%2Fs41568-018-0050-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Polyamine metabolism and cancer: treatments, challenges and opportunities</span></div><div class="casAuthors">Casero, Jr, Robert A.; Murray Stewart, Tracy; Pegg, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">681-695</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Advances in our understanding of the metab. and mol. functions of polyamines and their alterations in cancer have led to resurgence in the interest of targeting polyamine metab. as an anticancer strategy.  Increasing knowledge of the interplay between polyamine metab. and other cancer-driving pathways, including the PTEN-PI3K-mTOR complex 1 (mTORC1), WNT signalling and RAS pathways, suggests potential combination therapies that will have considerable clin. promise.  Addnl., an expanding no. of promising clin. trials with agents targeting polyamines for both therapy and prevention are ongoing.  New insights into mol. mechanisms linking dysregulated polyamine catabolism and carcinogenesis suggest addnl. strategies that can be used for cancer prevention in at-risk individuals.  In addn., polyamine blocking therapy, a strategy that combines the inhibition of polyamine biosynthesis with the simultaneous blockade of polyamine transport, can be more effective than therapies based on polyamine depletion alone and may involve an antitumor immune response.  These findings open up new avenues of research into exploiting aberrant polyamine metab. for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQkeuH5QZMbVg90H21EOLACvtfcHk0lg-X6mTlwSnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Gks7nF&md5=9bcfc74df8e65e0ce8a53203770bd1f1</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0050-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0050-3%26sid%3Dliteratum%253Aachs%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DMurray%2BStewart%26aufirst%3DT.%26aulast%3DPegg%26aufirst%3DA.%2BE.%26atitle%3DPolyamine%2520metabolism%2520and%2520cancer%253A%2520treatments%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D681%26epage%3D695%26doi%3D10.1038%2Fs41568-018-0050-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">An overview of polyamine metabolism in pancreatic ductal adenocarcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">1976</span>, <span class="refDoi"> DOI: 10.1002/ijc.31155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1002%2Fijc.31155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=29134652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOnsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2018&pages=1968-1976&author=O.+Phanstiel&title=An+overview+of+polyamine+metabolism+in+pancreatic+ductal+adenocarcinoma&doi=10.1002%2Fijc.31155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of polyamine metabolism in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1968-1976</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%.  With current therapies only giving rise to modest life extension, new approaches are desperately needed.  Even though targeting polyamine metab. is a proven anticancer strategy, there are no reports, which thoroughly survey the literature describing the role of polyamine biosynthesis and transport in PDAC.  This review seeks to fill this void by describing what is currently known about polyamine metab. in PDAC and identifies new targets and opportunities to treat this disease.  Due to the pleiotropic effects that polyamines play in cells, this review covers diverse areas ranging from polyamine metab. (biosynthesis, catabolism and transport), as well as the potential role of polyamines in desmoplasia, autophagy and immune privilege.  Understanding these diverse roles provides the opportunity to design new therapies to treat this deadly cancer via polyamine depletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdSGr8c3DwEbVg90H21EOLACvtfcHk0lg-X6mTlwSnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOnsrbP&md5=3e6f4cd63716572b3cc9e90e545150cc</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fijc.31155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31155%26sid%3Dliteratum%253Aachs%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DAn%2520overview%2520of%2520polyamine%2520metabolism%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2018%26volume%3D142%26spage%3D1968%26epage%3D1976%26doi%3D10.1002%2Fijc.31155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marton, L. J.</span></span> <span> </span><span class="NLM_article-title">Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nrd2243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrd2243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=17464296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslyiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=373-90&author=R.+A.+Caseroauthor=L.+J.+Marton&title=Targeting+polyamine+metabolism+and+function+in+cancer+and+other+hyperproliferative+diseases&doi=10.1038%2Fnrd2243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases</span></div><div class="casAuthors">Casero, Robert A., Jr.; Marton, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-390</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polyamines spermidine and spermine and their diamine precursor putrescine are naturally occurring, polycationic alkylamines that are essential for eukaryotic cell growth.  The requirement for and the metab. of polyamines are frequently dysregulated in cancer and other hyperproliferative diseases, thus making polyamine function and metab. attractive targets for therapeutic intervention.  Recent advances in our understanding of polyamine function, metabolic regulation, and differences between normal cells and tumor cells with respect to polyamine biol., have reinforced the interest in this target-rich pathway for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJOs-U3gFu-7Vg90H21EOLACvtfcHk0lheBr-4NFbcqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslyiu7k%253D&md5=d04f6b516f8eea49c761e2f171747b58</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1038%2Fnrd2243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2243%26sid%3Dliteratum%253Aachs%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DMarton%26aufirst%3DL.%2BJ.%26atitle%3DTargeting%2520polyamine%2520metabolism%2520and%2520function%2520in%2520cancer%2520and%2520other%2520hyperproliferative%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D373%26epage%3D90%26doi%3D10.1038%2Fnrd2243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wason, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altomare, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of antimetastatic agents predicated upon dihydromotuporamine C and its carbocyclic derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4023</span>– <span class="NLM_lpage">4034</span>, <span class="refDoi"> DOI: 10.1021/jm401906v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401906v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4023-4034&author=A.+Muthauthor=V.+Pandeyauthor=N.+Kaurauthor=M.+Wasonauthor=C.+Bakerauthor=X.+Hanauthor=T.+R.+Johnsonauthor=D.+A.+Altomareauthor=O.+Phanstiel&title=Synthesis+and+biological+evaluation+of+antimetastatic+agents+predicated+upon+dihydromotuporamine+C+and+its+carbocyclic+derivatives&doi=10.1021%2Fjm401906v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Antimetastatic Agents Predicated upon Dihydromotuporamine C and Its Carbocyclic Derivatives</span></div><div class="casAuthors">Muth, Aaron; Pandey, Veethika; Kaur, Navneet; Wason, Melissa; Baker, Cheryl; Han, Xianlin; Johnson, Teresa R.; Altomare, Deborah A.; Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4023-4034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The motuporamines isolated from the sea sponge Xestospongia exigua are of biol. interest because of their unique antimigration and antiangiogenic properties.  Key bioactive features were found to be a satd. 15-membered heterocycle and a norspermidine motif.  This paper describes new analogs that modulate the cytotoxicity of this compd. class and have enhanced antimigration properties.  By movement of the polyamine chain outside the ring, new carbocycles were discovered that doubled the antimigration potency and reduced compd. toxicity by 133-fold.  Mice injected with metastatic human L3.6pl pancreatic cancer cells demonstrated significant redn. in liver metastases when treated with N1-(3-aminopropyl)-N3-(cyclopentadecylmethyl)propane-1,3-diamine (I) compared with dihydromotuporamine C (II).  Significant changes in specific ceramide populations (N16:0 and N22:1) were noted in L3.6pl cells treated with dihydromotuporamine C but not for the cyclopentadecylmethylnorspermidine deriv., which had lower toxicity.  Both compds. gave increased levels of specific low mol. wt. sphingomyelins, suggesting that they may act upon sphingomyelin processing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDD0zypqDEbVg90H21EOLACvtfcHk0lheBr-4NFbcqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlSltbc%253D&md5=490cfc211e9f5a0f3443ccf95bffa9ef</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1021%2Fjm401906v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401906v%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DPandey%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DWason%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DJohnson%26aufirst%3DT.%2BR.%26aulast%3DAltomare%26aufirst%3DD.%2BA.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520antimetastatic%2520agents%2520predicated%2520upon%2520dihydromotuporamine%2520C%2520and%2520its%2520carbocyclic%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4023%26epage%3D4034%26doi%3D10.1021%2Fjm401906v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Skruber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Synthesis and bioevaluation of macrocycle-polyamine conjugates as cell migration inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8606</span>– <span class="NLM_lpage">8619</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2gsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8606-8619&author=K.+Skruberauthor=K.+J.+Chaplinauthor=O.+Phanstiel&title=Synthesis+and+bioevaluation+of+macrocycle-polyamine+conjugates+as+cell+migration+inhibitors&doi=10.1021%2Facs.jmedchem.7b01222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Bioevaluation of Macrocycle-Polyamine Conjugates as Cell Migration Inhibitors</span></div><div class="casAuthors">Skruber, Kristen; Chaplin, Kelvin J.; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8606-8619</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The motuporamines are natural products isolated from the New Guinea sea sponge Xestospongia exigua.  Dihydromotuporamine C contains a large macrocycle and an appended polyamine component and was shown to be both antimetastatic and cytotoxic to human L3.6pl pancreatic cancer cells.  A series of macrocycle-polyamine conjugates were prepd., and the sequence of the polyamine component was varied to optimize the antimigration properties (as measured in L3.6pl cells) of this mol. class.  A one-carbon spacer between the 15-membered carbocycle and the appended polyamine showed improved antimigration properties.  A survey of different polyamine sequences contg. two, three, or four carbon spacers revealed that the natural polyamine sequence (norspermidine, a 3,3-triamine) was superior in terms of inhibiting the migration of L3.6pl cells in vitro.  An investigation of the resp. ceramide and sphingomyelin populations in L3.6pl cells revealed that these mols. can modulate both ceramide and sphingomyelin pools in cells and inhibit cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLNuFxyknTrVg90H21EOLACvtfcHk0lheBr-4NFbcqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2gsbrF&md5=e805e362a4e80c4ab7f7436f90cad317</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01222%26sid%3Dliteratum%253Aachs%26aulast%3DSkruber%26aufirst%3DK.%26aulast%3DChaplin%26aufirst%3DK.%2BJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520bioevaluation%2520of%2520macrocycle-polyamine%2520conjugates%2520as%2520cell%2520migration%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8606%26epage%3D8619%26doi%3D10.1021%2Facs.jmedchem.7b01222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shicora, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayene, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th.</span></span> <span> </span><span class="NLM_article-title">Development of polyamine transport ligands with improved metabolic stability and selectivity against specific human cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5819</span>– <span class="NLM_lpage">5828</span>, <span class="refDoi"> DOI: 10.1021/jm400496a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400496a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2msbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5819-5828&author=A.+Muthauthor=J.+Kamelauthor=N.+Kaurauthor=A.+C.+Shicoraauthor=I.+S.+Ayeneauthor=S.+K.+Gilmourauthor=O.+Phanstiel&title=Development+of+polyamine+transport+ligands+with+improved+metabolic+stability+and+selectivity+against+specific+human+cancers&doi=10.1021%2Fjm400496a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Polyamine Transport Ligands with Improved Metabolic Stability and Selectivity against Specific Human Cancers</span></div><div class="casAuthors">Muth, Aaron; Kamel, Joseph; Kaur, Navneet; Shicora, Allyson C.; Ayene, Iraimoudi S.; Gilmour, Susan K.; Phanstiel, Otto, IV</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5819-5828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polyamine homeostasis is crit. for life and is accomplished via a balance of polyamine biosynthesis, degrdn., and transport.  Rapidly dividing cancer cells have been shown to have high polyamine transport activity compared to normal cells, likely due to their high requirement for polyamine metabolites.  The polyamine transport system (PTS) is a therapeutically relevant target, as it can provide selective drug delivery to cancer cells.  This report describes the synthesis and biol. evaluation of multimeric polyamine derivs. as efficient PTS ligands.  Arylmethyl-polyamine derivs. were synthesized to address two important concerns in PTS drug design: (a) PTS selectivity and (b) stability to amine oxidases.  N1,N1'-[Naphthalene-1,4-diylbis(methylene)]bis{N4-[4-(methylamino)butyl])butane-1,4-diamine}, 3b, was found to have an optimal balance between these parameters and demonstrated excellent targeting of melanoma (e.g., MALME-3M) and breast cancer cells (e.g., T47D) over other cancer cell lines.  These results provide a method to selectively target cancers via their intrinsic need for polyamine metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5w3QJ9zU5dbVg90H21EOLACvtfcHk0ljWtntzeH-lDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2msbzF&md5=f6e19f2b781583e66a55a0da2d0b5981</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1021%2Fjm400496a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400496a%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DKamel%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DShicora%26aufirst%3DA.%2BC.%26aulast%3DAyene%26aufirst%3DI.%2BS.%26aulast%3DGilmour%26aufirst%3DS.%2BK.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520polyamine%2520transport%2520ligands%2520with%2520improved%2520metabolic%2520stability%2520and%2520selectivity%2520against%2520specific%2520human%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5819%26epage%3D5828%26doi%3D10.1021%2Fjm400496a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konate, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Defining the molecular requirements for the selective delivery of polyamine conjugates into cells containing active polyamine transporters</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5129</span>– <span class="NLM_lpage">5138</span>, <span class="refDoi"> DOI: 10.1021/jm030223a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030223a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot1Ojtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5129-5138&author=C.+Wangauthor=J.-G.+Delcrosauthor=L.+Cannonauthor=F.+Konateauthor=H.+Cariasauthor=J.+Biggerstaffauthor=R.+A.+Gardnerauthor=O.+Phanstiel&title=Defining+the+molecular+requirements+for+the+selective+delivery+of+polyamine+conjugates+into+cells+containing+active+polyamine+transporters&doi=10.1021%2Fjm030223a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Molecular Requirements for the Selective Delivery of Polyamine Conjugates into Cells Containing Active Polyamine Transporters</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Cannon, Laura; Konate, Fanta; Carias, Horacio; Biggerstaff, John; Gardner, Richard Andrew; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5129-5138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several N1-substituted polyamines contg. various spacer units between nitrogen centers were synthesized as their resp. HCl salts.  The N1-substituents included benzyl, naphthalen-1-ylmethyl, anthracen-9-ylmethyl, and pyren-1-ylmethyl.  The polyamine spacer units ranged from generic (4,4-triamine, 4,3-triamine, and diaminooctane) spacers to more exotic [2-(ethoxy)ethanoxy-contg. diamine, hydroxylated 4,3-triamine, and cyclohexylene-contg. triamine] spacers.  Two control compds. were also evaluated:N-(anthracen-9-ylmethyl)-butylamine and N-(anthracen-9-ylmethyl)-butanediamine.  Biol. activities in L1210 (murine leukemia), α-difluoromethylornithine (DFMO)-treated L1210, and Chinese hamster ovary (CHO) and its polyamine transport-deficient mutant (CHO-MG) cell lines were investigated via IC50 cytotoxicity detns. Ki values for spermidine uptake were also detd. in L1210 cells.  Of the series studied, the N1-benzyl-4,4-triamine deriv. (6) had significantly higher IC50 values (lower cytotoxicity) in the L1210, CHO, and CHO-MG cell lines.  A cellular debenzylation process was obsd. in L1210 cells with 6 and generated "free" homospermidine.  The size of the N1-arylmethyl substituent had direct bearing on the obsd. cytotoxicity in CHO-MG cells.  The N1-naphthalenylmethyl, N1-anthracenylmethyl, and N1-pyrenylmethyl 4,4-triamines had similar toxicity (IC50s: ∼0.5 μM) in CHO cells, which have an active polyamine transporter (PAT).  However, this series had IC50 values of >100 μM, 66.7 μM, and 15.5 μM, resp., in CHO-MG cells, which are PAT-deficient.  The obsd. lower cytotoxicity in the PAT-deficient CHO-MG cell line supported the premise that the conjugates use PAT for cellular entry.  In general, moderate affinities for the polyamine transporter were obsd. for the N-arylmethyl 4,4-triamine series with their L1210 Ki values all near 3 μM.  In summary, the 4,4-triamine motif was shown to facilitate entry of polyamine conjugates into cells contg. active polyamine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEbyVe-vZALVg90H21EOLACvtfcHk0ljWtntzeH-lDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot1Ojtr8%253D&md5=df2bd3ad52a9a14ec1d5e821d1f66f72</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm030223a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030223a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DCannon%26aufirst%3DL.%26aulast%3DKonate%26aufirst%3DF.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DR.%2BA.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DDefining%2520the%2520molecular%2520requirements%2520for%2520the%2520selective%2520delivery%2520of%2520polyamine%2520conjugates%2520into%2520cells%2520containing%2520active%2520polyamine%2520transporters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5129%26epage%3D5138%26doi%3D10.1021%2Fjm030223a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm020598g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020598g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2672-2682&author=C.+Wangauthor=J.-G.+Delcrosauthor=J.+Biggerstaffauthor=O.+Phanstiel&title=Molecular+requirements+for+targeting+the+polyamine+transport+system.+Synthesis+and+biological+evaluation+of+polyamine-anthracene+conjugates&doi=10.1021%2Fjm020598g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Requirements for Targeting the Polyamine Transport System. Synthesis and Biological Evaluation of Polyamine-Anthracene Conjugates</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Biggerstaff, John; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2672-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of nine N1-(9-anthracenylmethyl)tetraamines (e.g., Ant-4,4,4-tetraamine) were synthesized and evaluated for cytotoxicity in L1210, α-difluoromethylornithine (DFMO)-treated L1210, Chinese hamster ovary (CHO), and CHO-MG cell lines.  Surprisingly, the 3,3,4- and 3,4,3-tetraamine motifs had the same or decreased cytotoxicity in DFMO-treated L1210 cells, whereas the rest of the tetraamine systems were usually more cytotoxic and gave lower IC50 values in this treated cell line.  The most sensitive derivs. to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogs, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, resp. Ki values for each of the anthracenylmethyl(Ant)-polyamine conjugates were detd. in L1210 cells and revealed that these systems are high-affinity ligands for the polyamine transporter (PAT).  Mixed results were obsd. in the CHO and CHO-MG assays.  The 4,4,4- and 5,4,4-tetraamine motifs were 3 times more toxic to CHO cells with active polyamine transporters.  For example, the Ant-4,4,4-tetraamine conjugate displayed IC50 values of 11 μM in CHO cells and 33 μM in CHO-MG cells, a PAT-deficient cell line.  This suggested that these derivs. used the PAT in part to access cells.  However, most of the other tetraamine derivs. had similar potencies in both the CHO and CHO-MG cell lines.  In terms of vector design, higher affinity for the PAT (lower Ki values) did not translate into higher potency for the tetraamine conjugate.  In contrast, the related triamine systems, which had micromolar Ki values in L1210 cells, were more efficacious and selective.  In one case, the 4,4-triamine motif imparted 150-fold higher potency in CHO cells than the CHO-MG mutant.  A deconvolution microscopy study in A375 melanoma cells revealed a rapid internalization of the Ant-4,4-triamine as fluorescent vesicles, whereas the Ant-4,4,4-tetraamine remained mostly at the cell surface.  These findings help define the key characteristics required for selective delivery of polyamine-drug conjugates into cell types with active polyamine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoooD6sQH5_LVg90H21EOLACvtfcHk0ljWtntzeH-lDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVahuro%253D&md5=b30edf689e4567ba70c35da214472815</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm020598g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020598g%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DMolecular%2520requirements%2520for%2520targeting%2520the%2520polyamine%2520transport%2520system.%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520polyamine-anthracene%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2672%26epage%3D2682%26doi%3D10.1021%2Fjm020598g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanstiel, O.,  4th</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as mo lecular recognition elements for the polyamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2663</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1021/jm030028w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030028w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2663-2671&author=C.+Wangauthor=J.-G.+Delcrosauthor=J.+Biggerstaffauthor=O.+Phanstiel&title=Synthesis+and+biological+evaluation+of+N1-%28anthracen-9-ylmethyl%29triamines+as+mo+lecular+recognition+elements+for+the+polyamine+transporter&doi=10.1021%2Fjm030028w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N1-(Anthracen-9-ylmethyl)triamines as Molecular Recognition Elements for the Polyamine Transporter</span></div><div class="casAuthors">Wang, Chaojie; Delcros, Jean-Guy; Biggerstaff, John; Phanstiel, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2663-2671</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient modular synthesis of N1-substituted triamines contg. different tether lengths between nitrogen centers was developed.  A series of N1-(9-anthracenylmethyl)triamines I (R = H, m = 3-5, n = 3-4; R = 4-MeC6H4SO2, m = 2-5, n = 4) were evaluated for biol. activity in L1210 (murine leukemia), α-difluoromethylornithine (DFMO)-treated L1210, Chinese hamster ovary (CHO), and CHO-MG cell lines.  All triamines I (R = H, m = 3-5, n = 3-4) had increased potency in DFMO-treated L1210 cells.  The 4,4- and 5,4-triamine systems I (R = H, m = n = 4; m = 5, n = 4) had the highest affinity for the polyamine transporter (PAT) with L1210 Ki values of 1.8 and 1.7 μM, resp.  This trend was also reflected in the CHO studies.  Surprisingly, the resp. 4,4- and 5,4-triamine systems had 150-fold and 38-fold higher cytotoxicity in CHO cells contg. active polyamine transporters.  Initial microscopy studies revealed the rapid formation of vesicular structures within A375 melanoma cells treated with the N1-(9-anthracenylmethyl)homospermidine (4,4-triamine) conjugate.  In summary, the 4,4- and 5,4-triamines were identified as selective vector motifs to ferry anthracene into cells via the PAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaq811vrP-LVg90H21EOLACvtfcHk0lhRYAN58n7_1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVWrs7s%253D&md5=4756335fbe6450c2dfac5183f5e5e8d4</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm030028w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030028w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DBiggerstaff%26aufirst%3DJ.%26aulast%3DPhanstiel%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N1-%2528anthracen-9-ylmethyl%2529triamines%2520as%2520mo%2520lecular%2520recognition%2520elements%2520for%2520the%2520polyamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2663%26epage%3D2671%26doi%3D10.1021%2Fjm030028w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor conjugates with polyamine vectors and their molecular mechanisms</span>. <i>Expert Opin. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1517/17425247.2010.504205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1517%2F17425247.2010.504205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=20636185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCntLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1049-1061&author=S.+Xieauthor=J.+Wangauthor=Y.+Zhangauthor=C.+Wang&title=Antitumor+conjugates+with+polyamine+vectors+and+their+molecular+mechanisms&doi=10.1517%2F17425247.2010.504205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor conjugates with polyamine vectors and their molecular mechanisms</span></div><div class="casAuthors">Xie, Songqiang; Wang, Jianhong; Zhang, Yahong; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1049-1061</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: A polyamine conjugate is a special polyamine deriv. composed of polyamine vectors appended directly or by a linker to a cargo with specific biol. functions.  In recent years, extensive researches have emphasized the fact that polyamine conjugates acting as promising antitumor candidates are becoming increasingly important in the polyamine field.  Areas covered in this review: Two key subjects are illustrated in this review.  First, various drug-polyamine conjugates and relevant structure-activity relationships are discussed with a focus on the mol. recognition of polyamine transport system (PTS).  Second, the design of polyamine conjugates is following a rational mechanism-based strategy.  Therefore, it is critically important to understand the intrinsic properties of PTS on the cell membrane, enhanced pharmacol. effects of polyamine vector on cellular components, and resulting comprehensive signaling networks.  What the reader will gain: A general design strategy of polyamine conjugates as well as recent progress in both fundamental mechanism studies and preclin. therapies are provided for the readers.  Take home message: The multiple functions of polyamine moieties in objective conjugates furnish broad development space for more efficacious antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_QN8mZHcCrVg90H21EOLACvtfcHk0lhRYAN58n7_1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCntLnP&md5=134d791bed69b73f5dac62f8779724f8</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1517%2F17425247.2010.504205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.2010.504205%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DAntitumor%2520conjugates%2520with%2520polyamine%2520vectors%2520and%2520their%2520molecular%2520mechanisms%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2010%26volume%3D7%26spage%3D1049%26epage%3D1061%26doi%3D10.1517%2F17425247.2010.504205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span> <span> </span><span class="NLM_article-title">Nonhematotoxic naphthalene diimide modified by polyamine: synthesis and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3502</span>– <span class="NLM_lpage">3512</span>, <span class="refDoi"> DOI: 10.1021/jm300168w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300168w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFelu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3502-3512&author=Y.+X.+Wangauthor=X.+Zhangauthor=J.+Zhaoauthor=S.+Q.+Xieauthor=C.+J.+Wang&title=Nonhematotoxic+naphthalene+diimide+modified+by+polyamine%3A+synthesis+and+biological+evaluation&doi=10.1021%2Fjm300168w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14eR"><div class="casContent"><span class="casTitleNuber">14e</span><div class="casTitle"><span class="NLM_cas:atitle">Nonhematotoxic Naphthalene Diimide Modified by Polyamine: Synthesis and Biological Evaluation</span></div><div class="casAuthors">Wang, Yuxia; Zhang, Xingbo; Zhao, Jin; Xie, Songqiang; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3502-3512</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of up-regulating antitumor efficacy and down-regulating adverse effects, three types of arom. imide and diimides were designed to couple with different polyamines.  The in vitro assays revealed that two naphthalene diimide-polyamine conjugates could inhibit the growth of multiple cancer cell lines more potently than amonafide. 9f (I), the most potent compd., was verified to efficiently induce apoptosis via a ROS mediated mitochondrial pathway in a preliminary mechanistic study.  The comprehensive in vivo trials on three H22 tumor transplant models demonstrated that 9f improved the indexes in terms of inhibitive effect and lifespan extension and reduced the hematotoxicity which is one of main drawbacks of amonafide.  More importantly, the obviously elevated ability in preventing lung cancer metastasis was obsd., which increased the value of 9f as a promising lead compd.  This work supported that the versatile function of polyamines may endow some intriguing biol. features to the parent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rbHd3GIdC7Vg90H21EOLACvtfcHk0lhRYAN58n7_1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFelu7c%253D&md5=66b25bbb51f0570e0fe36421d5a3359e</span></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm300168w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300168w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26atitle%3DNonhematotoxic%2520naphthalene%2520diimide%2520modified%2520by%2520polyamine%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3502%26epage%3D3512%26doi%3D10.1021%2Fjm300168w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e328359affd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1097%2FCAD.0b013e328359affd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=23032518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslantLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=32-42&author=M.+Liauthor=Q.+Liauthor=Y.+H.+Zhangauthor=Z.+Y.+Tianauthor=H.+X.+Maauthor=J.+Zhaoauthor=S.+Q.+Xieauthor=C.+Wang&title=Antitumor+effects+and+preliminary+systemic+toxicity+of+ANISpm+in+vivo+and+in+vitro&doi=10.1097%2FCAD.0b013e328359affd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14fR"><div class="casContent"><span class="casTitleNuber">14f</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro</span></div><div class="casAuthors">Li, Ming; Li, Qian; Zhang, Ya-hong; Tian, Zhi-yong; Ma, Hong-xia; Zhao, Jin; Xie, Song-qiang; Wang, Chao-jie</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Polyamines as a vector to ferry toxic agents have attracted attention, and naphthalimide-polyamine conjugates show potent activity and tumor cell selectivity.  The present study was carried out to evaluate the antitumor effects and preliminary systemic toxicity of ANISpm, a novel 3-amino-naphthalimide-spermine conjugate.  The polyamine transport system recognition of ANISpm, supported by α-difluoromethylornithine (DFMO)/spermidine (Spd) expts., is in accordance with its potent cell selectivity between human hepatoma HepG2 cells and normal QSG7701 hepatocyte.  The antiproliferative effect is because of ANISpm-induced cell apoptosis, a common characteristic of both naphthalimide and polyamine analogs.  Various apoptotic assessment assays have shown that ANISpm can induce apoptosis through the PI3K/Akt signal pathway.  The apoptotic signaling cascade involves Akt inactivation, which results in a series of cellular events.  The downstream pathway includes Bad dephosphorylation, dissocn. of 14-3-3 and Bad, and binding to Bcl-xL, which triggers the disruption of the mitochondrial membrane, release of cytochrome c, and caspases' cascade activation.  Furthermore, the Akt/mTOR signal pathway is also involved in ANISpm-mediated cell-cycle arrest.  Additive DFMO or Spd, which only enhances or attenuates ANISpm-mediated cell apoptosis, resp., does not alter the signal pathway.  In addn., preliminary toxicol. evaluation showed that ANISpm had no obvious system toxicity at a dose of 2.5 mg/kg, which exerted potent antitumor activity in vivo, esp. hematotoxicity.  Thus, ANISpm merits further investigation as a potential chemotherapeutic agent against hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdAeGa8w_3CbVg90H21EOLACvtfcHk0lhRYAN58n7_1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslantLfK&md5=ae1af1913d657be6acb0b0081103c9e4</span></div><a href="/servlet/linkout?suffix=cit14f&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328359affd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328359affd%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DTian%26aufirst%3DZ.%2BY.%26aulast%3DMa%26aufirst%3DH.%2BX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DAntitumor%2520effects%2520and%2520preliminary%2520systemic%2520toxicity%2520of%2520ANISpm%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2013%26volume%3D24%26spage%3D32%26epage%3D42%26doi%3D10.1097%2FCAD.0b013e328359affd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2Fj.ejmech.2016.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27236067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVWhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=110-119&author=Q.+Liauthor=Y.+Zhaiauthor=W.+Luoauthor=Z.+Zhuauthor=X.+Zhangauthor=S.+Xieauthor=C.+Hongauthor=Y.+Wangauthor=Y.+Suauthor=J.+Zhaoauthor=C.+Wang&title=Synthesis+and+biological+properties+of+polyamine+modified+flavonoids+as+hepatocellular+carcinoma+inhibitors&doi=10.1016%2Fj.ejmech.2016.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14gR"><div class="casContent"><span class="casTitleNuber">14g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors</span></div><div class="casAuthors">Li, Qian; Zhai, Yangyang; Luo, Wen; Zhu, Zixin; Zhang, Xin; Xie, Songqiang; Hong, Chen; Wang, Yuxia; Su, Yabin; Zhao, Jin; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-119</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of polyamine conjugates of flavonoids with a naphthalene motif were synthesized and evaluated for their anti-hepatocellular carcinoma properties using in vitro and in vivo assays.  Compd. 8a displayed favorable selectivity between hepatocellular carcinoma cells and normal hepatocyte cells, and the combination of 8a with aspirin resulted in additive inhibition of in vitro tumor cell growth and migration.  The 8a-aspirin combination also inhibited H22 liver tumor growth and pulmonary metastasis and improved body wt. index in animal models.  Preliminary mechanistic studies indicated that 8a increased the expression of apoptosis-related proteins such as p-p38, p-JNK, p53 and Bcl-2, an effect that was further amplified by aspirin.  Therefore, a cocktail therapy of flavonoid-polyamine conjugates with aspirin has potential use as an antitumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXcJ8WScB97Vg90H21EOLACvtfcHk0li86RDzLjwxEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVWhtrg%253D&md5=a37e727bb462c3f79e6cbfe78d2064ee</span></div><a href="/servlet/linkout?suffix=cit14g&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520properties%2520of%2520polyamine%2520modified%2520flavonoids%2520as%2520hepatocellular%2520carcinoma%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D110%26epage%3D119%26doi%3D10.1016%2Fj.ejmech.2016.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of mitochondria-targeted flavone-naphthalimide-polyamine conjugates with antimetastatic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2071</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2071-2083&author=F.+J.+Daiauthor=Q.+Liauthor=Y.+X.+Wangauthor=C.+C.+Geauthor=C.+Fengauthor=S.+Q.+Xieauthor=H.+Heauthor=X.+Xuauthor=C.+J.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+mitochondria-targeted+flavone-naphthalimide-polyamine+conjugates+with+antimetastatic+activity&doi=10.1021%2Facs.jmedchem.6b01846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14hR"><div class="casContent"><span class="casTitleNuber">14h</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity</span></div><div class="casAuthors">Dai, Fujun; Li, Qian; Wang, Yuxia; Ge, Chaochao; Feng, Chenyang; Xie, Songqiang; He, Haoying; Xu, Xiaojuan; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2071-2083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 90% of cancer-assocd. deaths result from disseminated tumors, indicating the ineffectiveness of current therapies and the imperative need of antimetastatic drugs.  A novel pharmacophore with flavonoid and naphthalimide moieties was constructed by using a fragment-based drug design and a series of eight flavone-naphthalimide-polyamine conjugates were synthesized.  In vitro evaluation revealed that compd. I with a homospermidine motif displayed better cell selectivity between cancerous and normal liver cells than amonafide did.  The in vivo assays on two hepatocellular carcinoma (HCC) models verified that I potently suppressed pulmonary metastasis with improved organ indexes compared to amonafide.  Various expts. showed that I as a potential fluorescent chem. probe could target the mitochondria.  Preliminary investigation into the mechanism of action of I indicated that it might harness a polyamine transporter for cell entrance, localize in the mitochondria, selectively cause reactive oxygen species (ROS) overprodn. in hepatoma cells instead of normal liver cells, and finally lead to HCC cell apoptosis and migration inhibition via multiple ROS-mediated signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnOVDRABi27Vg90H21EOLACvtfcHk0li86RDzLjwxEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D&md5=de5add465c72748224b38fd9a153f131</span></div><a href="/servlet/linkout?suffix=cit14h&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01846%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DF.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DGe%26aufirst%3DC.%2BC.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%2BQ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520mitochondria-targeted%2520flavone-naphthalimide-polyamine%2520conjugates%2520with%2520antimetastatic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2071%26epage%3D2083%26doi%3D10.1021%2Facs.jmedchem.6b01846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of the polyamine conjugate with benzo[ cd]indol-2(1 H)-one as a lysosome-targeted antimetastatic agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6814</span>– <span class="NLM_lpage">6829</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00694</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00694" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6814-6829&author=J.+Liauthor=R.+Tianauthor=C.+Geauthor=Y.+Chenauthor=X.+Liuauthor=Y.+Wangauthor=Y.+Yangauthor=W.+Luoauthor=F.+Daiauthor=S.+Wangauthor=S.+Chenauthor=S.+Xieauthor=C.+Wang&title=Discovery+of+the+polyamine+conjugate+with+benzo%5B+cd%5Dindol-2%281+H%29-one+as+a+lysosome-targeted+antimetastatic+agent&doi=10.1021%2Facs.jmedchem.8b00694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14iR"><div class="casContent"><span class="casTitleNuber">14i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Polyamine Conjugate with Benzo[cd]indol-2(1H)-one as a Lysosome-Targeted Antimetastatic Agent</span></div><div class="casAuthors">Li, Jinghua; Tian, Runguo; Ge, Chaochao; Chen, Ying; liu, Xiaodan; Wang, Yuxia; Yang, Yacheng; Luo, Wen; Dai, Fujun; Wang, Senzhen; Chen, Shuai; Xie, Songqiang; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6814-6829</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polyamine derivs. have a promising prospect in dealing with disseminated tumor cells, a major obstacle in cancer therapy.  To develop a bifunctional polyamine deriv. that can serve as a fluorescent probe and an antimetastatic agent, three kinds of polyamine conjugates with benzo[cd]indol-2(1H)-one as a scaffold were designed and synthesized.  Compd. 5e was selected as a lead by in vitro screening.  Two animal models demonstrated that 5e inhibited pulmonary metastasis and tumor growth.  As a fluorescent probe, 5e might partially enter cells via a polyamine transporter and subsequently localize in the lysosome.  Mechanistic investigations demonstrated the interdependence of 5e-triggered apoptosis and autophagy.  Compd. 5e modulated the expression of LC3-II, p62, cathepsins, and the expression of caspases 3, caspase 8, Bcl-2, and p53.  The SSAT-mediated Akt/β-catenin pathways were also inhibited by 5e.  The dual features of 5e make it a worthwhile lead compd. for further structural optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpgNjuODdNLVg90H21EOLACvtfcHk0li86RDzLjwxEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsbnI&md5=dd73db90492e94104a71a8dabdc46b5a</span></div><a href="/servlet/linkout?suffix=cit14i&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00694%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520the%2520polyamine%2520conjugate%2520with%2520benzo%255B%2520cd%255Dindol-2%25281%2520H%2529-one%2520as%2520a%2520lysosome-targeted%2520antimetastatic%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6814%26epage%3D6829%26doi%3D10.1021%2Facs.jmedchem.8b00694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span> <span> </span><span class="NLM_article-title">Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1092</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.18632%2Foncotarget.13582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27901475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvVGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1092-1109&author=C.+Wangauthor=P.+Ruanauthor=Y.+Zhaoauthor=X.+Liauthor=J.+Wangauthor=X.+Wuauthor=T.+Liuauthor=S.+Wangauthor=J.+Houauthor=W.+Liauthor=Q.+Liauthor=J.+Liauthor=F.+Daiauthor=D.+Fangauthor=C.+Wangauthor=S.+Xie&title=Spermidine%2Fspermine+N1-acetyltransferase+regulates+cell+growth+and+metastasis+via+AKT%2F%CE%B2-catenin+signaling+pathways+in+hepatocellular+and+colorectal+carcinoma+cells&doi=10.18632%2Foncotarget.13582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14jR"><div class="casContent"><span class="casTitleNuber">14j</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells</span></div><div class="casAuthors">Wang Cong; Ruan Ping; Zhao Ying; Li Xiaomin; Wang Jun; Wu Xiaoxiao; Liu Tong; Wang Shasha; Hou Jiuzhou; Li Wei; Fang Dong; Xie Songqiang; Li Qian; Li Jinghua; Dai Fujun; Wang Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1092-1109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common cancers across the world.  Therefore, identifying the potential molecular mechanisms that promote HCC and CRC progression and metastasis are urgently needed.  Spermidine/spermine N1-acetyltransferase (SSAT) is a catabolic enzyme that acetylates the high-order polyamines spermine and spermidine, thus decreasing the cellular content of polyamines.  Several publications have suggested that depletion of intracellular polyamines inhibited tumor progression and metastasis in various cancer cells.  However, whether and how SSAT regulates cell growth, migration and invasion in hepatocellular and colorectal carcinoma cells remains unclear.  In this study, depletion of polyamines mediated by SSAT not only attenuated the tumor cell proliferation but also dramatically inhibited cell migration and invasion in hepatocellular and colorectal carcinoma cells.  Subsequent investigations revealed introduction of SSAT into HepG2, SMMC7721 hepatocellular carcinoma cells and HCT116 colorectal carcinoma cells significantly suppressed p-AKT, p-GSK3β expression as well as β-catenin nuclear translocation, while inhibition of GSK3β activity or exogenous polyamines could restore SSAT-induced decreases in the protein expression of p-AKT, p-GSK3β and β-catenin.  Conversely, knockdown of SSAT in Bel7402 hepatocellular carcinoma cells and HT-29 colorectal carcinoma cells which expressed high levels of SSAT endogenously significantly promoted the expression of p-AKT, p-GSK3β as well as β-catenin nuclear translocation.  Taken together, our results indicated depletion of polyamines by SSAT significantly inhibited cell proliferation, migration and invasion through AKT/GSK3β/β-catenin signaling pathway in hepatocellular carcinoma and colorectal cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy24SyfiZNxD0O18WR3iAofW6udTcc2eZDFTUo7HcHUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvVGhug%253D%253D&md5=deacadffa9c604953b34a1930f6c9546</span></div><a href="/servlet/linkout?suffix=cit14j&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13582%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%26atitle%3DSpermidine%252Fspermine%2520N1-acetyltransferase%2520regulates%2520cell%2520growth%2520and%2520metastasis%2520via%2520AKT%252F%25CE%25B2-catenin%2520signaling%2520pathways%2520in%2520hepatocellular%2520and%2520colorectal%2520carcinoma%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1092%26epage%3D1109%26doi%3D10.18632%2Foncotarget.13582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span> <span> </span><span class="NLM_article-title">p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-0996-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fs41586-019-0996-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=30842655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567&publication_year=2019&pages=253-256&author=L.+Liauthor=Y.+Maoauthor=L.+Zhaoauthor=L.+Liauthor=J.+Wuauthor=M.+Zhaoauthor=W.+Duauthor=L.+Yuauthor=P.+Jiang&title=p53+regulation+of+ammonia+metabolism+through+urea+cycle+controls+polyamine+biosynthesis&doi=10.1038%2Fs41586-019-0996-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis</span></div><div class="casAuthors">Li, Le; Mao, Youxiang; Zhao, Lina; Li, Lijia; Wu, Jinjun; Zhao, Mengjia; Du, Wenjing; Yu, Li; Jiang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">567</span>
        (<span class="NLM_cas:issue">7747</span>),
    <span class="NLM_cas:pages">253-256</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer cells exhibit altered and usually increased metabolic processes to meet their high biogenetic demands.  Under these conditions, ammonia is concomitantly produced by the increased metabolic processing.  However, it is unclear how tumor cells dispose of excess ammonia and what outcomes might be caused by the accumulation of ammonia.  Here we report that the tumor suppressor p53, the most frequently mutated gene in human tumors, regulates ammonia metab. by repressing the urea cycle.  Through transcriptional downregulation of CPS1, OTC and ARG1, p53 suppresses ureagenesis and elimination of ammonia in vitro and in vivo, leading to the inhibition of tumor growth.  Conversely, downregulation of these genes reciprocally activates p53 by MDM2-mediated mechanism(s).  Furthermore, the accumulation of ammonia causes a significant decline in mRNA translation of the polyamine biosynthetic rate-limiting enzyme ODC, thereby inhibiting the biosynthesis of polyamine and cell proliferation.  Together, these findings link p53 to ureagenesis and ammonia metab., and further reveal a role for ammonia in controlling polyamine biosynthesis and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF69TVb-Lx-LVg90H21EOLACvtfcHk0lgJ9Tzk60vVzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurs%253D&md5=31e3f7a94ad9795604e12c26fa9143a5</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0996-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0996-7%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DP.%26atitle%3Dp53%2520regulation%2520of%2520ammonia%2520metabolism%2520through%2520urea%2520cycle%2520controls%2520polyamine%2520biosynthesis%26jtitle%3DNature%26date%3D2019%26volume%3D567%26spage%3D253%26epage%3D256%26doi%3D10.1038%2Fs41586-019-0996-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span> <span> </span><span class="NLM_article-title">Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E6806</span>– <span class="NLM_lpage">E6812</span>, <span class="refDoi"> DOI: 10.1073/pnas.1607152113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1073%2Fpnas.1607152113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27698118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Sitr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E6806-E6812&author=Y.+Ouauthor=S.+J.+Wangauthor=D.+Liauthor=B.+Chuauthor=W.+Gu&title=Activation+of+SAT1+engages+polyamine+metabolism+with+p53-mediated+ferroptotic+responses&doi=10.1073%2Fpnas.1607152113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses</span></div><div class="casAuthors">Ou, Yang; Wang, Shang-Jui; Li, Dawei; Chu, Bo; Gu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">E6806-E6812</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although p53-mediated cell-cycle arrest, senescence, and apoptosis remain crit. barriers to cancer development, the emerging role of p53 in cell metab., oxidative responses, and ferroptotic cell death has been a topic of great interest.  Nevertheless, it is unclear how p53 orchestrates its activities in multiple metabolic pathways into tumor suppressive effects.  Here, we identified the SAT1 (spermidine/spermine N1-acetyltransferase 1) gene as a transcription target of p53.  SAT1 is a rate-limiting enzyme in polyamine catabolism critically involved in the conversion of spermidine and spermine back to putrescine.  Surprisingly, we found that activation of SAT1 expression induces lipid peroxidn. and sensitizes cells to undergo ferroptosis upon reactive oxygen species (ROS)-induced stress, which also leads to suppression of tumor growth in xenograft tumor models.  Notably, SAT1 expression is down-regulated in human tumors, and CRISPR-cas9-mediated knockout of SAT1 expression partially abrogates p53-mediated ferroptosis.  Moreover, SAT1 induction is correlated with the expression levels of arachidonate 15-lipoxygenase (ALOX15), and SAT1-induced ferroptosis is significantly abrogated in the presence of PD146176, a specific inhibitor of ALOX15.  Thus, our findings uncover a metabolic target of p53 involved in ferroptotic cell death and provide insight into the regulation of polyamine metab. and ferroptosis-mediated tumor suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZFlA6cc7bLVg90H21EOLACvtfcHk0ljIcZil7NzDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Sitr7K&md5=a543ebc65f1b5bb49afde2a2f88d45e5</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1607152113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1607152113%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DActivation%2520of%2520SAT1%2520engages%2520polyamine%2520metabolism%2520with%2520p53-mediated%2520ferroptotic%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE6806%26epage%3DE6812%26doi%3D10.1073%2Fpnas.1607152113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8854</span>– <span class="NLM_lpage">8866</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.18632%2Foncotarget.12673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=27750219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtlOjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8854-8866&author=A.+Eastman&title=Improving+anticancer+drug+development+begins+with+cell+culture%3A+misinformation+perpetrated+by+the+misuse+of+cytotoxicity+assays&doi=10.18632%2Foncotarget.12673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays</span></div><div class="casAuthors">Eastman Alan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">8854-8866</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The high failure rate of anticancer drug discovery and development has consumed billions of dollars annually.  While many explanations have been provided, I believe that misinformation arising from inappropriate cell-based screens has been completely over-looked.  Most cell culture experiments are irrelevant to how drugs are subsequently administered to patients.  Usually, drug development focuses on growth inhibition rather than cell killing.  Drugs are selected based on continuous incubation of cells, then frequently administered to the patient as a bolus.  Target identification and validation is often performed by gene suppression that inevitably mimics continuous target inhibition.  Drug concentrations in vitro frequently far exceed in vivo concentrations.  Studies of drug synergy are performed at sub-optimal concentrations.  And the focus on a limited number of cell lines can misrepresent the potential efficacy in a patient population.  The intent of this review is to encourage more appropriate experimental design and data interpretation, and to improve drug development in the area of cell-based assays.  Application of these principles should greatly enhance the successful translation of novel drugs to the patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReT51ZB6VkgHELvajU9pjPfW6udTcc2eZIafFYRAWoD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtlOjtA%253D%253D&md5=cc8ee6536db13f7c09d01553fd81a641</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12673%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DImproving%2520anticancer%2520drug%2520development%2520begins%2520with%2520cell%2520culture%253A%2520misinformation%2520perpetrated%2520by%2520the%2520misuse%2520of%2520cytotoxicity%2520assays%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D8854%26epage%3D8866%26doi%3D10.18632%2Foncotarget.12673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzayans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span> <span> </span><span class="NLM_article-title">Do Multiwell Plate High Throughput Assays Measure Loss of Cell Viability Following Exposure to Genotoxic Agents?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1679</span>, <span class="refDoi"> DOI: 10.3390/ijms18081679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3390%2Fijms18081679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1679&author=R.+Mirzayansauthor=B.+Andraisauthor=D.+Murray&title=Do+Multiwell+Plate+High+Throughput+Assays+Measure+Loss+of+Cell+Viability+Following+Exposure+to+Genotoxic+Agents%3F&doi=10.3390%2Fijms18081679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Do multiwell plate high throughput assays measure loss of cell viability following exposure to genotoxic agents?</span></div><div class="casAuthors">Mirzayans, Razmik; Andrais, Bonnie; Murray, David</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1679/1-1679/10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cell-based assays in multiwell plates are widely used for radiosensitivity and chemosensitivity assessment with different mammalian cell types.  Despite their relative ease of performance, such assays lack specificity as they do not distinguish between the cytostatic (reversible/sustained growth arrest) and cytotoxic (loss of viability) effects of genotoxic agents.  We recently reported studies with solid tumor-derived cell lines demonstrating that radiosensitivity as measured by multiwell plate colorimetric (e.g., XTT) and fluorimetric (e.g., CellTiter-Blue) assays reflects growth arrest but not loss of viability.  Herein we report similar observations with cancer cell lines expressing wild-type p53 (A549 lung carcinoma) or mutant p53 (MDA-MB-231 breast carcinoma) after treatment with the chemotherapeutic drug cisplatin.  Importantly, we show that treatment of cancer cells with concns. of cisplatin that result in 50% effect (i.e., IC50) in multiwell plate assays trigger the emergence of growth arrested cells that exhibit highly enlarged morphol., remain viable and adherent to the culture dish, and metabolize the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to its formazan deriv.  The emergence of markedly enlarged viable cells complicates the interpretation of chemosensitivity data obtained with multiwell plate high throughput assays.  Relying solely on IC50 values could be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1IIZMjmkGLVg90H21EOLACvtfcHk0ljIcZil7NzDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7zE&md5=9a70f03a7e7fed08005584df4b62b8dc</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.3390%2Fijms18081679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081679%26sid%3Dliteratum%253Aachs%26aulast%3DMirzayans%26aufirst%3DR.%26aulast%3DAndrais%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DD.%26atitle%3DDo%2520Multiwell%2520Plate%2520High%2520Throughput%2520Assays%2520Measure%2520Loss%2520of%2520Cell%2520Viability%2520Following%2520Exposure%2520to%2520Genotoxic%2520Agents%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1679%26doi%3D10.3390%2Fijms18081679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massague, J.</span></span> <span> </span><span class="NLM_article-title">Metastasis: from dissemination to organ-specific colonization</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1038/nrc2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=19308067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=274-284&author=D.+X.+Nguyenauthor=P.+D.+Bosauthor=J.+Massague&title=Metastasis%3A+from+dissemination+to+organ-specific+colonization&doi=10.1038%2Fnrc2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metastasis: from dissemination to organ-specific colonization</span></div><div class="casAuthors">Nguyen, Don X.; Bos, Paula D.; Massague, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">274-284</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis to distant organs is an ominous feature of most malignant tumors but the natural history of this process varies in different cancers.  The cellular origin, intrinsic properties of the tumor, tissue affinities and circulation patterns det. not only the sites of tumor spread, but also the temporal course and severity of metastasis to vital organs.  Striking disparities in the natural progression of different cancers raise important questions about the evolution of metastatic traits, the genetic determinants of these properties and the mechanisms that lead to the selection of metastatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv8Sj9LL_MPLVg90H21EOLACvtfcHk0ljIcZil7NzDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSrsr4%253D&md5=c9a4a69159de28fe6477154df4d8ade8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrc2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2622%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BX.%26aulast%3DBos%26aufirst%3DP.%2BD.%26aulast%3DMassague%26aufirst%3DJ.%26atitle%3DMetastasis%253A%2520from%2520dissemination%2520to%2520organ-specific%2520colonization%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D274%26epage%3D284%26doi%3D10.1038%2Fnrc2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">GammaH2AX and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/nrc2523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1038%2Fnrc2523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=19005492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=957-967&author=W.+M.+Bonnerauthor=C.+E.+Redonauthor=J.+S.+Dickeyauthor=A.+J.+Nakamuraauthor=O.+A.+Sedelnikovaauthor=S.+Solierauthor=Y.+Pommier&title=GammaH2AX+and+cancer&doi=10.1038%2Fnrc2523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">γH2AX and cancer</span></div><div class="casAuthors">Bonner, William M.; Redon, Christophe E.; Dickey, Jennifer S.; Nakamura, Asako J.; Sedelnikova, Olga A.; Solier, Stephanie; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone H2AX phosphorylation on a serine four residues from the carboxyl terminus (producing γH2AX) is a sensitive marker for DNA double-strand breaks (DSBs).  DSBs may lead to cancer but, paradoxically, are also used to kill cancer cells.  Using γH2AX detection to det. the extent of DSB induction may help to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvJ8vnkfC0bVg90H21EOLACvtfcHk0lge_w066sfZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK&md5=b0a83efe87f2823e79146ba8a2edf808</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc2523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2523%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DDickey%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DSedelnikova%26aufirst%3DO.%2BA.%26aulast%3DSolier%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DGammaH2AX%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D957%26epage%3D967%26doi%3D10.1038%2Fnrc2523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">The ATP-dependent glutathione S-conjugate export pump</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(92)90489-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.1016%2F0968-0004%2892%2990489-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1455517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1992&pages=463-468&issue=11&author=T.+Ishikawa&title=The+ATP-dependent+glutathione+S-conjugate+export+pump&doi=10.1016%2F0968-0004%2892%2990489-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ATP-dependent glutathione S-conjugate export pump</span></div><div class="casAuthors">Ishikawa, Toshihisa</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">463-8</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    </div><div class="casAbstract">A review, with 34 refs., on the physiol. significance of the ATP-dependent glutathione S-conjugate pump (GS-X pump) with respect to the metab. of endo- and xenobiotics, as well as its potential role in the modulation of the proliferation of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ejhB8FHearVg90H21EOLACvtfcHk0lge_w066sfZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVSltQ%253D%253D&md5=806cd4e5ac20363c655a808a82072e3e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2892%2990489-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252892%252990489-V%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DThe%2520ATP-dependent%2520glutathione%2520S-conjugate%2520export%2520pump%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1992%26volume%3D17%26issue%3D11%26spage%3D463%26epage%3D468%26doi%3D10.1016%2F0968-0004%2892%2990489-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species (ROS) accumulation induced by mononaphthalimide-spermidine leads to intrinsic and AIF-mediated apoptosis in HeLa cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.3892/or.2011.1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=10.3892%2For.2011.1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=21290091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1099-1107&issue=4&author=L.+Yangauthor=J.+Zhaoauthor=Y.+Zhuauthor=Z.+Tianauthor=C.+Wang&title=Reactive+oxygen+species+%28ROS%29+accumulation+induced+by+mononaphthalimide-spermidine+leads+to+intrinsic+and+AIF-mediated+apoptosis+in+HeLa+cells&doi=10.3892%2For.2011.1173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species (ROS) accumulation induced by mononaphthalimide-spermidine leads to intrinsic and AIF-mediated apoptosis in HeLa cells</span></div><div class="casAuthors">Yang, Lianhe; Zhao, Jin; Zhu, Yanqin; Tian, Zhiyong; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1099-1107</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Developing polyamine conjugates having the potential of transporting naphthalimide selectively into tumor cells is attractive.  However, the evaluation of their cytotoxic mechanism has not been comprehensive.  This study focused on the effects of mononaphthalimide spermidine (MNISpd) conjugate on apoptosis induction and the relationship between MNISpd-induced apoptosis and reactive oxygen species (ROS) in HeLa cells.  Our findings indicated that 9 μM MNISpd induced apoptosis in HeLa cells during a 48-h period.  MNISpd induced apoptosis in HeLa cells following cytochrome c release, elevation of caspase 3/9 activity, apoptosis-inducing factor (AIF) translocation and up-/down-regulation of Bax/Bcl-2 protein expression, resp., and these effects were completely antagonized by pre-incubation with 10 mM NAC for 2 h.  MNISpd induced significant ROS accumulation following up-regulation of polyamine oxidase (PAO) activity and complex variations in glutathione levels.  It is concluded that MNISpd-induced apoptosis is related to intrinsic caspase-dependent and AIF-mediated caspase-independent apoptosis pathways in HeLa cells.  MNISpd-induced apoptosis correlates to MNISpd-induced ROS prodn. resulting from GSH (reduced form of glutathione) pool depletion, and PAO is likely to be the source of ROS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgdG1pmQgW7Vg90H21EOLACvtfcHk0lge_w066sfZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFWltbg%253D&md5=cd9732f40d7820a6255861aa43b4fa95</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3892%2For.2011.1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2011.1173%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DReactive%2520oxygen%2520species%2520%2528ROS%2529%2520accumulation%2520induced%2520by%2520mononaphthalimide-spermidine%2520leads%2520to%2520intrinsic%2520and%2520AIF-mediated%2520apoptosis%2520in%2520HeLa%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2011%26volume%3D25%26issue%3D4%26spage%3D1099%26epage%3D1107%26doi%3D10.3892%2For.2011.1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i38"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01641">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32030"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01641?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01641</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Full experimental details, NMR data, and bioassay information (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_001.pdf">jm9b01641_si_001.pdf (3.96 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01641/suppl_file/jm9b01641_si_002.csv">jm9b01641_si_002.csv (0.49 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01641&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01641%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01641" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d293fa4c3d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
